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ABSTRACT 
 
Immunological Mechanisms Controlling Chronic Inflammatory Diseases 
 By Olivier Cexus 
 
Autoimmune diseases (AID) are chronic inflammatory diseases (CID) mediated by self-
reactive T and B cells and are generally the results of the breakdown of T cell tolerance to 
self-antigen and failure of peripheral regulatory mechanisms. In this thesis I studied different 
mechanisms controlling the development of CIDs. I investigated the initial events involved in 
the activation of self-reactive CD4
+ T cells which mediate the destruction of the thyroid in a 
mouse model of spontaneous thyroiditis. TAZ10 transgenic mice express a human T cell 
receptor (TCR) specific for a cryptic epitope of thyroid peroxidise (TPO) generated upon 
endogenous  processing  by  thyroid  epithelial  cells  (TEC),  and  a  naturally  occurring 
antagonistic epitope presented by dendritic cells (DC) upon exogenous processing of TPO. 
I have characterized the function of myeloid derived suppressor cells (MDSCs) in TAZ10 
mice.  MDSCs  accumulate  in  lymphoid  and  non-lymphoid  organs  of  TAZ10  mice  during 
acute phases of inflammation and their number decrease as inflammation is fading. Despite 
their strong inhibitory function on T cell function and proliferation, MDSCs fail to prevent 
the activation of self-reactive T cells. I showed that the manipulation of MDSCs generated 
DCs  that  efficiently  promoted  the  activation  of  T  cells  from  TAZ10  mice.  By  contrast, 
peripheral  T  cells  from  patients  with  rheumatoid  arthritis  (RA)  and  lupus  had  a  high 
proliferative activity compared to controls. Further analysis revealed that RA patients had 
reduced amounts of inhibitory MDSCs in peripheral blood.  
I showed that in TAZ10 mice TEC upregulate MHC class II molecules and present the 
cryptic epitope to TAZ10 T cells inducing their activation. I have demonstrated that DCs are 
responsible for the spreading of the TPO cryptic epitope from the thyroid to draining lymph-
nodes (DLN) resulting in the strong activation of transgenic T cells from TAZ10 mice. By 
adoptive transfer experiments, I showed that the activation of naive TAZ10 T cells occurs 
within  days  both  in  the  thyroid  and  draining  lymph-nodes  (DLN)  and  resulted  in  the 
destruction of the thyroid. Altogether, this work shows for the first time that in a model 
devoid of any environmental insults, the normal turnover of TEC is sufficient to induce the 
activation of self-reactive T cells and the development of AID. 
In this thesis, I have highlighted the potential role of tissue transglutaminse 2 (TG2) in the 
treatment of CIDs. TG2 contributes to the pathogenesis of celiac disease and I have showed 
that TG2 activity promotes inflammation in patients with cystic fibrosis (CF). Mutation of the 
cystic  fibrosis  transmembrane  regulator  gene  (CFTR)  in  CF  patients  is  associated  with 
increased TG2 expression and activity. In CF, TG2 promoted the crosslinking of the anti-
inflammatory  peroxisome  proliferator-activated  receptor  γ  (PPARγ)  into  perinuclear 
agresomes. The functional sequestration of PPARγ was leading to increased inflammation. 
The finding of this function of TG2 in CF was relevant in TAZ10 mice as in-vivo inhibition 
of TG2 downregulated common markers of inflammation. 3 
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1-1/  The  Immune  Response:  the  combination  of  Innate  and 
Adaptive Immune systems 
 
Evolving in an environment full of infectious agents, living creatures represent a rich 
habitat for the replication of bacteria, parasites and viruses. In order to keep these pathogens 
at bay, immune responses have been developed to provide a line of defense against infections 
and  any  events  altering  cellular  or  tissue  homeostasis.  These  systems  have  been  shaped 
throughout  evolution  when  pathogens  have  developed  complicated  ways  to  evade  these 
systems (Hartl et al. 2007; Finlay et al. 2006), and are composed of two major components 
that are characterized by their specificity to the infectious agents. Present in nearly all forms 
of life, the innate immune response displays a rapid first line of defence regardless of the 
infectious agent. In vertebrates, the immune system has evolved and an adaptive immune 
system has been developed that is not present in amphibians. The adaptive immune system is 
made by specialized cells, is pathogen-specific and carries immunological memory. 
 
1-1-1/ The innate immune response 
 
First lines of defense, epithelia are considered as physiological barriers preventing the 
intrusion of pathogens into adjacent tissues. Although the epithelium of the skin is the major 
mechanical barrier, epithelium of the trachea or the gut also constitute an important line of 
defence against pathogens (Elias. 2007; Holt et al. 2008). The second arm of this systems is 
constituted by the cells of the immune systems whose response are based on the recognition 
of pathogen associated molecular patterns (PAMPs) that are not expressed by the host. The 
innate  immune  system  therefore  has  no  memory  and  each  breach  is  treated  individually. 
Mechanisms have however been put in place so as to distinguish infectious parasites from 
parasites that have co-evolved with the host such as the flora of the digestive system (Lee et 
al. 2006; Paragraph 1-2-1-1/). Defects in cells of the innate systems have been linked with an 
inability to mount an effective immune response against common pathogens leading to severe 
chronic inflammation such as Crohn’s disease in the guts.  
  
Immunity developed by vertebrates has long been shown to be highly effective when 
considering infection by pathogens. If first physical barriers are broken by the pathogen, the 27 
 
innate immune system will be the next line of defence. This system is crucial in promoting 
and coordinating the activity of the acquired or adaptive immune system that has long been 
described as the “optimal solution” despite some evolutionary weaknesses (Hedrick. 2004).  
 
1-1-2/ The adaptive immune response 
 
The importance of the adaptive immune system is well established and has been largely 
demonstrated. The acquired immune response feeds back by amplifying the innate immune 
response; arming it with specific receptors and functions so as to efficiently promote the 
destruction  of  foreign  agents.  It  also  feeds  back  on  itself  through  cytokines  and  other 
mediators.  Numerous  studies  of  bacterial  infections  have  demonstrated  that  adaptive 
immunity is crucial in resolving infections and in establishing memory to the individual so 
that protection will be provided in case of a further infection. Moreover, individuals with an 
acquired immunodeficiency are more vulnerable to common parasitic or bacterial infections 
(Fischer. 2004). In this respect, re-establishment of the immune system in immunodeficient 
children (X-linked severe combined immunodeficiency / SCID-X1) by gene therapy has been 
highly  successful  in  restoring  the  immune  system  and  curing  the  affected  children 
(Cavazzana-Calvo et al. 2000; Gaspar et al. 2004).  
In order to efficiently mount a specific immune response, the adaptive immune system 
must recognised non-self antigens from pathogens whereas the recognition of self antigens by 
the host must be avoided so as to avoid any autoimmune diseases.  Although this system is 
highly efficient, to avoid autoimmunity or “horror autotoxicus” (Himmelweit F. Collected 
Papers of Paul Ehrlich, London: Pergamon; 1956–1960), where the immune system is prone 
to attack and destroy its host, it must made a clear distinction between what is self and non-
self. 
Following  this  concept  of  “horror  autotoxicus”,  Jerne  proposed  the  “natural  selection 
theory”  (Jerne.  1955)  where  he  suggested  that  there  was  a  pre-existing  repertoire  of 
antibodies from which antigen selects. In this respect, he suggested that antigen-antibody 
complexes  are  taken  into  cells  where  the  antibody  is  then  replicated.  Burnet  proposed  a 
totally different approach; “the clonal selection theory” (Burnet. 1961; Burnet. 1976) that was 
based on the differences between self and non-self. The immune system only mounts an 
immune response against non-self whereas avoiding any attack against self. His work was 
based on the analysis of experiments on skin-graft where an individual will reject a graft from 28 
 
another donor whereas accepting his own graft. However, this theory could not explain the 
emergence of autoimmune diseases; the same “horror autoxicus” where the immune system 
would not only recognise the non-self but also the self. To address this question, Matzinger 
proposed the “danger model” (Matzinger. 2001; Matzinger. 2002). In this theory, the immune 
system  triggers  an  immune  response  only  when  confronted  with  sources  of  “Danger” 
regardless of self / non-self discrimination. Thus an immune response  could be mounted 
against either self or non-self as long as a danger signals are present. 
 
The nature of the danger modulates dendritic cell function to polarise different T cell 
responses triggering the adaptive immune response (Germain et al. 2004). 
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1-2/  Dendritic  cells  at  the  interface  between  innate  and  adaptive 
immune systems 
 
Dendritic cells (DCs) have been described as playing a major role in immune responses as 
they  are  at  the  interface  between  innate  and  adaptive  immunity.  This  is  due  to  their 
pleiotropic activities as sensors of danger as well as their efficiency in promoting both B and 
T cell responses. In the resting state, dendritic cells are immature and patrol the tissues until 
activated by  danger signals. These signals have different origins  and  can result from the 
recognition  of  pathogens  by  cells  of  the  innate  immune  system  such  as  epithelial  cells, 
dendritic cells or macrophages. In this context, immature DCs capture and process antigens 
shed  in  the  microenvironment  (Banchereau  et  al.  2000).  Maturing  and  migrating  to  the 
nearest proximal lymphoid organs, mature DCs present antigens to lymphocytes that are then 
stimulated  and  able  to  mount  an  effective  adaptive  immune  response  (Rossi  et  al.  2005; 
Colonna et al. 2006). 
 
It is therefore clear that in the “danger model”, DCs play a crucial role between the quick 
innate immune response and the antigen specific adaptive immune system. 
 
1-2-1/ Phenotype and maturation of dendritic cells 
 
In an inflammatory context, professional antigen presenting cells such as DCs, uptake 
extracellular  components  (Figure  1-1).  Proteins  are  then  processed  following  either 
endogenous or exogenous pathways and resulting epitopes are presented in the context of 
Major Histocompatibility Molecule Complex (MHC) Class I or II molecules to be recognised 
by  CD8
+  and  CD4
+  T  cells  respectively;  this  is  known  as  the  “first  activation  signal” 
(Banchereau et al. 2000). The efficient activation of T cells will however depend on the 
ability  of  dendritic  cells  to  provide  costimulatory  signals  to  T  cells  via  costimulatory 
molecules  such  as  proteins  of  the  B7  family  constitutively  expressed  by  DCs  and  CD28 
expressed by T cells (Greenfield et al. 1998). This first costimulatory signal (or “second 
activation signal”) between DCs and T cells triggers the release of DCs derived cytokines and 
the engagement of other costimulatory molecules newly expressed by T cells and mDCs. This 30 
 
provides the “third activation signals” necessary to fully activate T cells (Anderton et al. 
2002).  
 
 
Figure 1-1: The “Danger model” and activation of dendritic cells 
Danger or stress signals released by bacteria or cells undergoing necrosis activate immature antigen presenting 
cells (APC). Immature APC highly efficient in uptaking extracellular elements but showing a low expression of 
both  MHC-II  and  costimulatory  molecules  differentiate  into  mature  APCs.  Mature  APCs  upregulate  the 
expression of MHC-II and costimulatory molecules enabling an efficient T cell activation. The maturation of 
APCs is characterized by a reduced endocytic activity. 
  
Danger  signals  are  of  various  natures.  These  signals  are  differently  recognised  by 
immature DCs (iDCs) bearing a wide range of specific receptors, thus allowing the immune 
response to be finely tuned. 
 
 
 
 
 
 31 
 
1-2-1-1/ Nature of the “Danger signals” 
 
Danger signals are represented by molecules from the pathogen or molecules shed by 
dying cells from the host. These molecules characterized by a specific molecular structure or 
PAMP are recognized by antigen presenting cells by pattern recognition receptors (PRR). 
Among these PRRs, Toll-like receptors (TLR) are the most studied as they induce different 
immunological responses depending on the nature of the PAMP detected (Beutler. 2004). The 
interaction between a specific TLR and its ligand triggers a signalling cascade involving the 
pro-inflammatory protein NF-κB and mitogen–activated protein kinases (MAPK). This first 
signalling is often followed by a late pro-inflammatory response involving proteins such as 
interferon-regulatory factors (IRF) (Akira et al. 2004; Trinchieri et al. 2007). This results in 
the production of pro-inflammatory proteins and cytokines that are critical for the generation 
of the appropriate immune response against invading pathogens. 
 
To date, up to 13 TLR have been identified and can be present at the cell-surface or inside 
the cells (Table 1-1). TLR5 recognizes flagellin, TLR3 binds double stranded RNA while 
TLR7 recognizes single strand RNA and TLR9 binds viral and bacterial DNA that are rich in 
unmethylated CpG motifs. TLR ligands also include lipopolysaccharides (LPS), the main 
lipid constituting bacterial walls. LPS has been shown to induce the maturation of DCs via 
the ligation to Toll-like receptor 4 (Spörri et al. 2005).  
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Receptors  Ligands 
TLR1 / TLR2 
Lipoproteins: e.g. OspA 
Triacylated Lipopeptides 
TLR2 
Bacterial lipoproteins 
Glycosylphosphatidyl-inositol 
Glycolipids 
Porins 
TLR3 
Double-stranded RNA 
Poly I:C 
mRNA/tRNA 
TLR4 
Lipopolysaccharides  
Monophosphoryl lipid A 
Flavolipin 
Glycoinositolphospholipids 
TLR6 / TLR2 
Mycoplasmal Macrophage-activating lipopeptide 
Diacetylated Lipopeptide 
Soluble Tuberculosis Factor 
TLR5  Flagellin 
TLR11  Profilin 
TLR7 
Single-stranded RNA 
Polyuridylic acid 
TLR8 
Single-stranded RNA 
Polyuridylic acid 
TLR9  Unmethylated CpG DNA 
Table 1-1: Members of the Toll-Like Receptor (TLR) family bind a wide range of ligands 
Description of the ligands recognized by the different members of the toll-like receptor family. Adapted from 
www.nature.com/nri/focus.tlr and (Akira et al. 2004). 
 
It is now clear from numerous studies that the nature of the LPS allows DCs to finely tune 
the immune response (Netea et al. 2002). As a matter of fact, LPS molecules from different 
bacteria have been shown to bind TLR molecules with different affinity according to the 
shape of the Lipid A (from cylindrical to conical), a major component of LPS molecules. 
Indeed, LPS from Rhodobacter Sphaeroides (cylindrical Lipid A) can engage both TLR4 and 
TLR2, LPS from Porphytomonas Gingivalis (conical Lipid A with a small base) binds TLR2 
while Neisseria Meningitidis LPS (conical Lipid A with a large base) binds either TLR4 or 
TLR2 / TLR1 (Figure 1-2).   
The response to danger signals must however be controlled to provide immune tolerance 
to commensal bacteria in the airways or the guts. Indeed, it is estimated that up to 1x10
4 
bacteria  families  are  present  in  the  human  colon.  A  defective  or  inappropriate  immune 33 
 
response  to  commensal  bacteria  of  the  gut  is  involved  in  numerous  pathologies  such  as 
Crohn’s disease or ulcerative colitis (McGukin et al. 2009). A study (Lee et al. 2006) has 
recently shown how the immune response to commensal bacteria through TLR9 depends on 
the polarity of intestinal epithelial cells. Activation of TLR9 expressed  at the basolateral 
surface of intestinal epithelial cells leads to the activation of the NF-κB pro-inflammatory 
pathway.  By  contrast,  stimulation  of  TLR9  present  at  the  apical  membrane  leads  to  the 
ubiquitination  of  Iκ-Bα  that  prevents  NF-κB  from  being  activated.  Interestingly,  the 
stimulation of TLR9 at the apical membrane prevented any subsequent TLR stimulation at 
the basolateral membrane of gut epithelial cells. Therefore, the configuration of the mucosa 
(and  ultimately  of  epithelial  cells)  modulate  TLR  responses  to  control  tolerance  and 
inflammation to commensal and non-commensal pathogens. 
 
Recognition by TLRs must also allow some degree of flexibility to adapt to strategies 
developed by pathogens avoiding recognition by the immune system. We previously exposed 
that the shape of Lipid A from different LPS influences its ability to bind different TLRs 
(Figure 1-2). In a strategy to adapt to the environment, environmental changes and to escape 
the innate immune system, bacteria can acquire the capacity to modulate the structure of LPS 
by promoting a different degree of acetylation of the Lipid A recognized by TLR molecules. 
Indeed, Lipid A composing LPS from Pseudomonas Aeruginosa is hexa-acetylated in cystic 
fibrosis and penta-acetylated in chronic lung bronchiectasis or conventional bacterial culture. 
Interestingly, penta-acetylated LPS binding TLR4 does not lead to the generation of a strong 
and robust inflammatory response which is observed with hexa-acetylated LPS from patients 
with  cystic  fibrosis  (Hajjar  et  al.  2002).  This  difference  of  responses  to  LPS  from 
Pseudomonas Aeruginosa in cystic fibrosis and lung bronchiectasis depends on an 82 amino-
acid region of human TLR4; murine TLR4 molecules being unable to distinguish between the 
two different forms of LPS. Thus, human TLR4 is capable of recognizing specifically the 
degree  of  bacterial  adaptation  in  the  microenvironment  and  to  adapt  the  strength  of  the 
immune response to bacterial infections. 
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Figure  1-2: Binding  activities  of  LPS  from  different  bacterial  strains  induces  different  inflammatory 
responses 
The nature and morphology of LPS and more specifically the shape of the Lipid A dictates its ability to bind 
different TLRs, thus dictating the nature of the immune response generated. LPS from Neisseria Meningitidis 
(conical Lipid A) binds TLR1/TLR2 and TLR4 molecules while LPS from Escherichia Coli (conical Lipid A) 
binds only TLR4. LPS from Porphytomonas Gingivalis is recognized by TLR2 / TLR1. LPS from Rhodobacter 
Sphaeroides has a cylindrical Lipid A and can therefore bind either TLR4 or TLR2. Figure is adapted from 
(Netea et al. 2002). 
 
In the “Danger Model” proposed by Matzinger (Matzinger. 2001; Matzinger. 2002), the 
nature of the danger is sensed more than the self or non-self nature of the antigenic peptide. 
Indeed, although components of foreign infectious pathogens such as LPS or flagellin can 
trigger an immune response, cells or tissues from the host can be stressed and release “danger 
signals”.  By  contrast  to  apoptosis,  necrosis  leads  to  the  release  of  endogenous  Hsp70 
(Vabulas et al. 2002) and Hsp60 (Vabulas et al. 2001) into the microenvironment. Hsp60 and 
Hsp70 trigger an immune response through TLR4 and can therefore be considered as danger 
signals.   
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1-2-1-2/ Activation of the adaptive immune response by dendritic cells 
 
In presence of “danger”, iDCs undergo multiple functional and morphological changes 
and start to go through maturation steps to become mature DCs (mDCs). mDCs upregulate 
the  expression  of  MHC-II  as  well  as  costimulatory  molecules  necessary  for  the  full 
subsequent activation of T cells. Once activated, mDCs migrate to lymphoid tissues such as 
the lymph-nodes draining the tissue affected by inflammation, where they encounter T and B 
lymphocytes (Banchereau et al. 2000) (Figure 1-3).  
 
 
Figure 1-3: Cooperation of the Innate and Adaptive immune systems in response to danger signals 
Upon stimulation by danger signals, iDCs uptake antigens present in the microenvironment. Maturing iDCs 
migrate  to  the  nearest  lymphoid  organ.  In  the  lymph-nodes,  fully  competent  mature  DCs  (mDCs)  present 
antigens to B cells, CD4
+ and CD8
+ T cells. Activated lymphocytes then migrate to the site of inflammation 
where they coordinate with cells of the innate immune system to mount an effective immune response. Figure is 
adapted from (Banchereau et al. 2000). NK: Natural killer cells; MØ: macrophages. 
 
Naïve T cells circulating in the blood and lymph-nodes make contact with mDCs within 
lymphoid  organs.  As  soon  as  they  recognise  the  cognate  peptide  presented  by  MHC 
molecules, naive T cells will differentiate into specific T cell subsets depending on the nature 
of the peptide and the cytokine environment.  
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T cell activation by mDCs requires different signals. Activation signal 1 is represented by 
the interaction between the T cell receptor (TCR) and the peptide-MHC molecule complex 
(Anderton et al. 2002). Alone, this signal leads to T cell anergy unless full T cell activation is 
achieved via “Activation signals 2 and 3”. These latest signals are the production of DC- and 
T cell-derived cytokines (IL-6 secreted by mDCs, and IL-2 secreted by T cells etc.) and the 
engagement of costimulatory molecules (CD80/86 on mDCs interacting with CD28 on T 
cells) between T cells and mDCs (Anderton et al. 2002). Resulting T cell activation has been 
largely described and depends on the length and frequency of contact between mDCs and 
naive T cells. Stable and prolonged interactions between mDCs and T cells lead to T cell 
activation and immunity. However, in tolerogenic conditions and despite early activation and 
proliferation, naïve T cells will remain motile, thus establishing multiple short contacts with 
mDCs (Hugues et al. 2004). 
 
It is now established that not all mature DCs are able to efficiently promote a full T cell 
response involving proliferation and acquisition of effector functions. The production of IL-
10 by many tumours has been shown to have a detrimental effect on the ability of mDCs to 
activate T cells (Morel et al. 1997). Indeed, IL-10 can for example lead to the downregulation 
of costimulatory molecules by mDCs that leads to T cell anergy upon mDC/T cell encounter 
(Steinbrink  et  al.  2002).  iDCs  matured  with  bystander  inflammatory  molecules  (such  as 
TNFα  or  IFNα)  resulting  from  an  infection  are  not  fully  licenced  to  promote  the 
differentiation and acquisition of effector functions of CD4
+ T cells. However, iDCs directly 
stimulated with pathogen products via TLR allows mDCs to induce the proliferation and 
differentiation  of  CD4
+  T  cells  that  acquire  the  effector  functions  required  to  mount  an 
efficient immune response (Spörri et al. 2005; Heath et al, 2005).  
 
Activated T and B cells migrate towards the site of inflammation where they cooperate 
with cells of the innate system (natural killer cells, macrophages…) and dendritic cells to get 
rid of the source of danger (Banchereau et al. 2000). Once this goal is achieved, most of the T 
cells undergo apoptosis whereas a small proportion becomes memory T cells. Memory cells 
present  within  the  blood-stream  and  lymphoid  organs  will  trigger  an  immediate  immune 
response once in the presence of the cognate peptide (Lanzavecchia et al. 2005).  
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1-2-2/ Antigen processing and presentation  
 
The  efficient  activation  of  antigen-specific  CD8
+  and  CD4
+  T  cells  requires  first  the 
recognition by T cells of the appropriate peptide presented in the context of MHC-I and 
MHC-II molecules respectively.  
 
1-2-2-1/  Endogenous  pathway  of  antigen  processing  and  presentation  onto  MHC-I 
molecules 
 
All  nucleated  cells  present  their  pool  of  proteins  or  foreign  proteins  (from  viral  or 
bacterial  origin)  on  MHC-I  molecules.  Proteins  are  ubiquitinylated  by  three  different 
enzymes  (U1;  U2  and  U3  ubiquitin  ligases)  to  be  recognized  by  the  proteasome  for 
degradation.  9-mer  peptides  resulting  from  the  degradation  are  transported  into  the 
endoplasmic  reticulum  (ER)  by  chaperone  membrane  proteins  known  as  Transporter 
Associated Peptide 1 and 2 (TAP1 and TAP2). In order to bind MHC-I molecules, these 
peptides are further trimmed down to 8 amino-acids in the ER by different enzymes such as 
ERAP (ER aminopeptidase) or Bip (Saveanu et al. 2002; Elliott et al. 2005).  
 
MHC-I molecules are composed of a heavy-chain formed of 3 subunits (α1, α2 and α3), 
and the β2-microglubulin subunit. The binding of a specific antigen into the groove of MHC-
I molecules (formed by the α1 and α2 subunits of the heavy-chain) is controlled and occurs in 
different stages. Once synthesized, the heavy-chain is associated with chaperones such as 
calnexin and ERp57 (a thiol oxido-reductase) and the β2-microglobulin (β2m) subunit binds 
the  heavy-chain.  At  this  stage,  the  calnexin-ERp57  complex  is  replaced  by  calreticulin-
ERp57 until a peptide is loaded onto MHC-I molecule (Saveanu et al. 2002; Elliott et al. 
2005). The association of TAP proteins (Transporter associated with Antigen Processing and 
has two subunits: TAP1 and TAP2), the different chaperones and the empty MHC-I molecule 
forms  the  Peptide  Loading  Complex  (PLC)  that  allows  the  binding  of  peptides  with  the 
correct affinity onto MHC-I molecules. MHC-I molecules stabilised by the bound peptide are 
then freed from the different protein chaperones and migrate to the cell-surface to prime 
MHC-I restricted CD8
+ T cells (Figure 1-4).  38 
 
 
Figure 1-4: Processing of endogenous proteins and presentation in the context of MHC-I molecules 
Nascent α chain of the MHC molecule bound to the β2-microglobulin subunit (β2m) associates with different 
chaperones to form the Peptide Loading Complex (PLC). These chaperones include ERp57, calreticulin and the 
Transporter Associated with Antigen Processing (TAP1 and TAP2). Misfolded proteins or proteins at the end of 
their “life” are ubiquitinated and degraded by the proteasome into peptides. These peptides are transporter into 
the endoplamic reticulum via the TAP proteins and loaded onto MHC-I molecules. The stabilized MHC:peptide 
complex then migrates to the cell-surface to be recognized by CD8
+ T cells.  
 
During synthesis, nascent proteins are associated with chaperones and undergo complex 
folding  to  acquire  the  tridimensional  structure  required  to  exert  their  function(s).  Protein 
folding is an active process that requires chaperones such Hsp70, Hsp40 and Hsp90 (Hartl et 
al. 2002). While this system has long been considered to be efficient, recent studies have 
highlighted that this is not the case. Cells are opting for high speed protein synthesis thus 
increasing the probability to produce large amounts of misfolded proteins. These defective 
ribosomal products (DRiPs) are then ubiquitinated and degraded by the proteasome to avoid 
the accumulation of misfolded proteins that could potentially be toxic to the cells. Indeed, the 
accumulation of misfolded proteins in the ER leads to cellular stress and unfolded protein 
response (UPR). UPR is associated with numerous diseases such as prion or Alzheimer’s 
disease  (Kim  et  al.  2009).  A  common  feature  to  several  of  these  diseases  and  mainly 
neurodegenerative diseases is the accumulation of misfolded proteins into inclusions bodies 
such  as  aggresomes  (Kopito.  2000;  Garcia-Mata  et  al.  2002;  Kawaguchi  et  al  2003; 
Kaganovitch et al. 2008). 
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After folding and quality control has been performed by chaperone proteins, it has been 
estimated  that  for  one  protein,  about  30%  are  DRiPs  that  are  targeted  to  the  ubiquitin-
proteasome degradation pathway along with fully folded proteins at the end of their life-span 
(Schubert et al. 2000). These DRiPs have got important immunological functions. Indeed, 
peptides generated from the degradation of DRiPs by the proteasome are the major source of 
peptides  for  TAP  and  MHC-I  binding.  This  mechanism  allows  the  quick  presentation  of 
peptides from pathogens and mainly viruses to patrolling CD8
+ T cells for rapid recognition 
and clearance of infected cells (Schubert et al. 2000; Reits et al. 2000). This system however 
is not perfect and viruses have developed strategies to escape the immune system by altering 
the presentation of antigens in the context of MHC-I and MHC-II molecules (Ploegh. 1998; 
Hewitt et al. 2003). 
 
1-2-2-2/  Exogenous  pathway  of  antigen  processing  and  presentation  onto  MHC-II 
molecules 
 
Although the MHC-I processing pathway is ubiquitous in nucleated cells, professional 
APCs  such  as  dendritic  cells,  macrophages  and  B  cells  constitutively  express  MHC-II 
molecules. However, the expression of MHC-II is not restricted to professional APCs as 
other cells such  as epithelial cells can be induced to express these molecules under pro-
inflammatory conditions such as exposure to IFNγ. These non-professional APCs can present 
self-antigens to self-reactive T cells that have not been eliminated during the shaping of the 
TCR repertoire in the thymus: central tolerance (Kingston et al. 1989;  Suda et  al. 1995; 
Quaratino et al. 1996; Chan et al. 2006). Central tolerance will be discussed Paragraph 1-4-1/. 
Exogenous proteins are taken-up by endocytosis and digested in the lysosomes by acid-
dependent proteases such as cathepsins (Watts. 2004; Robinson et al. 2002). As for MHC-I 
molecules, MHC-II molecules are synthesised in the ER and are dimeric consisting of α and 
β chains. Transported into the lysosomes and MHC-II rich compartments, MHC-II molecules 
are associated with the invariant chain (Ii) (Stumptner et al. 1997). The Ii chain is digested in 
the  lysosomal  compartment  by  the  pH  sensitive  cathepsin-S  protease.  A  small  fragment 
called CLIP (Class-II Invariant chain Peptide) remains in the groove of MHC-II molecules. 
The CLIP peptide is then removed  from the peptide-binding  groove by  the MHC-II like 
molecule HLA-DM (H2-M in mice) and replaced with high affinity peptides (Gautam et al. 
1995; Thayer et al. 1999). The MHC:peptide complexes formed are then stable, dissociate 40 
 
from HLA-DM molecules and are transported to the cell surface for the priming of CD4
+ T 
cells (Watts. 2004; Robinson et al. 2002) (Figure 1-5). 
 
 
 
Figure 1-5: Processing of exogenous proteins and presentation in the context of MHC-II molecules 
MHC-II molecules are dimeric and formed of two chains (α and β chains) synthesized in the endoplasmic 
reticulum (ER). Folded MHC-II molecules are transported to the trans-golgi network (TGN) and then to the 
lysosomes and MHC-II rich compartments (MIIC). The invariant chain (Ii) is digested and a CLIP peptide 
remains  in  the  peptide-binding  groove  of  MHC-II  molecules  (cleft  formed  by  the  α1  and  α2  subunits). 
Competition with higher affinity peptides for the groove of MHC-II molecules leads to the binding of high 
affinity peptides. The MHC-II:peptide complex is then transported to the plasma membrane for the priming of 
CD4
+ T cells.  
 
By binding MHC-II molecules, Ii has the ability to regulate and optimize the loading of 
peptides through the interaction between CLIP and the peptide-binding groove of MHC-II 
molecules. Some MHC-II alleles have a low affinity for CLIP (I-A
k, I-A
d, I-E
k in mice) and 
therefore are less dependent on H-2M for the generation of the MHC-II:peptide repertoire. By 
contrast, some MHC-II alleles have a high affinity for the CLIP peptide (I-A
b in mice) and 
rely on HLA-DM to exchange CLIP with MHC-II peptides (Gautam et al. 1995). It has been 
suggested that a decreased affinity for CLIP facilitates the loading of MHC-II peptide thus 
escaping the editing process mediated by H2-M (Nanda et al. 2000). This would lead to the 
generation of a larger repertoire of MHC-II peptide presented to T cells and therefore would 
increase the probability to develop autoimmune diseases (Hitzel et al. 1996; Nanda et al. 
2000; Honey et al. 2004). 
 41 
 
Ii also plays a critical role in the transport of newly synthesized MHC-II molecules from 
the  ER  to  lysosomes  /  MHC-II  rich  compartments  (MIIC).  Indeed,  the  inhibition  of  Ii’s 
phosphorylation  reduces  the  trafficking  of  MHC-II  molecules  to  antigen-processing 
compartments  (Anderson  et  al.  1999).  Interestingly,  a  recent  study  has  highlighted  the 
important role of Ii in the regulation of the motility of mDCs. While the movements of mDCs 
alternate between episodes of high and low motility, Ii deficient DCs have fast and uniform 
movements (Faure-Andre et al. 2008). 
 
The  role  of  Ii  in  the  presentation  of  peptides  in  the  context  of  MHC-II  molecules  is 
therefore crucial as it is involved in the generation of the peptide repertoire presented to 
CD4
+ T cells. Ii also regulates the trafficking of newly synthesized MHC-II molecules from 
the  ER  to  the  antigen-processing  compartments.  Through  its  actions,  Ii  couples  antigen 
processing with cell motility thus enhancing DC’s functions during inflammation. 
 
1-2-2-3/  Cross-presentation  of  endogenous  antigens  onto  MHC-II  molecules  and  of 
exogenous antigens onto MHC-I molecules 
 
Common pathways of antigen-presentation consist in the presentation of antigens from 
exogenous origin onto MHC-II molecules and antigens from endogenous origin onto MHC-I 
molecules.  
 
Some professional APCs are able to perform the phenomenon of cross-presentation, in 
which  an  exogenous  antigen  is  loaded  onto  MHC-I  molecules  (Kurts  et  al.  1996). 
Endocytosed antigens can be directly loaded onto recycling MHC-I molecules. Endocytosed 
proteins can also be degraded in the lysosomes and exported into the cytoplasm via some 
transporters such as Sec61 (Lilley et al. 2004; Di Pucchio et al. 2008). These antigens can be 
further degraded by the proteasome or chaperones within the ER. Eventual binding of these 
epitopes onto MHC-I molecules allows the presentation of peptides from exogenous origin to 
CD8
+ T cells (Kurts et al. 1996; Burgdorf et al. 2008). DCs bearing the mannose receptor 
DEC-205 or CD8α have been shown to be efficient at cross-priming (Dudziak et al. 2007).  
 
Although endogenous proteins are presented in the context of MHC-I molecules, cross-
presentation onto MHC-II molecules can naturally occur. Cytosolic proteins are degraded in 
the cytosol before being translocated into the lysosome for loading onto MHC-II molecules 42 
 
(Dani et al. 2004). The cross-presentation of endogenous has an important immunological 
role.  Indeed,  viral  proteins  can  be  presented  onto  MHC-II  molecules  thus  promoting  an 
efficient recognition by the immune system and the rapid clearance of infected cells (Wan et 
al. 2005).  
 
A study has recently highlighted the ability of DCs to cross-present exogenous antigens to 
T cells several days after receptor-mediated uptake of the Ag. DCs were storing the antigen in 
early endosomes for up to 3 days thus allowing its presentation to CD4
+ and CD8
+ T cells 
(van Montfoort et al. 2009). 
 
1-3/  Lineage  decision  of  T  cells:  a  phenomenon  orchestrated  by 
dendritic cells  
 
The  generation  of  an  appropriate  T  cell  response  relies  on  the  ability  of  a  TCR  to 
recognize a specific antigen presented by APCs in the context of MHC molecules. This first 
signal alone leads to T cell anergy and costimulatory signals are necessary to initiate an 
efficient T cell response.  
 
1-3-1/ T cell priming: TCR recognizes MHC:peptide Complex 
 
T cells recognize the cognate peptide in the peptide-binding groove of MHC molecule 
through  the  TCR.  This  interaction  known  as  activation  signal  1  also  dictates  the  fate  of 
thymocytes during the selection occurring in the thymus: central tolerance (mechanisms of 
selection  in  central  tolerance  will  be  discussed  Paragraph  1-4-1/).  Indeed  thymocyte 
progenitors  arriving  at  the  thymus  from  the  bone-marrow  are  selected  on  their  ability  to 
recognise  self-MHC  molecules  but  not  self-antigens.  This  prevents  the  survival  of  self-
reactive T cells and the occurence of autoimmune diseases.  
 
The interaction of a TCR with a MHC:peptide complex depends on the overall avidity of 
the complex MHC:peptide/TCR. This avidity relies on the affinity of the MHC molecule for 
the specific antigen, the affinity of the TCR for a specific MHC:peptide complex but also on 
the concentration of the antigen (Anderton et al. 2002). By definition, the avidity of the TCR 43 
 
for a specific peptide/MHC complex is the concentration of peptide leading to the activation 
of 50% of the pool of antigen-specific T cells. This in turn defines a threshold of activation 
(van den Boorn et al. 2006). The strength of the signalling resulting from this interaction 
dictates  the  fate  of  T  cells  towards  anergy  or  activation.  The  level  of  expression  of 
MHC:peptide  and  TCR  by  APCs  and  T  cells  respectively  is  therefore  a  key  element  in 
inducing a T cell response (Figure 1-6).  
 
 
Figure 1-6: Elements dictating T cell avidity and activation 
The interaction between a T cell receptor (TCR) and a peptide bound to an MHC molecule presented by antigen 
presenting cells (APC) depends on numerous factors. The avidity of the complex MHC:peptide/TCR is defined 
by the affinity between a peptide and the MHC molecule, the affinity of the TCR for the MHC:peptide complex 
and the concentration of antigen (Ag) (Red-filled area). The first activation signal based on the recognition of 
the MHC:peptide complex by the TCR depends on the avidity of the MHC:peptide/TCR complex, the level of 
expression of MHC molecules, TCR and co-receptor (CD4 and CD8α) but also the strength of the signal after T 
cell engagement (red rectangle). A successful T cell activation will require the engagement of costimulatory 
molecules and the presence of cytokines secreted by DCs and T cells (blue rectangle). 
 
Peptides bind MHC through anchoring points in the peptide-binding grooves formed by 
the α1 and α2 subunits of MHC-I molecules and α1 and β1 subunits of MHC-II molecules. 
The association constant (Ka) or off-rate binding of the MHC-peptide complex depends on 
the strength and affinity of this interaction. Low affinity peptides have a low Ka or fast off-44 
 
rate binding while high affinity peptides interact more strongly with MHC molecules and 
have a high Ka or low off-rate binding. The definition of anchor amino-acid is at the origin of 
predilection techniques assessing the ability of a peptide to bind a specific MHC molecule 
(Young et al. 1995).  
 
Several studies have also highlighted the importance of manipulating peptides via the 
modification of some key anchor amino-acids to promote a T cell response. This technique 
has been developed to improve the affinity of self- and tumour specific- peptides for MHC 
molecules and therefore their immunogenicity in therapeutic strategies in cancer (Vertuani et 
al.  2004;  Borbulevych  et  al.  2005).  The  generation  of  altered-peptide  ligands  (APL)  that 
naturally  occurs  in-vivo  has  been  shown  to  be  important  in  the  generation  of  immune 
responses  both  in  cancer  and  autoimmune  diseases.  Indeed,  peptides  presenting  post-
translational  modifications  such  as  phosphorylation    (Mohammed  et  al.  2008)  or 
glycosylation  (Wood  et  al.  1998)  can  present  increased  affinity  to  MHC  molecules  and 
contribute to the peptide repertoire binding a specific MHC molecule (Engelhard et al. 2006). 
This will be discussed Paragraph 1-5-2/. 
 
A single TCR has therefore the ability to bind different epitopes with different strength (T 
cell degeneracy / cross-reactivity) (Kersh et al. 1996; Anderson et al. 2000). This highlight 
that the nature of the processed peptide, rather than the type of APC, determines the outcome 
of T cell activation: anergy or proliferation. 
 
1-3-2/ Different pathways for the generation of T cell response 
 
According to the nature of the pathogen or inflammation, DCs have the ability to polarize 
naïve CD4
+ T cells into different CD4
+ T effector cells. This phenomenon depends on the 
cytokines  produced  by  DCs  in  the  context  of  inflammation  and  induced  after  TCR 
engagement. 
 45 
 
 
Figure 1-7: DCs polarize the response of CD4
+ T cell in response to different TLR ligands 
The binding of different TLR ligands by dendritic cells shape the CD4
+ T cell response.  
* DCs exposed to TLR4 ligands (such as LPS from Escherichia Coli) release IL-12 and IL-18 that induce the 
generation of a Th1 response. Th1 cells release of TNFα and IFNγ.  
* DCs activated through TLR2 by LPS from Porphytomonas gingivalis produce IL-10 and IL-13 that favor the 
generation of a Th2 response and the subsequent release of IL-4 and IL-5 and IL-13.  
* Stimulation of DCs with the TLR2 ligand zymosan leads to the secretion of IL-10 and retinoic-acid that 
support the generation of regulatory T cells (Treg). Treg inhibit T cell response via the release of IL-10 and 
TGFβ.  
 
Different LPS bind different TLR on APCs (Paragraph 1-2-1-1/). One principal aspect of 
these receptors is the ability to polarize the CD4
+ T cell response into a Th1-, a Th2- or a 
Treg-like  response  (Netea  et  al.  2002;  Germain.  2004).  Exposure  of  DCs  to  LPS  from 
Escherichia Coli results in the binding of TLR4 and the subsequent release of IL-12 and IL-
18 by DCs (Banchereau et al. 2000). This enhances an  IFNγ-like Th1 response that will 
ultimately leads to the stimulation of cytotoxic T lymphocytes (CTLs) and macrophages. LPS 
from Porphytomonas Gingivalis will bind mainly to TLR2 and induces the release of IL-10 
and IL-13 by DCs. This promotes a Th2-like response that will favour the action of B cells 
(Agrawal et al. 2003; Dillon et al. 2004). By contrast, stimulation of DCs with the TLR2 
ligand  Zymosan  leads  to  the  production  of  IL-10  and  retinoic-acid  that  promote  the 
generation of regulatory T cells (Treg). Treg inhibit T cell response through the secretion of 
IL-10 and TGFβ (Manicassamy et al. 2009) (Figure 1-7). 
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1-3-2-1/ The different subsets of helper T cells – Plasticity of the T cell response 
 
The  hallmark  of  adpative  immunity  is  the  existence  of  lymphocytes  that  induce  and 
regulate immune responses. Activated in a specific cytokine environment in which APCs 
such as DCs have a crucial role, naïve CD4
+ T cells proliferate and differentiate into different 
subsets such as Th1, Th2, regulatory T cells or the newly described Th17 cells (Figure 1-8): 
 
•  Th1 cells are induced by exposure to cytokines such as IL-2, IL-12, IFNγ, IL-1β 
and  TNFα.  In  this  cytokine  environment,  naïve  CD4
+  T  cells  express  the 
transcription-factors STAT-1 and T-BET (Szabo et al. 2000; Afkarian et al. 2002). 
Further stimulation with DC-derived IL-12 and IL-18 induces the expression of 
the transcription-factor STAT4. At this point, CD4
+ T cells are mature Th1 cells. 
Th1 cells secrete different cytokines such as IL-2, very low amounts of IL-10, 
members of the TNF family and high amounts of IFNγ. Th1 cells are generally 
generated in response to intracellular infections such as mycobacteria (Murphy et 
al. 2002). 
 
•  In an environment rich in IL-4, IL-10, IL-5, IL-13 and GM-CSF, naive CD4
+ T 
cells  upregulate  the  expression  of  STAT6  and  GATA3  transcription-factors 
skewing their phenotype toward Th2 (Farrar et al. 2001; Zhu et al. 2001). Th2 
cells secrete diverse cytokines such as IL-4, IL-5, IL-13 and IL-10 (low amounts) 
and  stimulate  the  production  of  IgE  by  B  cells  to  promote  the  clearance  of 
extracellular pathogens. Th2 cells have a preponderant role in mucosal barriers 
(trachea, gut) and promote the functions of mast-cells and eosinophils (Murphy et 
al. 2002). 
 
•  Recently a newly recognised subset of CD4
+ T cells has been described. These 
cells  secrete  IL-17A  and  have  a  major  role  in  autoimmune  diseases.  Upon 
stimulation  with  IL-6  (or  IL-21)  and  TGFβ,  naïve  CD4
+  T  cells  express  the 
transcription-factors STAT-1 and RORγT (Manel et al. 2008). This first phase 
allows for the secretion of IL-21 by maturing Th17 cells and the full expression of 
the IL-21 receptor (Korn et al. 2007; Zhou et al. 2007). IL-21 is required for the 
amplification  of  the  Th17  response  in  an  autocrine/paracrine  manner.  This 
amplification leads to the expression of a functional IL-23 receptor on Th17 T 47 
 
cells. IL-23 secreted by APCs promotes the full maturation and stabilization of 
Th17 cells that secrete IL-17A, IL-17F, IL-22 and IL-10 (Volpe et al. 2008). The 
generation of Th17 is altered by IL-25, IL-27, IL-4 and IFNγ (Kleinschek et al. 
2007). 
 
•  Similar to Th17 cells, inducible Foxp3
+ Treg require TGFβ to differentiate while 
IL-6 inhibits their generation (Betelli et al. 2006). IL-6 plays an important role in a 
TGFβ rich environment as it promotes the generation of pathogenic Th17 cells 
and  inhibits  the  development  of  Treg.  CD4
+  CD25
+  Foxp3
+  Treg  are  at  the 
forefront of the mechanisms of peripheral tolerance and a deficiency of Tregs has 
been associated with the development of AID (Sakaguchi et al. 1995; Asano et al. 
1996; Suri-Payer et al. 1998). Tregs inhibit T cell proliferation and function via 
different mechanisms (Brandenburg et al. 2008). They exert their function via the 
neutralization of cytokines such as IL-2 (Pandiyan et al. 2007) and the release of 
IL-10 and TGFβ. By aggregating on DCs, Treg also alter the function of DCs by 
reducing the expression of costimulatory molecules and cytokines (Onishi et al. 
2008). While Treg are involved in cancer and AID, they play an important role in 
other pathologies such as the recovery process following a stroke (Liesz et al. 
2009). 
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Figure 1-8: Plasticity of the T cell response mediated by dendritic cells and the cytokine environment 
Dendritic cells (DC) induce the development of various CD4
+ T cell subsets such as Th1, Th2, Th17 or Tregs. 
TGFβ favors the generation of Foxp3
+ Tregs that inhibit T cell response via the release of IL-10 and TGFβ. Il-6 
blocks the generation of Tregs. Acting in synergy with TGFβ, IL-6 promotes the generation of IL-17A/F and IL-
22 secreting RORγT
+ Th17 T cells. While IL-27 inhibits the generation of Th17 T cells, its association with 
TGFβ leads to the generation of suppressive Tr1 T cells characterized by the production of IL-10 and IFNγ. In 
an environment rich in IL-2, IL-12 and IFNγ, naïve T cells express the transcription factors STAT1 and T-BET 
and differentiate into Th1 T cells secreting IFNγ, IL-2 and TNFα. Upon IL-4, naïve T cells express STAT6 and 
GATA3 and acquire a Th2 phenotype. Th2 T cells release different cytokines such as IL-4, IL-5, IL-10 and IL-
13. 
 
Upon stimulation with TGFβ and IL-4, Th2 T cells skew their phenotype and secrete IL-9 and IL-10 (Th9 T 
cells). Th17 T cells adjust their phenotype according to the inflammatory nature of the microenvironment. If 
Th17 cells are still in an environment containing IL-6 and TGFβ, Th17 cells release less IL-10 and become 
more and more pathogenic. On the other hand, absence of TGFβ and IL-6 will skew the phenotype of Th17 
cells into Th17 cells producing more IL-10, thus presenting a more regulatory and a less pathogenic phenotype. 
In the presence of IL-6, IL-1β, and strong TRC signals delivered by APCs, TGFβ secreting Tregs express the 
Th17 cytokine IL-17. Foxp3
+ IL17
+ Tregs express IL-17 in this cytokine environment and contribute to the 
inflammatory response. 
 
In  green  are  represented  the  cytokines  secreted  by  the  specific  Th  subsets.  In  red  are  represented  the 
transcription factors and in black the cytokines promoting or preventing the generation / differentiation of the 
different T cell subsets. 
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The ability of DCs to promote the differentiation of CD4
+ T cells into different T cell 
subsets must allow a certain degree of plasticity to finely tune the T cell response to the 
inflammation over time (Figure 1-8).  
 
-  The first evidence on the plasticity of the adaptive immune response is the ability for 
Th1 and Th2 cells to interconvert. This phenomenon is antigen-specific and depends 
on the expression of costimulatory molecules, ICAM-1 and the level of IL-12, IFNγ 
and IL-12 present in the microenvironment. However, this reversibility is lost in fully 
differentiated Th1 and Th2 cells (Murphy et al. 1996; Radhakrishnan et al. 2007).  
 
-  The  role  of  Th17  in  AID  and  host-defence  against  pathogens  has  been  largely 
described (Bettelli et al. 2008). The combinations of TGFβ / IL-6 and TGFβ / IL-21 
promote  the  generation  of  RORγT
+  Th17  T  cells.  In  a  situation  of  continuous 
inflammation, a prolonged exposure of Th17 to TGFβ and IL-6 (associated or not 
with IL-23) abrogates their pathogenic functions while increasing the amounts of IL-
10 they secrete. IL-10 producing Th17 T cells are less pathogenic and display a more 
regulatory phenotype associated with the dampening of the immune response. In the 
absence of IL-6 and TGFβ, stimulation of Th17 with IL-23 preserves the secretion of 
IL-17. IL-6 and TGFβ have therefore a dual role as they promote the differentiation 
of Th17 while restraining their pathogenic functions (McGeachy et al. 2007). 
 
-  After stimulation with IL-4 and in the presence of TGFβ, Th2 T cells upregulate the 
expression  of  Foxp3.  Foxp3  directly  interacts  with  GATA3  resulting  in  the 
downregulation  of  Th2  specific  genes.  Foxp3
+ GATA3
+  Th2  cells  do not  secrete 
common Th2 cytokines (IL-4, IL-5 and IL-13) but produce IL-9 and IL-10 to become 
“Th9”  T  cells.  Although  Foxp3  and  GATA3  are  required  throughout  this 
differentiation process, terminally differentiated Th9 T cells do not express any of 
these  transcription  factors,  and  no  specific  transcription  factors  have  so  far  been 
identified (Tato et al. 2008). Interestingly, Th9 cells provide protection in response to 
infections by the helminth Trichuris muris probably via the recruitment of mast cells 
(Veldhoen et al. 2008). Th9 cells do not inhibit the proliferation and functions of 
effector T cells in a mouse model of autoimmune colitis. Yet, adoptive-transfer of 
Th9 cells worsens the disease and mice presented a more severe inflammation of the 
guts (Dardalhon et al. 2008). Thus, Th9 lacking suppressive function on T cells are 50 
 
beneficial in host-pathogen infections and detrimental in T cell driven autoimmune 
diseases. 
 
-  TGFβ has an important role in the generation of Th17, Tregs and Th9 cells. Studies 
in mice have recently indicated that Tregs secreting TGFβ and IL-10 can produce IL-
17 upon stimulation with IL-6 (Xu et al. 2007; Radhakrishnan et al. 2008). Only a 
specific subset of Tregs (CD4
+ CD25
hi CCR6
+ HLA-DR
- Foxp3
+) in humans could 
express  IL-17. This subset retained its suppressive functions in response to weak 
TCR stimulation after binding APCs. However, upon high TCR stimulation and the 
secretion of IL-6 and IL-1β by APCs, these Tregs transiently lose their suppressive 
activity  and  secrete  IL-17.  Inflammation  can  therefore  drive  HLA-DR
-  Tregs  to 
acquire an effector Th17-like phenotype. This mechanism allows the rapid adaptation 
of T cell response to suppress or activate pro-inflammatory responses (Beriou et al. 
2009). 
 
1-3-2-2/ The importance of Th17 and Th1 in the development of autoimmune diseases 
- The new Th1 / Th2 / Th17 paradigm? 
 
For  many  years,  Th1  and  Th2  T  cells  have  been  at  the  centre  of  immunological-
classification of different chronic inflammatory diseases. Th2 T cells were associated with 
allergy and asthma whereas Th1 T cells were linked with the development of autoimmune 
diseases. This Th1/Th2 classification or paradigm could not explain various diseases and 
results obtained. Indeed, treatment of EAE models developing multiple sclerosis with IFNγ 
does not worsen but reverses disease (Voorthuis et al. 1990). In contrast, blocking IFNγ is 
detrimental as disease worsens (Billiau et al. 1988). This highlights that IFNγ has different 
roles according to the stage of disease. 
 
The recent identification of Th17 T cells has helped to clarify some of the discrepancies 
resulting from the Th1/Th2 paradigm (Korn et al. 2007; Zhou et al. 2007; Manel et al. 2008). 
However new findings have highlighted a new dilemma when considering the action of Th1 
and Th17 cells in the pathogenesis of AID such as experimental autoimmune uveitis (EAU 
mice)  resembling  experimental  autoimmune  encephalomyelitis  (EAE  mice)  in  the 
pathogenesis of the disease (Steinman et al. 2008; Kroenke et al. 2008; Luger et al. 2008). 
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In EAU mice, injection of the cognate antigen (IRBP: intra-retinal binding protein) in 
CFA induces disease. Interestingly, addition of blocking αIL-17A antibodies (Ab) dampened 
clinical signs in ongoing disease while it altered the onset of the disease. On the other hand, 
blocking of IL-23 with αIL-23 Ab was only beneficial if added early during priming phases 
of  the  disease.  This  was  further  confirmed  by  the  use  of  specific  knock-out  mice.  Mice 
lacking  subunits  for  IL-23  and  IL-12/IL-23  (p19
-/-  and  p40
-/-  mice  respectively)  were 
protected against disease when immunized with IRBP and CFA. Lack of IL-12 in p35
-/- mice 
resulted in increased disease activity upon immunization. These results confirmed that IL-23 
is necessary for the priming of the disease and Th17 cells but not for their effector functions 
mediated by IL-17, IL-17F and IL-22 (Luger et al. 2008) (Figure 1-9/A). 
Interestingly, Luger et al. demonstrated that adoptive transfer of IRBP-specific Th1 and 
Th17 cells were able to induce EAU in WT mice. WT mice were immunized with IRBP and 
CFA, draining lymph-nodes harvested and T cells polarized to Th1 (IRBP peptide, IL-12 and 
αIL-4  antibody)  or  Th17  (IRBP  peptide,  IL-23,  TGFβ,  IL-6  and  anti-IL-4  Ab)  T  cells. 
Adoptive transfer of Th1 polarized T cells induced EAU in WT mice treated or not with αIL-
17 Ab. However, blocking of IFNγ with an αIFNγ Ab prevented the occurrence of EAU. 
Interestingly,  WT  and  IFNγ
-/-  mice  develop  EAU  upon  immunization with  IRBP-specific 
Th17 T cells (Figure 1-9/B) (Luger et al. 2008).  
 
 Analysing cellular infiltrates in the central nervous system (CNS) of WT mice immunized 
with pathogenic Th1 and Th17 T cells from EAE mice, Kroenke et al demonstrated that EAE 
mediated  by  Th1  and  Th17  T  cells  was  associated  with  macrophage  and  neutrophil 
infiltration respectively (Kroenke et al. 2008). This confirmed another study demonstrating 
that Th17/Th1 ratio dictated the severity of EAE disease. Indeed, mice with high Th17/Th1 
ratio develop severe EAE mainly in the CNS. Mice with low Th17/Th1 presented a mild 
disease activity that localized in the spinal cord (Stromnes et al. 2008) 
 52 
 
 
 
Figure 1-9: Influence of Th1 and Th17 cells on the pathogenesis of experimental autoimmune uveitis 
(EAU) – Place of Th17 in the Th1/Th2 paradigm 
(A) EAU is induced in WT mice by immunization  with  IRBP and CFA. Blockade of IL-17 using  αIL-17 
antibodies (Ab) reduced disease activity at the onset, after induction and in ongoing disease activity. Blockade 
of IL-23 with αIL-23 Ab was only effective during disease induction. A reduction of EAU in p19
-/- and p40-/- 
mice lacking IL-23 and IL-12/13 respectively was observed, whereas increased disease activity was observed in 
p35
-/- mice lacking IL-12. (B) Adoptive transfer of in-vitro polarized Th1 and Th17 cells induced EAU in WT 
mice. The severity of the disease was not affected when IFNγ
-/- mice where immunized with polarized Th17 
cells. However, blockade of IFNγ in WT mice immunized with Th1 polarized cells reduced the severity of the 
disease; blocking of IL-17 did not have any effects. (C) IRBP pulsed matured DCs were injected into mice 
subsequently inoculated with pertussis toxin after 2 days. Immunized WT mice developed EAU associated with 
high production of IFNγ and low production of IL-17. EAU was decreased in IFNγ
-/- mice despite a strong IL-17 
production. Figure is adapted from (Steinman. 2008) 
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Immunization of WT mice with IRBP pulsed-DCs promoted EAU associated with high 
amounts  of  IFNγ  and  reduced  amounts  of  IL-17.  IFNγ
-/-  mice  however  seemed  to  be 
protected against EAU upon immunization with IRBP pulsed DCs despite a robust IL-17 
production (Figure 1-9/C). These results are different from results exposed figure 1-9/B and 
1-9/C. This can be explained by the use of CFA adjuvant in the immunization of WT with 
IRBP  peptide.  Indeed,  CFA  contains  killed  mycobacteria  that  are  able  to  skew  T  cell 
phenotypes. Indeed CFA is a strong IL-6 inducer while IFA fails to promote the induction of 
IL-6 and contributes to the conversion of Foxp3
- cells to Foxp3
+ cells in-vivo (Dr. Thomas 
Korn, British Society for Rheumatology Annual Meeting 2008, Liverpool, UK; Korn et al. 
2008). 
 
These data clearly demonstrated that Th1 and Th17 can act independently of each other to 
induce autoimmune diseases. We cannot conclude that Th1 are more pathogenic and able to 
induce AID than Th17 and vice versa. This question was at the centre of a recent review on 
the  role  of  Th17  in  immunity  and  for  many  reasons  such  as  those  highlighted  in  this 
paragraph, the conclusion was that both Th1 and Th17 are able to induce AID (Bettelli et al. 
2007, Steinman, 2007; Steinman, 2008). Thus, rushing into a new Th1/Th2/Th17 paradigm 
seems inadequate and one must consider that the nature of inflammation, cellular interactions 
and cellular signalling pathways dictates the outcome and the different subsets involved in 
AID. Finally, precautions must be taken when considering results from studies requiring the 
use of adjuvants and in-vitro polarized T cell subsets as they may not reflect reality. 
 
The ability of the adaptive immune response to be shaped or formed in relation to the 
nature of inflammation is essential to mount an effective immune response. This however 
requires  that  the  immune  system  is  strictly  recognizing  self-MHC  molecules  whilst  not 
reacting against self antigens so as to avoid the emergence of AID. The shaping of the T cell 
repertoire is therefore essential to prevent the immune system to recognise self antigens. 
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1-4/ Shaping of the T cell repertoire – Role of central and peripheral 
tolerance 
 
The  shaping  of  the  T  cell  repertoire  is  a  prerequisite  for  the  efficient  activity  of  the 
immune system. Two systems exist to prevent the generation and activation of self-reactive T 
cells:  central  and  peripheral  tolerance.  In  this  paragraph  will  be  exposed  the  different 
mechanisms governing these two systems. 
 
1-4-1/ Central Tolerance 
 
Central tolerance is a mechanism developed by mammals throughout evolution by which 
developing T cells are selected on their ability not to recognize self antigens. By contrast to 
peripheral tolerance, central tolerance occurs while T cell precursors mature in the thymus 
before being released into the peripheral blood and the periphery. 
 
Thymocyte  progenitors  from  the  bone-marrow  enter  the  thymus  through  the  cortex-
medulla junction. At this stage, they do not express either the CD4 or CD8α co-receptor 
chains but a pre-TCRβ chain (von Boehmer et al. 2003). Only those Double Negative cells 
(DN)  that  have  correctly  rearranged  their  TCRβ  chain  with  an  endogenous  α  chain, 
upregulate both co-receptors to become CD4
+ CD8α
+ double positive (DP) thymocytes. DP 
thymocytes then go through a very stringent selection process within the thymus resulting in 
the death of about 95% of thymocyte precursors (Figure 1-10). The selection is based on the 
overall avidity of the peptide-MHC:TCR complex (Paragraph 1-3-1/).  
During positive selection DP thymocytes are selected through the binding of their TCR 
to self-MHC molecules expressed by cortical thymic epithelial cells (cTEC). DP that bind 
self-MHC molecules receive survival signals and migrate to the medulla. Those unable to 
bind self-MHC molecules undergo apoptosis by neglect. Among the high and low affinity DP 
thymocytes positively selected, some can recognise “self” and therefore could promote AID 
(Baldwin et al. 2004).  
To eliminate these self-reactive T cells, a second selection occurs in the medulla of the 
thymus: the negative selection (Reviewed in Palmer. 2003). This crucial mechanism leads to 
the clonal deletion of thymocytes recognising self-MHC:self-antigen complexes. TCRs with 
a very high affinity for self-MHC:self-antigen complexes die by apoptosis. Thymocytes with 55 
 
intermediate affinity will become Treg whereas those with low affinity TCR will be selected 
and  become  mature  naive  T  cells  that  leave  the  thymus  into  the  blood  stream  (Zuniga-
Pflucker et al. 2004; Hogquist et al. 2005; Ladi et al. 2006).  
 
Negative selection is possible as peripheral antigens or tissue specific antigens (TSA) are 
expressed in the thymus (Palmer. 2003). The expression of high number of genes is specific 
of thymic epithelial cells from the medulla (mTEC). It allows the presentation of a broad 
range of self-peptide representing the self-repertoire under the influence of a transcription 
factor: the autoimmune  regulator AIRE (Derbinski et al. 2001; Gillard et al, 2005). This 
transcription factor controls the expression of a cluster of genes that encode for TSA. The 
importance of this transcription factor has been shown in AIRE knock-out mice and patients 
with  a  deficiency  in  AIRE  (Autoimmune  PolyEndocrynopathy  Candidiasis  Ectodermal 
Dystrophy or APECED) expression, as they develop multiple AID (Anderson et al. 2002). 
Moreover, it has been shown recently that the induction of antigen specific tolerance and 
therefore the prevention of autoimmune diseases could be performed by inducing the thymic 
expression of a single self-antigen. The self antigens chosen are not constitutively presented 
by mTECs, and their expression is induced intra-thymically using lentiviruses (DeVoss et al. 
2006; Marodon et al. 2006).  
Cortical  thymic  epithelial  cells  do  not  express  AIRE  and  therefore  do  not  mediate 
negative selection. On the contrary immature medullary thymic epithelial cells (Imm mTEC) 
express this transcription factor at a low level. As they mature, they upregulate the expression 
of  AIRE  after  engagement  of  lymphotoxin-β  receptor  (LTβR)  and  have  therefore  an 
increased ability to express TSAs and mediate the negative selection (Kyewski et al. 2004). 
The importance of dendritic cells has also been shown in mediating both negative selection 
and the generation of naturally arising regulatory T cells (Treg).  
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Figure 1-10: Central tolerance in the thymus: positive and negative selections 
Thymocyte  progenitors  enter  the  thymus  through  the  cortex  medulla  junction  where  they  proliferate  and 
differentiate in double-negative (DN) cells. Double positive (DP) thymocytes bind cortical thymic epithelial 
cells  (cTEC)  and  are  going  through  positive  selection.  Thymocytes  positively  selected  migrate  toward  the 
medulla and are going through negative selection via the binding of their TCR to self tissue associated antigens/ 
MHC molecule complexes. According to their affinity to the complex they are either depleted by negative 
selection or positively selected to become mature single positive (mature SP) effector T cells or regulatory T 
cells. Immature medullary thymic epithelial cells (Imm mTEC) express low level of AIRE. As they mature (mat 
mTEC), they upregulate the expression of AIRE via the contact of LTβR present at the surface of thymocytes. 
Tissue specific antigens from Imm or mat mTEC can be transferred to mature DCs (mDCs) thus enhancing 
negative selection. Hassall’s corpuscles secreting TSLP lead to the maturation of DCs that subsequently favor 
the generation of regulatory T cells (Treg). Figure is adapted from (Zuniga-Pflucker et al. 2004) and (Anderson 
et al. 2001). 
 
Thymic medullary DCs have an important role in central tolerance by cross-presentation 
of antigens from dying immature and mature thymic epithelial cells (Hogquist et al. 2005). 
Dendritic  cells  in  Hassall’s  corpuscle  in  the  thymus  can  be  activated  by  thymic  stromal 
lymphopoietin TSLP released by cells from the corpuscles (Liu et al. 2006; Watanabe et al. 
2005). Resulting mature DCs are then able to induce both proliferation and differentiation of 
naturally occurring CD4
+ CD25
+ Foxp3
+ Tregs. This function has been described to depend 
on the expression of costimulatory molecules like CD80 and CD86 as well as the secretion of 
IL-2 (Watanabe et al. 2005). 57 
 
 
Central thymic selection is very efficient and depends on the avidity displayed by a TCR 
for a specific TSA/MHC complex (Figure 1-11). The majority of thymocytes with a low TCR 
avidity undergo death by neglect. Thymocytes with intermediate TCR avidity mature and 
become either regulatory or effector T cells. Finally, thymocytes with high avidity TCRs 
undergo negative selection and death by apoptosis.  
 
 
Figure 1-11: TCR avidity of a T cell for a MHC:self-TSA complex defines its fate 
Selection of T cells depends on the T cell avidity for self-Tissue specific antigen (TSA):MHC complex. The 
majority of the cells exhibits a low affinity for the MHC molecules and die by neglect (Positive selection). On 
the other hand, TCR presenting a high avidity for the TSA/MHC complex are eliminated by negative selection.  
T cells with intermediate avidity are positively selected and give rise to effector or regulatory T cells. Figure is 
adapted from (Hogquist et al. 2005). 
 
Thymocytes or naïve effector T cells that have been positively selected leave the thymus 
and circulate between the blood and lymphoid organs until they recognise the cognate peptide 
in a context of “danger”.  
 
This system is however not perfect and some self-reactive T cells are not eliminated. This 
is the case if the TCR has a high affinity for a TSA whose expression in the thymus is not 
dependent on AIRE, or if its expression occurs later in life when the T cell repertoire has 
already been created. These T cells are in a state of anergy in the periphery. With a very high 
activation  threshold,  these  cells  are  very  unwilling  to  proliferate  and  need  a  high 
concentration of antigen to be activated (Jordan et al. 2001). Other mechanisms are in place 58 
 
in  order  to  keep  these  self-reactive  T  cells  at  bay;  this  is  the  phenomenon  of  peripheral 
tolerance. 
 
1-4-2/ Peripheral Tolerance 
 
Peripheral tolerance regroups different components to provide immunological tolerance 
after mature naive T cells leave the thymus to the periphery. Two different systems are in 
place; intrinsic (depending on the antigen and the costimulation) and extrinsic (relying on 
inhibitory cells of the immune system) (Walker et al. 2002). 
 
1-4-2-1/ Mechanisms of intrinsic peripheral tolerance  
 
Mechanisms  of  intrinsic  T  cell  peripheral  tolerance  depend  on  the  level  of  MHC:Ag 
complexes as well as on the nature and amount of costimulation. Four different cases can be 
considered: 
 
-  Self-reactive T cells in the periphery might never encounter the self-peptide. This 
occurs if the peptide is not accessible to T cells or if the amount of antigen present is 
not able to trigger T cell activation despite their intermediate TCR avidity (Walker 
et al. 2002). These T cells are therefore ignorant. 
 
-  The recognition of a peptide presented by APCs can lead to T cell anergy (van 
Duivenvoorde  et  al.  2006).  At  the  beginning  it  was  considered  that  the  lack  of 
costimulation was responsible for T cell anergy. It is now acknowledged that the 
involvement  of  specific  receptors  such  as  PD-1  (Programmed  cell  Death-1)  or 
CTLA-4 (Cytotoxic T Lymphocyte Associated antigen-4) on T cells and PDL1/2 or 
CD80/86 on APCs leads to the functional inactivation of T cells. Evidence support 
the participation of these specific receptors, as mice lacking either of these receptors 
develop autoimmune and lymphoproliferative disorders (Eagar et al. 2002). 
 
-  T cell activation results from the recognition of an antigen presented by APCs in a 
context of “danger”. In this respect, engagement of the TCR leads to strong signals. 
However, variants of the antigenic peptides or Altered Peptide Ligands have been 59 
 
shown to act either as TCR agonists or TCR antagonists producing weak signals 
resulting in T cell anergy (Quaratino et al. 2000). These peptides have been shown 
to be both MHC Class I and II restricted (Jameson et al. 1993; De Magistris et al. 
1992).  
 
-  Self-reactive T cells encountering a high concentration of self-antigen or being in a 
highly inflammatory microenvironment are deleted via apoptosis. This activation 
induced cell-death (AICD) is linked to the upregulation of Fas-L on T cells (Zhang 
et al. 2004; Ryan et al. 2005). 
 
1-4-2-2/ Mechanisms of extrinsic peripheral tolerance  
 
Extrinsic mechanisms of peripheral T-cell tolerance involve different cell subsets of the 
innate and adaptive immune systems.  
 
-  CD4
+ CD25
+ Foxp3
+ regulatory T cells have been largely described to play an 
important role in peripheral tolerance (Kim et al. 2007; von Herrath et al. 2003). 
Two  subsets  of  Tregs  exist:  thymic  derived  and  peripheral  antigen-induced 
regulatory  T  cells.  These  cells  have  been  shown  to  inhibit  T  cells  via  cell-cell 
contact  and  the  release  of  IL-10  and  TGFβ  respectively.  Tregs  also  induce  the 
apoptosis of effector T cells by depleting the micro-environment of cytokines such 
as IL-2 (Pandiyan et al. 2007). 
 
-  Other regulatory T cells have been described such as IL-10 secreting Tr1 and TGFβ 
secreting Th3 cells. Recent work has also focussed on the role of double negative T 
cells in the inhibition of T cell responses (Zhang et al. 2000; Fischer et al. 2005). 
 
-  Early precursor cells of the myeloid lineage, Myeloid Derived Suppressor Cells 
(MDSCs) have been shown to strongly inhibit T cell proliferation (Bronte et al. 
2000) (This is discussed Paragraph 1-4-3/). 
 
-  Although  extremely  powerful  at  inducing  autoimmune  diseases,  dendritic  cells 
have  been  shown  to  play  a  major  role  in  inhibiting  T  cell  response  (partially 60 
 
described Figure 1-10) (Rutella et al. 2006). The intrinsic mechanisms previously 
described can be applied to DCs inducing tolerance. It is noteworthy that the same 
type of tolerance can be induced by non professional APCs such as epithelial cells. 
We will here focus on the cellular side of peripheral tolerance that depends on DCs 
(Figure 1-12). 
 
Uptake of antigens via the DEC-205 mannose receptor or uptake of apoptotic bodies does 
not induce maturation of DCs. iDCs presenting antigens to T cells can lead to T cell death or 
T cell anergy. This is highlighted in recent studies, targeting of the DEC-205 receptor using 
an α-DEC-205 antibody conjugated to an Ag (Bonifaz et al. 2002; Bonifaz et al. 2004). Sole 
injection  of  the  Ab:Ag  complex  leads  to  tolerance  to  the  Ag  whereas  co-injection  with 
αCD40 results in the stimulation of CD4
+ T cells as well as CD8
+ T cells by Ag cross-
presentation (Bonifaz et al. 2002; Bonifaz et al. 2004) (Figure 1-12/A). 
 De-novo induction of regulatory T cells (Treg) by both immature and mature DCs has 
been largely documented. This phenomenon has been shown to be mediated by TGFβ but 
also  other  molecules  such  as  integrin  receptor  CD11b  on  DCs  (von  Herrath  et  al.  2003) 
(Figure 1-12/B). 
In the presence of the cognate peptide presented in the context of MHC-II molecules, 
thymic  derived  Tregs  are  able  to  expand.  Their  inhibitory  activity  on  T  cells  is  well 
documented  and  deficiency  in  Tregs  has  been  linked  with  an  increased  frequency  of 
autoimmune disorders (Kim et al. 2007) (Figure 1-12/C). mDCs presenting the Ag to T cells 
can lead either to T cell anergy (involvement of CTLA-4 and PD-1 on APCs) or T cell death 
(involvement of Fas and Fas-L) (Figure 1-12/D). In certain conditions, iDCs and mDCs can 
release immunoregulatory cytokines that have been shown to inhibit DCs and T cell functions 
(Rutella et al. 2006) (Figure 1-12/E). Under stimulation by various factors such as IFNγ, 
PGE2,  mDCs  upregulate  the  expression  of  indoleamine  2,3-dioxygenase  (IDO).  IDO 
degrades tryptophan into kynurenines. This leads to the inhibition of T cells, the alteration of 
DC functions and the generation of Tregs (Puccetti et al. 2007) (Figure 1-12/F). 
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Figure 1-12: Examples of peripheral tolerance mediated by dendritic cells 
(A) Uptake of antigens  via the DEC-205  mannose receptor or uptake of apoptotic bodies does not induce 
maturation of dendritic cells (DCs). iDCs presenting antigens to T cells can lead to T cell death or T cell anergy. 
(B) The de-novo induction of regulatory T cells (Treg) by both immature and mature DCs has been largely 
documented. (C) In the presence of the cognate peptide presented in the context of MHC-II molecules, thymic 
derived Tregs are able to expand. (D) As described in the extrinsic mechanisms of peripheral tolerance, mDCs 
presenting the Ag to T cells can lead to either T cell anergy (involvement of CTLA-4 and PD-1) or T cell death 
(involvement of  Fas and Fas-L). (E) In certain conditions, iDCs and  mDCs can release immunoregulatory 
cytokines that inhibit DCs and T cells. (F) Under stimulation by various factors such as IFNγ, PGE2, mDCs 
upregulate the expression of IDO. IDO degrades tryptophan into kynurenines leading to the inhibition of T cells, 
the alteration of DCs’ functions and the generation of Tregs. 
 
DCs play therefore a dual role in promoting an efficient immune response while they are 
also key players in peripheral tolerance.  
 
1-4-3/ Myeloid Derived Suppressor Cells (MDSCs) 
 
Myeloid derived suppressor cells (MDSCs) express the myelomonocytic markers Gr1 and 
CD11b.  MDSCs  constitute  a  heterogeneous  population  of  myeloid  cells  originating  from 
Common Myeloid Precursor cells and MDSCs differentiate into macrophages, granulocytes 
or DCs depending on the nature of inflammation (Bronte et al. 1998; Bronte et al. 2000). 62 
 
Although they are present in the spleen and bone-marrow of healthy mice, they accumulate in 
different lymphoid and non-lymphoid tissues both in tumour bearing mice and humans with 
cancer (Bronte et al. 2000; Almand et al. 2000) (Figure 1-13). A significant decrease in the 
number of myeloid DCs is associated with an increased number of MDSCs in the blood of 
patients with head and neck squamous-cell carcinomas and breast cancers (Almand et al. 
2000). 
 
 
Figure 1-13: MDSCs and inflammation 
Myeloid Derived Suppressor Cells (MDSCs) are precursor cells of the myeloid lineage. Upon inflammation 
such as cancer, infection or trauma, MDSCs accumulate in lymphoid organs and the tissue affected by the 
inflammatory  process.  MDSCs  differentiate  in  mature  myeloid  cells  (dendritic  cells  or  macrophages  or 
granulocytes) according to the nature of inflammation. 
 
Attracted to the site of inflammation via the release of inflammatory cytokines such as 
GM-CSF, MDSCs play an important role in anti-tumor immunity by inhibiting CD8
+ T cell 
proliferation and functions in response not only to α-CD3/CD28 antibodies or superantigens 
but also to antigens in part via the modulation of L-arginine metabolism (Pak et al. 1995; 
Bronte et al. 2000; Bronte et al. 2005). Different mechanisms by which MDSCs inhibit T cell 
function  and  activity  have  been  described  including  the  inducible  nitric  oxide  synthase 
(iNOS) and / or Arginase I (ARG1). The activity of these two enzymes depends on the levels 
of Th1 and Th2 cytokines respectively. Bacterial products (such as LPS) and Th1 cytokines 
(such  as  IFNγ  or  TNFα)  lead  to  an  increased  production  of  nitric  oxide  (NO)  via  the 
activation of iNOS and inhibition of ARG1 (Mazzoni et al. 2002) (Figure 1-14/A). Release of 63 
 
NO alters the IL-2R signalling pathway thus rendering T cells non-responsive to IL-2. By 
contrast, Th2-like cytokines (such as IL-4, IL-10 and IL-13) strongly induce ARG1 synthesis 
and inhibit iNOS activity (Figure 1-14/B). ARG1 activation is associated with the increased 
expression of the cationic amino-acid transporter 2B (CAT2B) (Yeramian et al. 2006; Bronte 
et al. 2005) and with the degradation of L-arginine into urea and polyamines. This leads to 
the depletion of the extracellular environment in L-arginine and impaired T cell function 
resulting  from  a  default  in  the  synthesis  of  CD3ζ  chains.  Products  of  degradation  of  L-
arginine also alter T cell functions. Urea alters the translation of various mRNA species while 
polyamines  have  an  anti-inflammatory  role  by  inhibiting  the  release  of  pro-inflammatory 
cytokines by monocytes (Rodriguez et al 2004). Finally, both ARG1 and iNOS can act in 
synergy to generate superoxides, thus promoting the production of reactive nitrogen oxide 
species  (RNOS)  and  reactive  oxygen  species  (ROS)  (Bronte  et  al.  2005).  Together,  this 
production  has  a  strong  inhibitory  effect  on  T  cells  that  can  potentially  lead  to  T  cell 
apoptosis.  
 
 
Figure 1-14: Mechanisms of action of Myeloid Derived Suppressor Cells (MDSCs) 
(A) Upon stimulation by Th1-like cytokines, MDSCs express the inducible nitric oxide synthase (iNOS). iNOS 
degrades L-arginine (L-Arg) into citrulline and nitric oxide (NO). This leads to T cells having a default in the 
IL-2 receptor (IL-2R) signaling pathway. (B) MDSCs stimulated by Th2-like cytokines such as IL-4, 10 and 13 
upregulate the expression of arginase 1 (ARG1). Degradation of L-arginine into urea and polyamines leads to a 
decrease in CD3ζ chain expression in T cells. 
 
While very efficient, some self-reactive T cells can escape negative and positive selection 
occurring  in  the  thymus  during  central  tolerance.  Peripheral  tolerance  is  indeed  a 64 
 
supplementary mechanism that allows the inhibition of self-reactive T cells in the periphery 
and therefore the emergence of AID. In some situations however, a breakdown of tolerance 
can occur that will trigger AID. 
 
1-5/  Breakdown  of  tolerance  and  emergence  of  autoimmune 
diseases 
 
Breakdown  of  tolerance  has  been  linked  to  genetic  susceptibility.  The  expression  of 
specific HLA molecules is associated to increased risk in developing some AID.  Indeed, 
some self-peptides are more prone to binding some specific MHC molecules than others. 
Indeed people bearing HLA-DR3, HLA-DR4 and HLA-DQ8 are at risk to develop type 1 
diabetes while HLA-DR2 is protective (Aly et al. 2006). Genetic influence on certain specific 
genes such as FAS or CTLA-4 has also been linked to some AID (Ueda et al. 2003).  
 
Beyond this genetic susceptibility, some factors lead to the activation of self-reactive T 
cells that have not been eliminated during central tolerance. This means that the different 
arms involved in peripheral tolerance have failed to keep self-reactive T cells at bay, thus 
triggering AID. The activation of self-reactive T cells means that somehow the TCR has been 
able to recognize some epitopes in the context of MHC-molecules that are hidden or do not 
exist in physiological conditions. 
 
 
1-5-1/ Molecular mimicry, epitope spreading and bystander activation 
 
External factors able to induce AID are factors that can cause tissue damage and therefore 
the dissemination of auto-antigens that can lead to the activation of self-reactive T cells. The 
following theories have considered the involvement of persistent microbial infections leading 
to a breakdown of tolerance via different mechanisms (Vanderlugt et al. 2002). 
 
-  Following  tissue  destruction  during  an  infection,  self-antigens  released  by  dying 
cells can mimic foreign antigens from the pathogens thus amplifying the activation 
of pathogen-specific or  self-reactive  T cells (Benoist et al. 2001; Christen et  al. 
2004). This mimicry is possible if self-peptides share a similar antigenic surface 65 
 
with bacterial (Elli et al. 2005) or viral peptides (Christen et al. 2004) (Figure 1-
15/A).   
Shape mimicry is an alternative situation when peptides are shifting in the MHC 
groove  (Bankovich  et  al.  2004).    Two  peptides  from  thyroid  peroxidase  (TPO) 
antigen (TPO536-547: N-LDPLIRGLLARPAKLQ-C) could induce the proliferation 
of the same T cell clone. The two peptides (TPO535-55: N-DPLIRGLLARPA-C) and 
TPO539-550:  N-IRGLLARPAKLQ-C)  had  different  anchor  residues  in  the  HLA 
molecule but shared a similar antigenic surface (Quaratino et al. 1995). 
 
-  Inflammatory and pathogen specific T cells attracted to the site of inflammation can 
generate a powerful environment of pro-inflammatory cytokines (Figure 1-15/B). 
This cytokine milieu promotes the bystander activation or non-specific activation 
of  self-reactive  T  cells  that  in  turn  increases  tissue  damage  or  trigger  the 
development of autoimmune diseases in tissues other than the one infected (Bangs 
et al. 2006).  
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Figure 1-15: Breach of tolerance can induce autoimmune diseases 
This is based on the consequences of a primary bacterial or viral infection. (A) Molecular mimicry occurs when 
self  antigens  released  are  similar  in  antigenic  surface  to  bacterial  antigens.  (B)  Epitope  spreading:  foreign 
antigens presented by APCs stimulate T cells that migrate to the target tissue along with inflammatory cells. 
This promotes tissue damage and the release of self-antigens that in turn activate self-reactive T cells. (C) The 
pro-inflammatory cytokine milieu caused by persistent infections leads to the non specific bystander activation 
of self-reactive T cells. pT: pathogenic specific T cells; sT: self-reactive T cells, Ags: antigens; APCs: antigen 
presenting cells; MØ: macrophages. 
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-  In  the  situation  of  a  persistant  infection  /  inflammation  where  T  cells  are 
continuously  activated,  tissue  damage  can  occur  resulting  in  the  release  of  self 
antigens. These self-antigens are loaded by APCs that activate self-reactive T cells. 
This intermolecular epitope spreading can also result in more self-antigens being 
released by the damaged tissue, which promotes the stimulation of a wider range of 
self-reactive T cells (Figure 1-15/C) (McMahon et al. 2005). As the inflammation 
persists,  more  self-antigens  are  shed  and  multiple  epitopes  can  be  generated  by 
APCs from the same antigen, thereby amplifying the extent of the inflammatory 
process (intramolecular epitope spreading) (Sercarz et al. 2000; Vandergult et al. 
2002). 
 
1-5-2/ Generation of cryptic epitopes 
 
During thymic selection, some self-reactive T cells are not depleted as the epitope for 
which they are specific may not be available or is inefficiently processed and presented in the 
thymus. Therefore, if these epitopes are then displayed in the periphery, self-reactive T cells 
can  be  activated  and  become  pathogenic.  AID  are  therefore  the  result  of  the  unexpected 
pathogenic  presentation  of  normally  hidden  cryptic  epitopes  (Lanzavecchia  et  al.  1995). 
Cryptic epitopes can be unmasked in different conditions such as: 
 
-  In physiological conditions, the cryptic epitope might not be produced in sufficient 
quantities  to  be  efficiently  presented  or  recognize  by  T  cells.  Increased 
concentration  of  Ag  as  a  result  of  tissue  destruction  leads  to  an  increased 
production of cryptic epitopes that are then presented to T cells (Figure 1-16/A).  
Processing of antigens can be boosted by receptor down-regulation. gp120 protein 
from  HIV  promotes  the  down-regulation  of  cell-surface  CD4  marker.  Increased 
degradation of CD4 leads to the generation of a previously-invisible cryptic epitope 
that elicits the activation of self-reactive T cells (Salemi et al. 1995; Lanzavecchia et 
al. 1995). 
 
-  An Ab binding to the Ag can modulate Ag uptake and processing by APCs and the 
generation of different epitopes is either increased or suppressed. The presentation 
of a cryptic epitope to T cells can occur if the generation of an immunodominant 68 
 
epitope is downregulated as a result of altered processing (Simistek et al. 1995; 
Lanzavecchia et al. 1995; Quaratino et al. 2005) (Figure 1-16/B).  
 
-  During inflammation, high levels of pro-inflammatory cytokines can affect the 
level of expression of MHC-I and MHC-II molecules as well as the protease content 
of  the  cells.  In  this  respect,  inflammation  mimicked  by  IFNγ  leads  to  the 
upregulation of MHC-I and MHC-II molecules, affects the content of proteases and 
promotes  new  pathways  of  endocytosis  (Delamarre  et  al.  2005).  Upon  these 
changes, APCs can generate or unmask cryptic epitopes capable of activating self-
reactive T cells (left panel, Figure 1-16/D).  
The  differential  processing  of  an  antigen  by  the  proteasome  (in  iDCs)  and 
immunoproteasome (mDCs and stimulation with IFNγ) is largely admitted. Upon 
stimulation  with  IFNγ,  three  subunits  of  the  proteasome  are  replaced  by  the 
inducible subunits  LMP2,  LMP7 (low-molecular mass polypeptide 2  and 7) and 
MECL-1  (multicatalytic  endopeptidase  complex-like  1)  conferring  new  catalytic 
activities to immunoproteasomes (Goldberg et al. 2002). Processing of ubiquitinated 
proteins  by  the  immunoproteasome  has  been  associated  with  the  generation  of 
cryptic epitopes from HIV and LCMV viruses (Sewell et al. 1999; Schwarz et al. 
2000). Proteasome activity is also involved in the shaping of the T cell repertoire 
(Osterloh et al. 2006) (right panel, Figure 1-16/D). 
 
-  Cryptic epitopes can be naturally generated by epithelial cells but the absence of 
MHC-II molecules is not allowing their presentation. Upon inflammation astrocytes 
can present self-antigens to self-reactive T cells in a mouse model of experimental 
autoimmune encephalomyelitis (EAE). These effects can be mimicked in-vitro upon 
stimulation with IFNγ (Soos et al. 1998; Stüve et al. 2002) and have been described 
in other epithelial cells such as hepatocytes (Herkel et al. 2003) (Figure 1-16/C). 
 
-  Cryptic  epitopes  may  arise  from  alternative  translational  products  of  a  single 
mRNA  if  its  translation  has  occured  from  a  different  open  reading  frame.  This 
mechanism is not restricted to tumors or virally infected cells, and can occur in 
normal  cells  (Review  by  Ho  et  al.  2006).  This  mechanism  has  been  shown  to 
provide immune protection against retroviruses by eliciting a strong CD8
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response (Ho et al. 2006) while providing additional source of peptides to generate 
T cell tolerance (Schwab et al. 2003). 
 
-  Post-translational  modifications  of  certain  proteins  such  as  by  phosphorylation 
(Mohammed et al. 2008), glycosylation (Wood et al. 1998) or oxidation of certain 
amino-acids (Kurien et al. 2008) can increase the affinity of a peptide for MHC 
binding (Engelhard et al. 2006).  
 
-  The disruption of protein structure during oxidative stress such as ROS can result 
in alternative processing and production of cryptic epitopes. This phenomenon has 
been  demonstrated  in  AID  of  the  kidneys  and  lungs  (Goodpasture  Syndrome) 
characterised by the generation of an adaptive immune response to collagen. 
 
 
 
 
 
 
 
 70 
 
 
Figure 1-16: Generation of cryptic epitopes 
Cryptic epitopes are revealed through different processes. (A) Increased antigen (Ag) concentration processed 
by antigen presenting cells (APCs) leads to more cryptic epitope being produced and presented to T cells. (B) 
Auto-antibodies (Ab) binding the Ag can modulate the route of uptake and processing of Ag by APCs, thus 
favoring the generation of cryptic epitopes. (C) Epithelial cells naturally generate the cryptic epitope but lack 
the  appropriate  MHC  molecule.  Upon  inflammation,  epithelial  cells  upregulate  the  expression  of  MHC 
molecules allowing the presentation of cryptic epitopes to T cells. (D) Upon stimulation, APCs change the pool 
of  proteases  necessary  to  process  Ag  to  generate  the  cryptic  epitope  (left  panel).  Upon  maturation,  APCs 
synthesize  new  catalytic  subunit  of  the  proteasome  to  form  the  immunoproteasome.  Degradation  of 
ubiquitinated Ag by the immunoproteasome generates or destroys cryptic epitopes (right panel). 
 
These inflammatory mechanisms are of no or little impact when considering mice models 
developing spontaneous autoimmune diseases in specific-pathogen-free conditions where the 
actions of external factors such as bacterial or virus infections are excluded.  
In a recent study by Sakaguchi’s group (Hirota et al. 2007), this question was addressed 
in a mouse model of autoimmune arthritis. In these mice self-reactive T cells are activated in 
the periphery by APCs presenting the cognate peptide. This activation resulted in the release 
of  IL-6  by  DCs  that  was  driving  the  differentiation  of  naïve  self-reactive  T  cells  into 
pathogenic Th17 cells. Deficiency of either IL-6 or IL-17 prevented the development of the 
disease  (Hirota  et  al.  2007;  Bailey  et  al.  2007).  This  breakdown  of  tolerance  was  also 
observed in a mouse model of multiple sclerosis (EAE mice - Experimental mouse model of 
Autoimmune Encephalitis). The activation of self-reactive T cells in these mice are the result 
of epitope-spreading into the central nervous system (CNS) mediated by DCs (McMahon et 71 
 
al. 2005). In these two studies, it was clear that the genetically determined self-reactive TCR 
induced the formation of a cytokine milieu favouring the development of AID. This was 
possible  by  the  spreading  of  the  cognate  epitope  by  DCs  in  the  CNS  (EAE  model)  and 
peripheral lymphoid organs (autoimmune arthritis) (McMahon et al. 2005; Hirota et al. 2007 
respectively) 
 
1-6/ The TAZ10 transgenic mouse model of autoimmune thyroiditis 
 
In  this  thesis,  we  will  study  some  mechanisms  influencing  the  pathogenesis  of  some 
chronic inflammatory diseases such as autoimmune thyroiditis.  
 
TAZ10 transgenic mice express the human TCR (Vβ1/Vα15) isolated from the thyroid 
infiltrating T cell clone 37 from a patient with Hashimoto’s thyroid disease. In the thyroid of 
this patient nearly half of the T cell-clones generated were specific for a main thyroid auto-
antigen:  thyroid  peroxidase  (TPO).  Among  them,  18%  were  specific  for  the 
immunodominant  TPO  epitope  TPO535-551  (N-LDPLIRGLLARPAKLQ-C)  (Dayan  et  al. 
1991; Quaratino et al. 1996).  
 
The immuno-dominant T cell clone 37 is specific for TPO536-547 (N-DPLIRGLLARPA-
C), identified as a cryptic epitope as it was presented only by thyroid epithelial cells (TEC) 
and not by DCs (Quaratino et al. 1996). On the contrary, DCs pulsed with exogenous TPO 
presented a natural antagonist epitope (TPO537-548: N-PLIRGLLARPAK-C) that induced T 
cell anergy in T clone 37. TPO537-548 and TPO536-547 induced a similar down-regulation of 
the TCR but TPO537-548 did not lead to T cell proliferation and IL-2 secretion. TPO537-548 is 
therefore an altered peptide ligand (antagonist peptide of TPO536-547) that is recognized by 
the same TCR but inducing T cell anergy (Quaratino et al. 2000).  
 
Interestingly,  two  peptides  from  thyroid  peroxidase  (TPO)  antigen  (TPO535-551:  N-
LDPLIRGLLARPAKLQ-C)  could  induce  the  proliferation  of  T  cell  clone  37.  The  two 
peptides  (TPO536-547:  N-DPLIRGLLARPA-C)  and  TPO539-550:  N-IRGLLARPAKLQ-C) 
had  different  anchor  residues  in  the  HLA-DQ6  molecule  but  shared  a  similar  antigenic 
surface.  This  highlighted  that  rather  than  identical  sequences,  the  shape  of  the  antigenic 
surface characterized epitope mimicry (Quaratino et al. 1995). 72 
 
 
From these studies, it appeared that T cell clone 37 was interesting and further in-vivo 
studies were needed to ascertain its major role in autoimmune thyroiditis, thus the generation 
of the TAZ10 model. The extra cellular domain of human TCR Vβ1/Vα15 was ligated to the 
intracellular domain of the mouse TCR to allow normal TCR signalling in mice (Quaratino et 
al. 2000). The chimeric TCR α and β chains were then cloned in the expression cassette 
VahCD2 under the hCD2 promoter and injected in fertilized eggs from C57BL/6xCBA F2 
offspring pregnant females. Extensive backcrossing led to the generation of TAZ10 mice 
(Quaratino et al. 2004). 
 
Interestingly, both CD4
+ and CD8
+ T cells from TAZ10 mice could recognize the TPO 
cryptic  epitope  when  presented  by  APCs  in  the  context  of  human  HLA  DQB1*0602-
DQA1*0102 (DQ6) and murine H2-A
b and H2-A
k MHC-II molecules. Transgenic T cells 
from  TAZ10  mice  recognize  the  human  TPO  cryptic  epitope  (TPO536-547:  N-
DPLIRGLLARPA-C)  and  the  murine  equivalent  (TPO524-535:  N-DPIVRGLLARPA-C) 
when presented in the context of H2-A
k murine MHC-II molecules. Molecular modelling of 
human  TPO536-547:HLA-DQ6  and  human  TPO536-547:H2-A
k  compared  with  molecular 
modelling of human TPO536-547:H2-A
k and mouse TPO524-535:H2-A
k revealed that H2-A
k 
and HLA-DQ6 molecules display a close similar antigenic surface of TPO536-547 recognized 
by the same TCR Vβ1/Vα15. It also showed that the murine TPO524-535 and human TPO536-
547  cryptic  epitope  presented  a  similar  antigenic  surface  despite  the  residue  differences 
(amino-acids at position 3 and 11). 
 
TAZ10  transgenic  mice  spontaneously  developed  autoimmune  thyroiditis  sharing  the 
same  clinical  signs  (gain  of  weight),  hormonal  changes  (increased  amounts  of  TSH  and 
decreased levels of T4) and histological modifications (destruction of the thyroid associated 
with mononuclear cellular infiltrates) as patients with Hashimoto’s thyroiditis (Quaratino et 
al.  2004).  Interestingly,  CD4
+  and  CD8
+  T  cells  from  Rag
-/-  TAZ10  mice  presented  an 
activated phenotype as they did not express CD62L while expressing high levels of CD44. At 
4 months of age, almost 100% of TAZ10 mice had developed severe autoimmune thyroiditis 
highlighted by extensive destruction of the thyroid (Quaratino et al. 2004). 
 
Although the study on TAZ10 mice provided evidence of the role of cryptic epitopes in 
the  pathogenesis  of  human  autoimmune  diseases,  it  also  highlighted  the  role  played  by 73 
 
unconventionally MHC-II selected CD8
+ T cells in the development of the disease. Early 
experiments have addressed the ability of thyroid epithelial cells (TECs) to upregulate MHC-
II molecules in Hashimoto’s thyroiditis. These cells were able to promote the activation of 
thyroid specific T cells, suggesting that thyroid epithelial cells can present antigens to T cells 
(Londei et al. 1984; Londei et al 1985). However the role of TEC and the origin of the cryptic 
epitope leading to the activation of T cells from TAZ10 mice in the induction of the disease 
are still elusive.  
 
1-7/ The role of Tissue transglutaminase 2 in the pathogenesis of 
Celiac Disease 
 
It has been described that patients with autoimmune thyroiditis (Hashimoto’s thyroiditis) 
have an increased chance of developing celiac disease (CDis) and vice-versa (Naiyer et al. 
2008;  Duntas,  2009).  CDis  is  a  common  pathology  caused  by  an  inappropriate  immune 
response to wheat and gluten and is characterised by local (small intestine) and systemic 
manifestations (Schuppan et al. 2000). Important histological features of untreated patients 
with CDis include the activation of gliadin specific T cells, the infiltration of intraepithelial 
lymphocytes and the flattening of the mucosa of the small intestine (Schuppan et al. 2000). 
 
CDis is triggered by a non-immunodominant gliadin peptide which stimulates the innate 
immune response and induces epithelial damage and death by apoptosis (Maiuri et al. 2003). 
This  non-immunodominant  peptide  induces  the  upregulation  of  tissue  transglutaminase  2 
(TG2) whose inhibition controls the activation of epithelial changes and damages and the 
subsequent  activation  of  pathogenic  gliadin-specific  T  cells  (Maiuri  et  al.  2005  and 
Submitted). While the non-immunodominant gliadin peptide p31-43 induced the death of 
epithelial cells of the gut via Fas/Fas-L engagement (Maiuri et al, 2001; Maiuri et al. 2003), 
these effect are abrogated by blocking TG2 expressed at the cell-surface with a monoclonal 
antibody (Maiuri et al. 2005). 
 
In celiac disease (CDis), TG2 plays a fundamental role in the pathogenesis of the disease 
by operating a crucial deamidation of glutamine to glutamic acid of immunodominant gliadin 
epitopes that drive the adaptive immune response (van de Wal et al. 1998; Arentz-Hansen et 
al. 2000; Molberg et al 2008). However, a recent study has highlighted a new unexpected role 74 
 
of TG2 in celiac disease where the inhibition of TG2 activity controlled the activation of 
gliadin-specific T cells. Patients with CDis present high titres of autoantibodies to TG2 that 
has therefore been described as the main autoantigen in CDis (Dieterich et al. 1997; Marsh, 
1997). 
 
However,  the  enzymatic  activity  of  TG2  is  not  its  only  function  as  it  displays  other 
multiple  biological  activities  (Akimov  et  al.  2000  and  2001)  and  is  upregulated  upon 
inflammation (Lorand et al. 2003; Ientile et al. 2007). TG2 is a calcium-dependent enzyme 
with  a  transamidating  activity  that  also  results  in  the  cross-linking  of  proteins  via  ε(γ-
glutamyl)  lysine  bonds  (Fesus  et  al.  2002).  More  recent  studies  have  highlighted  the 
important role played by TG2 in the pathogenesis of numerous neurodegenerative diseases. 
Indeed,  in  Parkinson’s  disease,  TG2  mediates  the  cross-linking  and  aggregation  of  α-
synuclein in Lewy inclusion bodies (Junn et al. 2003). 
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AIMS: 
The  aims  of  my  project  are  to  characterize  different  mechanisms  controlling  the 
development and inflammation of different chronic inflammatory diseases (CIDs).  In this 
thesis I have investigated the early events leading to the presentation of the TPO cryptic 
epitope in the TAZ10 mouse model of autoimmune thyroiditis whereas also addressing the 
impact  of  a  new  regulatory  network  formed  by  MDSCs.  I  also  described  how  the 
manipulation  of  MDSCs  in-vitro  affected  the  proliferation  of  self-reactive  T  cells  from 
TAZ10 mice. I then assessed whether these findings on MDSCs from TAZ10 mice could be 
transposed to human CIDs such as rheumatoid arthritis and systemic lupus erythematosus.  
Finally, I evaluated the impact of tissue transglutaminase 2 (TG2) in the generation of the 
inflammatory response in patients with cystic fibrosis. These findings were transposed into 
TAZ10 mice to address whether TG2 could control the ongoing inflammation that leads to 
the destruction of the thyroid. 
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2/ Materials and Methods 
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2-1/ Material and Methods Part 1: Mouse work 
2-1-1/ Mice and cell-lines 
Wild-type C57Bl/6 and CBA, TAZ10 and Rag2
-/- trasngenic mice were housed and bred 
at the Tenovus animal facility in accordance with home-office guidelines for animal welfare. 
All mice used were aged from 3 weeks to 6 months of age. TAZ10 Rag-/- transgenic mice 
were  maintained  under  specific  pathogen-free  conditions.  B16  melanoma  and  CT26-GM 
colon  carcinoma  cell-lines  was  grown  in  complete  RPMI-1640  medium  (Cambrex,  UK) 
supplemented  with  10%  Foetal  Calf  Serum  (Globepharm,  UK),  0.3  mg/mL  L-glutamine 
(Cambrex,  UK),  100  U/mL  Penicillin/streptomycin  (Cambrex,  UK),  1mM  non  essential 
amino-acids (Cambrex, UK) and 1 mM sodium pyruvate (Cambrex, UK) at 37°C with 5% 
CO2. 
 
2-1-2/ Flow-Cytometry and antibodies 
Cells were collected and washed in cold FACS Buffer (1X PBS supplemented with 0.1% 
FCS  and  0.05%  Sodium  Azide).  Antibodies  used  were  conjugated  to  fluorescein 
isothiocyanate  (FITC),  phycoerythrin  (PE),  peridinin  chlorophyll  protein  (PerCP)  and 
allophycocyanin (APC). Tandem dyes were also used: cyanin conjugated to phycoerythrin 
(PE-Cy5  and  PE-Cy7),  allophycocyanin  (APC-Cy7)  and  peridinin  chlorophyll  protein 
(PerCP-Cy5). Cells were stained with monoclonal antibodies against MHC class-II (I-A
b, Rat 
IgG2b, clone M5/114.15.2; BD Pharmingen), CD4 (rat IgG2b, clone L3T4; BD Pharmingen), 
CD8α  (rat  IgG2a,  clone  Ly-2;  BD  Pharmingen),  CD11b  (rat  IgG2b,  clone  M1/70; 
eBiosciences), CD11c (N418, Hamster IgG; BD Pharmingen), CD19 (rat IgG2a, clone 1D3; 
BD Pharmingen), CD25 (rat IgM, clone 7D4; BD Pharmingen), CD31 (rat IgG2a, clone 390; 
BD  Pharmingen),  CD62L  (mouse  IgG1,  clone  DREG-56;  eBiosciences),  CD80  (hamster 
IgG,  clone  16-10A1;  BD  Pharmingen),  CD86  (rat  IgG2a,  clone  GL1;  eBiosciences), 
CD95/Fas (mouse IgG1, clone 15A7; eBiosciences), CD95-L/Fas-L (Hamster IgG, clone 
MFL3; eBiosciences), CD127 ( Rat IgG2a, clone A7R34; eBiosciences),CD205/DEC-205 
(rat  IgG2a,  clone  NLDC-145;  made  in  house),  Gr1  (rat  IgG2b,  clone  RB6-8C5; 
eBiosciences),  F4/80 (rat IgG2a,κ, clone BM8; eBiosciences) and human TCR Vβ1 (rat 
IgG1,  clone  BL37.2;  Beckman  Coulter).  Samples  were  acquired  with  FACSCanto  and 
analysed using the FACS Diva Software (BD Biosciences). 
 78 
 
2-1-3/ ELISA 
Production of cytokines was assessed by ELISA. Supernatants were tested for cytokine 
content such as IL-10 and GM-CSF (All purchased from R&D Systems, UK). Flat-bottom 
96-well maxisorp plates (Nunc, UK) were coated overnight at room temperature with capture 
antibody diluted in PBS (100µL per well). Capture antibody was discarded and plate was 
washed three times with washing-buffer (0.05% Tween-20 in PBS, pH 7.2-7.4) by inverting 
the plate onto clean paper towels. Plate was blocked for a minimum of 1 hour with 300µL of 
blocking-buffer  (1%  BSA  in  PBS,  pH  7.2-7.4)  per  well  at  room  temperature.  Plate  was 
washed  three  times  as  previously  described  and  100µL  of  standard  or  sample  diluted  in 
blocking-buffer was added per well and the plate incubated at room temperature for 2 hours. 
Plate  was  washed  as  previously  described  and  biotinylated  detecting  antibody  diluted  in 
blocking-buffer  was  plated  out  (100µL  per  well)  and  incubated  for  2  hours  at  room 
temperature. 
Wells were washed 3 times with washing-buffer and 100µL/well of a  1:1000 dilution of 
avidin alkaline-phosphatase (Sigma, UK) in blocking-buffer and the plate incubated for 40 
minutes at room temperature. After 3 washes, 100µL Sigmafast pNPP substrate (Sigma, UK) 
was added per well and watched for color development. Absorbance was read on Biorad 
model 680 plate reader using Microplate manager software (BioRad, UK) at 405nm. Results 
were analysed and graphs plotted using Prism 4 (GraphPad). 
 
2-1-4/ Purification of T cells and Gr1
+ cells from wild-type and TAZ10 
mice 
Where indicated, T lymphocytes were enriched from spleens or lymph-nodes using the 
MACS  magnetic  technology  (Myltenyi  Biotech,  Germany).  Briefly,  splenocytes  were 
obtained by passing the spleen through a 70µm cell strainer. Red blood cells were lysed by 
incubating the cell suspension in ACK red blood cell lysis buffer (155 mM NH4Cl, 10 mM 
KHCO3 and 0.1 mM EDTA). Splenocytes were resuspended in MACS buffer (2 mM EDTA 
and 0.5% BSA in PBS) and incubated with micro-beads conjugated to mAb anti-CD4 (clone 
L3T4) and anti-CD8 (clone Ly-2) for 15 minutes at 4°C. Excess of free micro-beads was 
washed away with MACS buffer and labelled cells passed through a separating MS column 
on a magnetic field. In all experiments, the purity was assessed by flow cytometry and ranged 
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For the isolation of Gr1
+ cells, splenocytes were incubated with micro-beads conjugated 
to mAb anti-Gr1 (BD Biosciences, San Diego, CA) for 15 minutes at 4°C before being run 
through an MS column (Miltenyi Biotec, Germany).  
All  experiments  were  performed  using  RPMI-1640  medium  (Cambrex,  UK) 
supplemented  with  10%  Foetal  Calf  Serum  (Globepharm,  UK),  0.3  mg/mL  L-glutamine 
(Cambrex,  UK),  100  U/mL  Penicillin/streptomycin  (Cambrex,  UK),  1mM  non  essential 
amino-acids (Cambrex, UK) and 1 mM sodium pyruvate (Cambrex, UK) at 37°C with 5% 
CO2. 
 
2-1-5/ Generation of bone-marrow derived dendritic-cells 
4 to 12 week old mice were used. Bone-marrow from femurs and tibiae was flushed-out 
and red blood cells lysed in ACK buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 
7.4). DCs were generated by culture in RPMI-1640 medium (Cambrex, UK) supplemented 
with 10% low-endotoxin FCS (Autogen Bioclear, UK), 0.3 mg/mL L-glutamine (Cambrex, 
UK),  100  U/mL  Penicillin/streptomycin  (Cambrex,  UK),  1mM  non  essential  amino-acids 
(Cambrex, UK) and 1 mM sodium pyruvate (Cambrex, UK) at 37°C with 5% CO2. CT26-
GM supernatant was used as a source of GM-CSF and IL-4 was from Peprotech, UK. 
Immature and mature DCs were used for functional assays and their phenotype analysed 
by FACS. 
“Inaba’s method” (Inaba et al. 1992) 
2x10
6 bone-marrow cells were seeded at 1mL  of medium per well of  24 well-plates. 
Every two days, the plate was gently swirled and 75% of the medium replaced with fresh 
medium. iDCs obtained 7 days later were replated overnight before LPS (1µg/mL) was added 
overnight for complete maturation.  
“Son’s method” (Son et al. 2002) 
1x10
6 bone-marrow progenitors were seeded in 5mL of medium per well of 6 well-plates. 
At  day  4  and  7,  the  medium  was  only  supplemented  with  GM-CSF  until  DCs  were 
considered to be immature at day 8. Non-adherent iDCs were replated overnight and full 
maturation achieved by overnight stimulation with LPS (1µg/mL). 
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“Lutz’s method” (Lutz et al. 1999) 
2x10
6 cells were seeded in 100 mm petri-dishes in medium supplemented with 25% of 
GM-CSF from CT26-GM cell-conditioned-medium. The concentration of GM-CSF assessed 
by  ELISA  (Biosource,  UK)  ranged  from  200  to  400ng/mL.  On  Day  3,  10  mL  of  fresh 
medium supplemented with GM-CSF was added to each culture dish. On day 6 and 8, 10 mL 
of the culture medium was collected, centrifuged, the cell pellet resuspended in 10mL of 
fresh GM-CSF containing medium and seeded back into the original petri-dishes. Immature 
DCs obtained at day 10 were harvested and seeded at 2x10
6 cells per well of a 6 well-plate. 
For complete maturation, 1 µg/mL of LPS E.Coli E26:B6 (Sigma, UK) was added per 
well on day 11 and the cells cultured for 18 hours.  
 
2-1-6/ Primary culture of thyroid epithelial cells 
Primary cultures of thyrocytes were prepared as previously described (Jeker et al. 1999). 
Thyroid lobes were aseptically removed from the trachea of wild-type (C57Bl/6) or TAZ-10 
transgenic  mice,  placed  in  a  petri  dish  in  Eagle`s  Minimum  Essential  Medium  (EMEM) 
(Autogen Bioclear, UK) and cut into pieces using a scalpel. Disrupted thyroid lobes were 
digested  in  1  mL  of  EMEM  containing  5ug/mL  type  I  collagenase  (Sigma,  UK)  and 
2,5mg/mL Dispase I (Roche, UK) for 45 minutes at 37 ° C. The tube was gently swirled 
every 10 minutes to allow a homogeneous digestion. The digestion allowed the release of 
single thyroid follicles with few single thyrocytes. After digestion, the mix was resuspended 
in 10mL of Hams F-12 medium (Autogen Bioclear, UK) and spun down for 3 minutes at 
1200rpm.  Supernatant  containing  mainly  single  thyrocytes  is  discarded  and  the  pellet 
containing partially digested thyroid follicles resuspended in complete thyroid medium. The 
culture medium was: Nu-Serum IV (BD Biosciences, San Diego, CA) diluted 2.5 times in 
Hams F-12 medium and supplemented with 10ng/mL somatostatin (Sigma, UK) and 2ng/ml 
glycyl-L-histidyl-L-lysine acetate (Sigma, UK). Medium was changed one day after the start 
of the culture and replaced every 2 days. IFNγ (Peprotech, UK) was added when stated at 200 
units/mL; but only one day after the beginning of the culture. Thyrocytes were seeded either 
in 96 well-plates for proliferation assay using thymidine incorporation or 6 well-plates for 
expansion or fluorescence microscopy.  
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2-1-7/ T cell proliferation assay by (
3H) thymidine incorporation 
T  cell  proliferation  was  assessed  by  thymidine  incorporation.  Briefly,  freshly  isolated 
splenocytes were cultured in triplicate in 96 well plates at 2.5 x10
5 cells per well in culture 
medium containing soluble or plate-bound α-CD3 (clone RC5-4C11, CRUK) at 10µg/mL 
and/or soluble α-CD28 (clone 37.51, made in house). Where indicated mature bone-marrow 
derived  dendritic  cells  seeded  at  1x10
5  cells  per  well  were  pulsed  with  TPO536-547  (N-
DPLIRGLLARPA-C) peptide at 0.1µg/mL for 3 days. T cells where then added at DCs: T 
cell ratio of 1:30 and myeloid derived suppressor cells (MDSCs) were eventually added at a 
T:MDSC ratio of 1:1 or 1:5.  
When thyroid epithelial cells were used, 25µL of thyroid digestion mix (Paragraph 2-1-
6/) was cultured in 96 well-plates in 200µL for 3 days prior to the addition of T cells. 
Cells were co-cultured for 72 hours at 37°C in 5% CO2. Each well was then pulsed with 1 
µCi 
3H thymidine for the last 12 hours of culture. Plates were harvested onto filtered plates 
(Perkin Elmer) and 
3H thymidine incorporation measured in a microplate scintillation counter 
(Packard). Data are expressed in cpm (count per minute) and were plotted as mean of the 
triplicates. 
 
2-1-8/ CFSE labeling of T cells for in-vitro proliferation assays 
In some experiments, proliferation was assessed by CFSE labelling. Purified lymphocytes 
from either WT or TAZ10 mice were resuspended at 2 to 4 x10
7 cells per mL in FCS free 
medium. 5µM CFSE (Carboxyfluorescein succinimidyl ester, Invitrogen, UK) was added to 
the  cells  for  10  minutes  at  37⁰C.  Cells  were  washed  three  times  in  FCS  supplemented 
medium to remove any excess of CFSE. Cells were plated at the appropriate concentrations 
with thyroid epithelial cells with or without SED (staphylococcal enterotoxin D) at 10ng/mL 
or αCD3 (made in house). After 3 to 5 days, cells were harvested and stained with mouse 
monoclonal antibodies for T cell markers. Proliferation was assessed by flow cytometry as 
CFSE dilution.  
 
2-1-9/ Adoptive transfer of CFSE labelled T cells for in-vivo tracking and 
proliferation 
Purified  lymphocytes  were  washed  twice  in  PBS  and  resuspended  in  PBS  at 
1x10
7cells/mL. CFSE was added at 5µM  and  cells incubated  at 37⁰C in the dark for 15 82 
 
minutes.  Cells  were  washed  three  times  in  PBS.  Cells  were  resuspended  in  PBS  at  the 
appropriate concentration and 2x10
6 cells were injected to Rag2
-/- mice intravenously (IV) 
into the lateral vein at the base of the tail. After 7 days, cardiac blood samples were collected 
with from mice under anesthesia following conditions imposed by the Home Office. Blood 
was collected in eppendrof tubes supplemented with heparin. Mice were culled and spleen, 
blood, cervical and mesenteric lymph-nodes, and thyroids removed. Cells were stained for 
specific markers and analysed by flow cytometry. 
 
2-1-10/ MTT assay to assess cell-viability 
Thyroid epithelial cells were seeded in wells of 96 well plates (flat-bottom) and incubated 
at 37⁰C. At the end of the assay, 20µL of a 5mg/mL solution of MTT (3-(4,5-Dimethylthiazol 
2-yl)-2,5-diphenyltetrazolium bromide, Sigma, UK), in PBS. The plate was incubated at 37⁰C 
for 4 hours. Supernatant was discarded from the well and cells washed in PBS. 200µL of 
DMSO was added to each well and mixed thoroughly. Plate was incubated for 5 minutes at 
37⁰C to help for the removal of air bubbles. Absorbance was read at 550nm. 
 
2-1-11/ Single cell lysis assay 
Lysis assay was performed as described in Schwab et al (Schwab et al. 2005) 
 
•  Staining of Target cells 
10
7 Purified lymphocytes from WT and TAZ10 mice were resuspended in 0.5ML Diluent 
C. 0.5mL of a 4µM PKH26 dye solution (Sigma, UK) diluted in Diluent C was added to the 
cells and incubated for 3 to 5 minutes at room temperature with periodic shaking. 1mL of 
Fetal Calf Serum was added to the cells and incubated for 1 minute at room temperature. 
2mL of medium was then added to the cells before being centrifuged for 5 minutes at 300g. 
Supernatant was poured-off and cells resuspended in 10mL of PBS. Cells were centrifuged 
for 10 minutes at 200g to clean as much as possible the cells from cell debris and pellet 
resuspended in medium to final concentration.  
 
•  Cell Lysis assay 
10
5 target cells were used per well and assays were done in triplicate. Incubations were 
kept as short as possible so that the dead cells have not completely disintegrated and are thus 83 
 
visible by flow cytometry analysis at the end of the assay. In our case, TECs and T cells were 
co-cultured for 6 hours. 
 
•  Staining for dead cells using YO-PRO1 / Cell type specific antibody staining 
At the end of the assay, YO-PRO1 (Molecular Probes, Invitrogen, UK) was added to a 
final concentration of 1µM and cells were stained with anti-CD4 antibodies to target purified 
CD4
+T cells. Cells were incubated on ice for 30 minutes before being centrifuged at 300g for 
3  minutes.  Cells  from  the  wells  in  triplicate  were  pooled  together  were  resuspended  in 
medium before being analysed by flow cytometry. 
 
2-1-12/  Determination  of  nitric-oxide  (NO)  production  using  the  Griess 
method 
Cells were seeded at 2x10
5 in 200µL in 96 well-plates in the presence of anti-CD3 alone 
or in combination with anti-CD28 antibody. After 72 hours, the amount of NO released in the 
medium was measured using the Griess reagent system (Promega, UK). Briefly, 50µL of 
culture  supernatant  was  incubated  in  the  dark  with  50µL  sulfanilamide  solution  (1% 
sulfanilamide in 5 % phosphoric acid) for 10 minutes at room temperature in a 96 well flat 
bottom  plate.  The  same  volume  of  NED  solution  (0.1%  N-1-napthylethylenediamine 
dihydrochloride diluted in water) was added to the reaction. After 10 minutes of incubation in 
the dark, absorbance at 550nm was read using a microplate reader (BioRad). Measurements 
were  performed  in  duplicate  and  NO  concentrations  were  determined  by  comparing  the 
absorbance  values  obtained  for  the  sample  to  the  standard  curve  generated  by  the  serial 
dilution of a 0.1M nitrite sodium solution. Medium used to assess the amount of NO was 
phenol-red free (Sigma, UK). 
 
2-1-13/ Measurement of intracellular NO by flow cytometry 
Intracellular  NO  concentration  was  measured  using  the  DAF-FM  diacetate  probe 
(Molecular  Probes,  UK).  Briefly,  10
6  splenocytes  were  incubated  for  1  hour  at  37°C  in 
phenol-red  free  RPMI  medium  (Sigma)  containing  5µM  DAF-FM  diacetate.  Cells  were 
washed in medium to remove excess probe and incubated for an additional 20 minutes to 
allow complete de-esterification of the intracellular diacetates. Cells were then washed in 
cold PBS and stained for MSCs’ markers. Treated samples were analysed by flow cytometry. 84 
 
2-1-14/ Fluorescence microscopy 
When fluorescent microscopy was done on DCs and TECs, coverslip were pre-coated 
with poly-L-lysine (Sigma, UK) for 10 minutes at room temperature and washed three times 
with 1X PBS.  
Cells were washed 3 times with 1X PBS, and 4% paraformaldehyde (PFA) in PBS added 
to the cells for 7 minutes at room-temperature (RT). PFA was washed off by rinsing the cells 
3 times with PBS. 200 µL of 0.1% Triton X-100 in PBS was added to the cells for 5 minutes 
at RT and cells were subsequently washed 3 times with PBS. First antibody was added at the 
appropriate concentration in PBS containing 1% BSA (Sigma, UK) to the cells and incubated 
for  20  minutes  at  RT  in  the  dark.  Coverslips  were  washed  3  times  with  PBS  and  the 
secondary antibody added in PBS with 1% BSA for a further 20 minutes at RT in the dark. 
Cells were washed three times and DAPI (Molecular Probe, UK) nuclear counterstain added 
at 1 µg/mL in PBS with 1% BSA for 10 minutes at RT in the dark. Coverslips were washed 4 
times in PBS and mounted on a slide with some mounting medium (VectroLab, UK). Slides 
were left overnight in the dark at 4° C to allow the mounting medium to harden. Slides were 
read on a fluorescent microscope (Leica, UK) at different magnifications (x40 and x100) and 
meaning of fluorescence analysed using OpenLab3.1.5 software (OpenLab, USA). 
For cytokeratin detection, mouse mAb to human cytokeratin 5, 6, 8, 17 and probably 19 
(mouse IgG1, clone MNF116; Dako-Denmark) and cross reactive with mouse cytokeratin 
was  used.  Secondary  antibody  was  a  FITC-labelled  rabbit  antibody  to  mouse  F(ab)’2 
(DakoCytomation).  Mouse  MHC  II  molecule  was  detected  using  a  pan  mouse  MHC  II 
molecules  (rat  IgG2b,  clone  M5/114.15.2;  Santa-Cruz)  and  the  secondary  was  a  FITC 
labelled goat anti-rat IgG. Tissue transglutaminase 2 was detected using a rabbit polyclonal 
antibody H-237 clone (rabbit IgG, Santa Cruz). 
 
2-1-15/ Detection of TG2 activity 
TG2 enzyme activity was detected by fluorescence microscopy. Thyroid epithelial cells 
were gorwn in medium or stimulated with a combination of IFNγ (Peprotech, UK; 200 units 
/mL), TNFα (Peprotech, UK; 200 units /mL) and IL-1β (Peprotech, UK; 200 units /mL). At 
the end of the assay, cells were incubated in TG2 assay buffer (965µL of 100mM Tris/HCl 
(pH 7.4), 25µL of 200mM CaCl2) for 15 minutes. 10µL of a 10mM solution of biotinylated 
monodansyl-cadaverine (Cambridge Biosciences, UK) for 1 hour at room temperature. The 
reaction was stopped with 25mM EDTA for 5 minutes at room temperature. The cells were 85 
 
gently washed once with PBS abd fixed with 4% paraformaldehyde for 10 minutes at room 
temperature.  The  detection  for  the  incorporation  of  the  cadaverine  substrate,  cells  were 
incubated which was detected using streptavidin-FITC (Sigma, UK, 1:75). 
Coverslips were washed 4 times in PBS and mounted on a slide with some mounting 
medium  (VectroLab,  UK).  Slides  were  left  overnight  in  the  dark  at  4°  C  to  allow  the 
mounting medium to harden. Slides were read on a fluorescent microscope (Leica, UK) at 
different  magnifications  (x40  and  x100)  and  data  analysed  using  OpenLab3.1.5  software 
(OpenLab, USA). 
 
2-1-16/ Treatment of TAZ10 mice with Cystamine 
As described in a transgenic mouse model of Huntington diseases (Karpuj et al, 2002; 
Dedeoglu et al 2002), TAZ10 mice were treated with 100uL of 0.01M daily injection of 
cystamine dihydrochloride (Sigma, UK) dissolved in PBS. Treatment lasted for 7 days. 
Cardiac blood samples were collected from mice under anesthesia following conditions 
imposed by the Home Office. Blood was collected in eppendorf tubes supplemented with 
heparin. Mice were culled and spleen, cervical and mesenteric lymph-nodes isolated. Cells 
were stained for specific markers and analysed by flow cytometry. 
 On  the  other  hand  thyroids  were  frozen  down  in  LAMB  OCT  embedding  medium 
(Raymond A Lamb, UK) for further histology. 
 
2-1-17/ Statistical Analysis 
Statistical differences between groups were determined with the unpaired Student’s t test 
using  Prism  software  (GraphPad,  USA).  Values  of  probability  were  considered  to  be 
significant when p< 0.05. 
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2-2/ Material and Methods Part 2: Human Work 
2-2-1/ Cell-lines 
IB3-1 (human bronchial cell-line bearing the common CF mutation ∆F508 of the CFTR 
gene) and C38 (Isogenic CFTR rescued IB3-1 cell-line) cell lines were grown in petri-dishes 
pre-coated in LHC-Basal medium (Invitrogen, UK) containing 0.5mg/mL Fraction V BSA 
(Calbiochem, UK), 10µg/mL fibronectin (BD Biosciences, San Diego, CA) and 35µg/mL 
collagen II (BD Biosciences, San Diego, CA) for a minimum of 2 hours at 37°C. Cells were 
grown in LHC-8 medium (Invitrogen, UK) supplemented with 5% of low-endotoxin FCS 
(Autogen Bioclear, UK) and 100 U/mL Penicillin/streptomycin (Cambrex, UK). 
Where specified, were stimulated for 6 h with R283 (250 µM) or KCC009 (250 µM), 
ionomycin (1 µM; Calbiochem), BAPTA-AM (5 µM, Calbiochem), EUK 134 (50 µg/ml), 
rosiglitazone  (10  µM),  NAC  (10  mM),  proteasome  inhibitor  MG132  (50  µM  for  6  h; 
Calbiochem),  or  R283  for  24  h,  followed  by  6-h  rosiglitazone.  Normal  human  bronchial 
epithelial 16HBE cells were cultured in the same way. 
 
2-2-2/ Patients 
All patients signed consent form prior to the study. Study was performed according to the 
protocol  approved by the National Research Ethics Service, Southampton and south west 
Hampshire Research Ethics Committee (Reference Number 07/H0502/117): “Understanding 
the role played by myeloid derived suppressor cells (MDSCs) in patients with rheumatoid 
arthritis (RA) and the effect of anti-TNFα therapy”. 
 
2-2-3/ Flow cytometry and antibodies 
PBMCs were collected and washed in cold FACS Buffer (1X PBS supplemented with 
0.1%  FCS  and  0.05%  Sodium  Azide).  Antibodies  used  were  conjugated  to  fluorescein 
isothiocyanate  (FITC),  phycoerythrin  (PE)  or  peridinin  chlorophyll  protein  (PerCP)  or 
allophycocyanin (APC). Tandem dyes were also used: cyanin conjugated to phycoerythrin 
(PE-Cy5  and  PE-Cy7)  or  allophycocyanin  (APC-Cy7)  or  peridinin  chlorophyll  protein 
(PerCP-Cy5). Samples were acquired with FACSCanto and analysed using the FACSDiva 
Software (BD Biosciences). Cells were stained for CD11b (mouse IgG1, clone CBRM1/5; 
eBiosciences), CD11c (mouse IgG1, clone 3.9; eBiosciences), CD14 (mouse IgG1, clone 87 
 
61D3; eBiosciences), CD15 (mouse IgM, clone HI98; eBiosciences), CD33 (mouse IgG1, 
clone WM53; eBiosciences), CD34 (mouse IgG1, clone 563; BD Pharmingen) and HLA-DR 
(mouse IgG2b, clone LN3; eBiosciences). 
Samples were acquired with FACSCanto and analysed using the FACS Diva Software 
(BD Biosciences). 
 
2-2-4/ ELISA 
Production of cytokines was assessed by ELISA. Supernatants were tested for cytokine 
content such as IL-1β, IL-6, IL-8 and TNFα (All purchased from R&D Systems, UK). Flat-
bottom 96-well maxisorp plates (Nunc, UK) were coated overnight at room temperature with 
capture antibody diluted in PBS (100µL per well). Capture antibody was discarded and plate 
was  washed  three  times  with  washing-buffer  (0.05%  Tween-20  in  PBS,  pH  7.2-7.4)  by 
inverting the plate onto clean paper towels. Plate was blocked for a minimum of 1 hour with 
300µL of blocking-buffer (1% BSA in PBS, pH 7.2-7.4) per well at room temperature. Plate 
was washed three times as previously described and 100µL of standard or sample diluted in 
blocking-buffer was added per well and the plate incubated at room temperature for 2 hours. 
Plate  was  washed  as  previously  described  and  biotinylated  detecting  antibody  diluted  in 
blocking-buffer  was  plated  out  (100µL  per  well)  and  incubated  for  2  hours  at  room 
temperature. 
Wells were washed 3 times with washing-buffer and 100µL/well of a  1:1000 dilution of 
avidin alkaline-phosphatase (Sigma, UK) in blocking-buffer and the plate incubated for 40 
minutes at room temperature. After 3 washes, 100µL Sigmafast pNPP substrate (Sigma, UK) 
was added per well and watched for color development. Absorbance was read on an Biorad 
model 680 plate reader using Microplate manager software (BioRad, UK) at 405nm. Results 
were analysed and graphs plotted using Prism 4 program. 
 
2-2-5/ Isolation of PBMCs from the blood of control individuals, patients 
with Rheumatoid Arthritis and Systemic Lupus Erythematosus 
50mLs of blood from patients was harvested and diluted 1:1 with sterile PBS, 20mLs of 
diluted blood was carefully layered onto 20mLs of FicoLite-H at a density of 1.077 g/mL 
(LINARIS Biologische Produkte GmbH, Germany) and spun down for 20 minutes at 600g at 88 
 
21°C. The interphasse containing PBMCs was carefully harvested using a Pasteur pipette and 
washed twice in PBS. Cells were counted and used in subsequent assays. 
 
2-2-6/ Purification of CD34
+ cells from PBMCs 
CD34
+ cells were isolated using micro-beads conjugated CD34 microbeads (Myltenyi 
Biotech, Germany) as previously described. 
Briefly, purified PBMCs (Paragraph 2-2-5/) were resuspended in MACS buffer (2 mM 
EDTA and 0.5% BSA in PBS) and incubated with micro-beads conjugated with anti-CD34 
mAb (clone L3T4) for 15 minutes at 4°C. Excess of free micro-beads was washed away with 
MACS buffer and labelled cells passed through a separating MS column on a magnetic field. 
All experiments were performed using DMEM medium (Cambrex, UK) supplemented 
with 10% Foetal Calf Serum (Globepharm), 0.3 mg/mL L-glutamine (Cambrex, UK), 100 
U/mL Penicillin/streptomycin (Cambrex, UK), 1mM non essential amino-acids (Cambrex, 
UK) and 1 mM sodium pyruvate (Cambrex, UK) at 37°C with 5% CO2. 
 
2-2-7/ T cell proliferation by (
3H) thymidine incorporation 
T cell proliferation was assessed by measurement of tritiated thymidine incorporation. 
Briefly, freshly isolated PBMCs were cultured in triplicate in 96 well plates at 5x10
4 cells per 
well  in  culture  medium  containing  soluble  α-CD3  (clone  OKT-3,  made  in  house)  at 
10µg/mL. Purified CD34
+ cells were eventually added at a PBMC:CD34
+ cells ratio of 1:1 or 
1:5.  
Cells were co-cultured for 72 hours at 37°C in 5% CO2. Each well was then pulsed with 1 
µCi 
3H Thymidine for the last 12 hours of culture. Plates were harvested onto filtered plates 
(Perkin Elmer) and 
3H thymidine incorporation measured in a microplate scintillation counter 
(Packard). Data are expressed as cpm (count per minute) and were plotted as mean average of 
the triplicates. 
 
2-2-8/ Fluorescence microscopy 
C38 and IB3-1 cell-lines: coverslips were pre-coated for a minimum of 2 hours in LHC-
Basal medium (Invitrogen, UK) containing 0.5mg/mL Fraction V BSA (Calbiochem, UK), 89 
 
10µg/mL  fibronectin  (BD  Biosciences,  San  Diego,  CA)  and  35µg/mL  collagen  II  (BD 
Biosciences, San Diego, CA). 
Cells were washed 3 times with 1X PBS, and 4% paraformaldehyde (PFA) in PBS added 
to the cells for 7 minutes at room-temperature (RT). PFA was washed off by rinsing the cells 
3 times with PBS. 200 µL of 0.1% Triton X-100 in PBS was added to the cells for 5 minutes 
at  RT  and  cells  were  subsequently  washed  3  times  with  PBS.  The  first  antibody  at  the 
appropriate concentration in PBS containing 1% BSA (Sigma, UK) was added to the cells 
and incubated for 20 minutes at RT in the dark. Coverslips were washed 3 times with PBS 
and the secondary antibody added in PBS with 1% BSA for a further 20 minutes at RT in the 
dark. Cells were washed three times and DAPI (Molecular Probe, UK) nuclear counterstain 
added at 1 µg/mL in PBS with 1% BSA for 10 minutes at RT in the dark. Coverslips were 
washed 4 times in PBS and mounted on a slide with some mounting medium (VectroLab, 
UK). Slides were left overnight in the dark at 4° C to allow the mounting medium to harden. 
Slides were read on a fluorescence microscope (Leica, UK) at different magnifications (x40 
and x100) and data analysed using OpenLab3.1.5 software (OpenLab, USA). 
For primary antibodies, anti-phosphotyrosine PY99 mAb (mouse IgG2b, Santa Cruz), 
anti-PPARγ  (clone  E8,  mouse  IgG1,  Santa  Cruz)  and  anti  TG2  mAb  (clone  CUB1402, 
NeoMarkers)  were  used.  FITC  conjugated  rabbit  anti  mouse  IgG  (Sigma)  was  used  as  a 
secondary antibody. 
 
2-2-9/ Confocal microscopy 
Cell  lines  were  fixed  in  methanol  and  permeabilized  with  0.5%  Triton  X-100  prior 
incubation with primary Abs. Frozen tissue sections were fixed in acetone for 10 min. Anti-
phospho-p42/p44  (1:500;  Cell  Signaling  Technology),  anti-phosphotyrosine  PY99  mAb 
(1:80, mouse IgG2b), anti- PPARγ (clone E8, sc-7273, 1:100, mouse IgG1; clone H100, sc-
7196, 1:100, rabbit polyclonal IgG; Santa Cruz Biotechnology), anti-ubiquitin (1:100 clone 
FL-76, rabbit polyclonal IgG), anti-histone deacetylase 6 (HDAC6; 1:100 clone H300, rabbit 
polyclonal IgG), anti-p65 NF-κB (F-6; 1:100), and anti-ICAM-1 (15.2; 1:200) (Santa Cruz 
Biotechnology)  Abs  were  used  for  first  Ab.  The  Ag  expression  and  distribution  were 
visualized by indirect immunofluorescence at confocal microscope (Leica). 
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2-2-10/ Detection of TG2 activity 
TG2 enzyme activity was detected by fluorescence microscopy. Thyroide epithelial cells 
were gorwn in medium or stimulated with a combination of IFNγ (Peprotech, UK; 200 units 
/mL), TNFα (Peprotech, UK; 200 units /mL) and IL-1β (Peprotech, UK; 200 units /mL). At 
the end of the assay, cells were incubated in TG2 assay buffer (965µL of 100mM Tris/HCl 
(pH 7.4), 25µL of 200mM CaCl2) for 15 minutes. 10µL of a 10mM solution of biotinylated 
monodansyl-cadaverine  (Cambridge  Biosciences,  UK)  was  added  for  1  hour  at  room 
temperature. The reaction was stopped with 25mM EDTA for 5 minutes at room temperature. 
The cells were gently washed once with PBS abd fixed with 4% paraformaldehyde for 10 
minutes at room temperature. The detection for the incorporation of the cadaverine substrate, 
cells were incubated which was detected using streptavidin-FITC (Sigma, UK, 1:75). 
Coverslips were washed 4 times in PBS and mounted on a slide with some mounting 
medium  (VectroLab,  UK).  Slides  were  left  overnight  in  the  dark  at  4°  C  to  allow  the 
mounting medium to harden. Slides were read on a fluorescent microscope (Leica, UK) at 
different  magnifications  (x40  and  x100)  and  data  analysed  using  OpenLab3.1.5  software 
(OpenLab, USA). 
 
2-2-11/ Quantitative and semi-quantitative RT-PCR 
Quantitative  RT-PCR  was  performed  using  iCycler  iQ  Multicolour  Real-Time  PCR 
Detector (Bio-Rad) with iQ TM SYBR Green supermix (Bio-Rad). A relative quantitative 
method  was  applied  for  TG2  mRNA  (Qiagen;  catalog  QT00081277),  normalized  by  the 
control GAPDH mRNA. 
Semi-quatitative PCR was performed to assess the relative expression of TNFα (forward 
primer:  5’-ggcccaggcagtcagatcatcttctcg-3’;  reverse  primer  5’-ggatgttcgtcctcctcacagggcaatg-
3’),  IL-1β  (forward  primer:  5’-ccctaaacagatgaagtgctccttccagg-3’;  reverse  primer:  5’-
gggatctacactctccagctgtagag-3’)  and  TG2  (forward  primer:  5’-ccgttttccactaagagatgc-3’; 
reverse  primers:  5’-aacataccttggaattttggg-3’)  and  β-actin  (forward  primer:  5’-
gatgacccagatcatgtttgagacc-3’; reverse primer: 5’-ggagcaatgatcttgatcttcattg-3’). 
 
2-2-12/ RNA interference 
IB3-1 cells were transfected with 50 nM human TG2, human PPARγ, and scramble small 
interfering RNAs (siRNAs) duplex using Hiperfect Transfection Reagent (Qiagen) at 37°C 91 
 
for 72 h. The target sequence of TG2 siRNA was 5’-CCGCGTCGTGACCAACTACAA-3’, 
and the whole-cell lysate was then analyzed for Western blot. The PPARγ siRNA is a pool of 
three  sequences,  as  follows:  CCAAGUAACUCUCCUCAAAtt, 
GAAUGUGAAGCCCAUUGAAtt,  and  CUACUGCAGGUGAUCAAGAtt.  Transfected 
cells  were  then  analyzed  by  confocal  microscopy  for  expression  using  anti-PPARγ  mAb 
clone E8 
2-2-13/ Western-Blot analysis 
First Abs anti-phospho-p42/p44 MAPKs (Cell Signaling Technology), PPARγ (clone E8 
sc-7273;  Santa  Cruz  Biotechnology),  TG2  (clone  CUB7402;  DakoCytomation),  Nε(γ-L-
glutamyl)-L-lysine isopeptide (clone 81DIC2; Covalab), and ubiquitin (1:100 clone FL-76, 
rabbit polyclonal IgG) were counterstained by a HRP-conjugated anti-IgG Ab (Amersham, 
General Healthcare). The amounts of proteins were determined by a Bio-Rad protein assay to 
ensure equal protein loading before Western blot analysis. Fifty micrograms of cell lysate 
were loaded in each lane. 
2-2-14/ Statistical Analysis 
Statistical differences between groups were determined with the unpaired Student’s t test 
using Prism software. Values of probability were considered as significant when < 0.05. 
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3/ Characterization of different subsets of 
myeloid cells: myeloid Dendritic Cells 
(DCs) and Myeloid Derived Suppressor 
Cells (MDSCs) 
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3-1/ Introduction 
 
Dendritic  cells  (DCs)  can  act  as  powerful  inducers  of  an  adaptive  immune  response. 
Because of their properties, DCs have been and are still used as tools in immunotherapeutic 
strategies to boost the immune system in cancer (Banchereau et al. 2005; Cerundolo et al, 
2004; Figdor et al. 2004). Tumor induced defects in DCs have been extensively studied. 
Patients with early-stage head and neck squamous-cell carcinoma have low levels of DCs 
(decrease of approximately 2 fold) in their peripheral blood with even fewer cells at later 
stages  (4 fold decrease) (Pak et al. 1995; Garrity et al. 1997; Almand et al. 2000). This 
decrease in the amount of immunocompetent DCs was associated with an increased number 
of immature DCs and immature myeloid cells. The accumulation of myeloid precursors at the 
tumor site and other lymphoid and non-lymphoid organs has been the focus of numerous 
studies in the last decade to explain the failed anti-tumor immune response (Reviewed in 
Bronte et al. 2005; Kim et al. 2006; Frey. 2006; Gabrilovitch. 2004). 
Myeloid  Derived  Suppressor  Cells  (MDSCs)  express  mainly  the  myelomonocytic 
markers  Gr1  and  CD11b  (Bronte  et  al.  1998  and  2000)  and  are  recruited  at  the  site  of 
inflammation  by  numerous  cytokines  such  as  G-CSF  or  GM-CSF  that  are  often  actively 
secreted by tumor cells (Kim et al. 2006; Serafini et al. 2004). MDSCs have been shown to 
strongly inhibit T cell proliferation both in mouse and human cancer (Bronte et al. 2000; Pak 
et al. 1995). Indeed, therapies aiming at reducing the pool of MDSCs (Suzuki et al. 2005) or 
inhibiting their actions (Bronte et  al. 2005) have been shown to strongly improve T cell 
proliferation and therefore anti-tumor immunity.  
 
While  the  role  of  MDSCs  in  tumor  expansion  has  been  extensively  documented 
(Gabrilovitch  et  al.  2004),  it  is  however  unclear  if  MDSCs  have  any  regulatory  role  in 
inflammation  in  general  and  in  autoimmune  diseases  both  mouse  and  human.  It  is  now 
apparent  that  there  is  a  strict  correlation  between  anti-tumor  responses  and  autoimmune 
diseases; in patients with melanoma for example, a good prognostic factor is the development 
of an autoimmune disease of the skin, vitiligo (Yee et al. 2000; Gogas et al. 2006).  
 
Indeed,  MDSCs  might  prevent  autoimmunity  by  inhibiting  pathogenic  self-reactive  T 
cells in a similar fashion as operated by the classic CD4
+ CD25
+ regulatory T cells (Tang et 
al.  2004)  whilst  suppressing  anti-tumor  responses.  To  address  the  role  of  MDSCs  in 
autoimmunity, we are using a humanized transgenic mouse model of autoimmune thyroiditis 94 
 
(TAZ10 model; Quaratino et al. 2004). In the TAZ10 model T cells express a human TCR 
isolated from T cells infiltrating the thyroid of a patient with thyroiditis (Quaratino et al. 
2004). The TAZ10 transgenic mice spontaneously develop autoimmune thyroiditis sharing 
the same clinical and histological changes as patients with Hashimoto’s thyroiditis.  
In this chapter I will discuss how using different methods to generate DCs from the bone-
marrow, and therefore the manipulation of MDSCs, can influence both the yield and quality 
of the DC population obtained. I will then describe the role and functions of MDSCs in the 
TAZ10 model of autoimmune disease. Finally, with the results obtained in mice, we will 
discuss  how  a  defect  of  MDSCs  influences  the  function  of  CD34
+  cells  in  patients  with 
Rheumatoid Arthritis and Systemic Lupus Erythematosus. Amid confusions on the nature and 
phenotype of MDSCs in human, I will clarify their phenotype to reflect their function and 
myeloid origins. 
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3-2/ Results Part 1: Generation of potent dendritic cells: Different 
methods, different outcomes 
 
Strategies to boost the immune system against cancer have been extensively studied and 
some are now being tested in various clinical trials. Although the results are encouraging, the 
effectiveness by which tumor cells create a powerful immuno-suppressive environment is 
detrimental to anti-tumor strategies (Khong et al. 2002; Dunn et al. 2002; Zitvogel et al. 
2006). 
DCs  are  at  the  forefront  of  an  effective  immune  response  as  they  bridge  innate  and 
adaptive immune responses. Numerous studies have exploited the ability of DCs to migrate to 
lymphoid tissues and efficiently induce the activation and proliferation of T lymphocytes. 
One example used DCs engineered to present specific tumor antigens to induce the activation 
of antigen-specific T cells (Pardoll et al. 2002).  
Before we embarked on such a project, it was important to optimize the technique to 
obtain a reproducibly high number of DCs with the highest presenting capacity. Here we 
describe how different techniques used to generate DCs from bone-marrow precursors can 
have an impact on the quality and yield of DCs obtained 
 
3-2-1/ Introduction – The spleen as a limited source of dendritic cells 
 
Different  subsets  of  dendritic  cells  have  been  described  in  mouse  tissues  such  as  the 
spleen, lymph-nodes or thymus (Vremec et al. 1992 and 2000; Kamath et al 2000; Henri et al. 
2001 and Hochrein et al 2001). In the spleen, three major populations of DCs expressing 
CD11c can be distinguished according to their expression of CD4 and CD8α. CD11c
+ DCs 
not expressing CD4 or CD8α favour the generation of regulatory responses by inducing the 
development of IL-10 secreting CD4
+ T regulatory 1 cells via the release of TGFβ (Zhang et 
al. 2005). Both CD4
+ CD8α
- and CD4
- CD8α
+ CD11c
+-DCs have been shown to promote 
strong T cell responses with CD8α
+ DCs being more efficient as they also express the DEC-
205  marker  involved  in  the  cross-presentation  of  exogenous  antigens  onto  MHC-Class  I 
molecules (Paragraph 1-2-2/; Dudziak et al. 2007; Bonifaz et al 2002 and 2004).  
We first explored the mouse spleen as a potential source of DCs. Flow cytometric analysis 
was  performed  on  splenic  cells  using  antibodies  directed  against  the  DC-specific  marker 
CD11c, MHC Class-II molecules (I-A
b) and activation marker CD86. Both CD86 and I-A
b 
markers  are  expressed  at  low  levels  by  immature  DCs  (iDCs)  and  are  upregulated  upon 96 
 
inflammation  (Banchereau  et  al.  2000).  Finally,  expression  of  CD8α  by  DCs  has  been 
associated with an increased ability of dendritic cells to cross-present antigens to MHC Class-
I molecules, especially those from apoptotic cells (Dudziak et al. 2007). 
 
 
Figure 3-1: The spleen is a limited source of dendritic cells 
Splenocytes from wild-type mice were stained for the expression of the CD11c marker (A). CD11c
+ cells were 
then  assessed  for  their  expression  of  MHC  Class-II  molecules  I-A
b,  CD86  and  CD8α  (B).  Samples  were 
analyzed by flow cytometry. Data shown is representative of 2 experiments. 
 
6 to 7% of the total splenic population expressed the myeloid marker CD11c (Figure 3-
1/A). These cells express a high level of I-A
b MHC class-II molecules (80%) and CD86 (~ 40 
%). Also, more than 30 % of the CD11c
+ cells expressed the CD8α marker (Figure 3-1/B). 
 
Despite a phenotype associated with potent immunogenic DCs, their numbers were too 
low to perform experiments with freshly isolated DCs or to produce the high quality DCs 
required for the development of DC based vaccines. Thus, other sources had to be considered 
to generate high numbers of professional DCs. 
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3-2-2/  Three  different  methods  to  generate  bone-marrow  derived 
dendritic cells 
 
Different  methods  have  been  published  describing  the  generation  of  DCs  from  bone-
marrow progenitors capable of generating a potent T cell response (Inaba et al. 1992; Lutz et 
al.  1999;  Son  et  al.  2002).  All  these  methods  have  in  common  the  use  of  GM-CSF  at 
20ng/mL  throughout  the  generation  and  LPS  used  to  induce  maturation.  GM-CSF  is  a 
cytokine  that  promotes  haematopoietic  stem-cells  to  differentiate  into  granulocytes  and 
monocytes (Burgess et al. 1980), justifying its use for the generation of dendritic cells from 
bone-marrow precursors. Methods are described in Figure 3-2. 
 
The supernatant from the culture of CT26GM, the CT26 colon carcinoma cell-line, stably 
transfected with a retrovirus containing the gene for murine GM-CSF (Dranoff et al. 1993) 
was used as a source of GM-CSF for the generation of BM-DCs using the three methods. 
Content of GM-CSF was assessed by ELISA and used at a final concentration of 20ng/mL. In 
many tumors, the production of IL-10 has been shown to alter the ability of mature dendritic 
cells  to  efficiently  promote  antigen-specific  T  cell  proliferation  and  the  maturation  of 
immature DCs through the decreased expression of costimulatory molecules (Reviewed in 
Gabrilovitch et al. 2004). By ELISA, I confirmed that CT26GM culture supernatant did not 
contain IL-10. Qualitatively and quantitavely, the use of CT26GM culture medium produced 
better BM-DCs than commercial GM-CSF. This could be due to other factors secreted by the 
tumor  cell-line  that  could  enhance  the  differentiation  and  maturation  of  BM-DCs 
(Gabrilovitch et al. 2004).  
 
One method known as “Inaba’s method” (Inaba et al. 1992) (Figure 3-2/A) involved the 
seeding of bone-marrow cells at 2x10
6 cells per mL in 24 well-plates. Medium is removed 
every two days and replaced with 1mL of fresh medium supplemented with GM-CSF. iDCs 
obtained  7  days  later  are  replated  before  LPS  is  added  the  following  day  and  incubated 
overnight for complete maturation.  
A second method or “Son’s method” (Son et al. 2002) (Figure 3-2/B), seeds 1x10
6 bone-
marrow progenitors in 5mL of GM-CSF containing medium per well of 6 well-plates. At day 
4 and 7 additional GM-CSF is added until DCs were considered to be immature 8 days later. 
Non-adherent  iDCs  were  replated  overnight  and  full  maturation  achieved  by  overnight 
stimulation with LPS. 98 
 
The  third  method  or  “Lutz’s  method”  (Lutz  et  al.  1999)  (Figure  3-2/C)  seeds  bone-
marrow progenitors in 100mm petri-dishes at 2x10
6 cells in 10mL of medium supplemented 
with GM-CSF. At Day 3 of the culture, 10mL of medium supplemented with GM-CSF is 
added to the petri-dishes. At day 6 and 8, plates are swirled to homogeneously resuspend the 
cells and 10mL of medium was harvested, centrifuged and the pellet resuspended in 10mL of 
fresh medium with GM-CSF. The resuspended cells are then seeded back to the same petri-
dishes.  At  day  10,  non-adherent  cells  considered  as  iDCs  were  harvested  and  replated 
overnight at 2x10
6 cells per well on 6 well-plates with 5 mL of medium. DCs obtained at this 
stage  were  considered  as  being  semi-mature  before  being  matured  by  an  overnight 
stimulation with LPS. 
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Figure 3-2: Description of the three different methods to generate bone-marrow derived dendritic cells 
(A) Method described by (Inaba et al. 1992). (B) Method described by (Son et al. 2002). (C) Method described 
by (Lutz et al. 1999). In all the different methods, GM-CSF was used at 20 ng/mL.  
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3-2-3/ Differential phenotype of BM-DCs following different methods of 
generation 
 
To  compare  their  efficiencies,  bone-marrow  derived  dendritic  cells  (BM-DCs)  were 
generated using these different protocols and their ability to stimulate T cells evaluated. 
 
During  the  generation  of  DCs  following  Inaba’s  method  (Inaba’s  DCs),  75%  of  the 
medium was discarded after the plate had been gently swirled before being replaced with 
1mL of fresh GM-CSF containing medium. In contrast, cells harvested during Lutz’s method 
were not discarded but resuspended into fresh medium supplemented with GM-CSF before 
being  seeded  back  to  the  same  petri-dishes.  I  counted  and  analysed  these  cells  by  flow 
cytometry  to  assess  whether  any  cells  of  the  myeloid  lineage  were  removed  during  the 
washing steps (Figure 3-3). 
 
 
Figure 3-3: Removal of non-adherent cells during the generation of BM-DCs removes myeloid cells and 
precursors 
Cells removed in Inaba’s  method at day 2 and 4  were counted (A) and their phenotype analyzed by  flow 
cytometry using the CD11c, Gr1 and CD19 markers (B). Cells harvested at day-8 during the generation of BM-
DCs following Lutz’s method were replated overnight and the expression of CD11c, Gr1 and CD19 assessed by 
FACs (C). Data are representative of two experiments. 
 
About 5x10
7 cells were seeded at the start of the culture whereas about 5x10
6 cells were 
removed in the washes performed at day 2 and 4 (Figure 3-3/A). Cells removed during each 101 
 
wash  were  then  analysed  for  their  expression  of  the  myeloid  marker  CD11c,  the  B  cell 
marker  CD19  and  Gr1  as  a  marker  for  cells  of  the  granulocyte  lineage  (Figure  3-3/B). 
Although CD19
+ cells were discarded after each step, high levels of CD11c
+ myeloid cells 
were also removed. Furthermore, at day-2 and 4, about 2 to 5 % of the cells removed were 
expressing the Gr1 marker. Because Gr1 has been described as a marker for cells of the 
granulocyte  lineage,  I  could  conclude  that  the  washing  steps  removed  this  contamining 
population. However, the Gr1 marker is also primarily  expressed in the bone-marrow by 
Myeloid Derived Suppressor Cells (MDSCs) (Refer to Chapter 3-2). MDSCs expressing the 
Gr1 and CD11b markers have been shown to  be the progenitors of cells of the myeloid 
lineage such as dendritic cells, macrophages and granulocytes (Bronte et al. 2000). Therefore, 
the removal of the Gr1
+ cells during Inaba’s method was detrimental as it meant the removal 
of myeloid precursors. In fact, the generation of BM-DCs following Inaba’s method led to a 
reduced yield compared to the two other methods (Figure 3-4/A). 
 
To further assess the effect of replating cells removed during washing in both Inaba’s and 
Lutz’s methods, non-adherent cells harvested at day 8 of the Lutz’s protocol were seeded 
back  into  fresh  wells  overnight  and  their  phenotype  analysed  (Figure  3-3/C).  Replating 
induced a decrease in expression of Gr1 (30% to 5%) and CD19 (20% to 8%). Decreased 
expression  of  Gr1  by  MDSCs  is  associated  with  their  differentiation,  the  replating  steps 
would further promote differentiation and maturation of myeloid precursors. Indeed, Lutz’s 
method whereby cells are re-seeded in the dishes after washing should enhance both the 
quality and yield of the final DC preparation. 
 102 
 
 
Figure 3-4: Yield and quality of immature and  mature DCs (iDCs and  mDCs respectively) obtained 
varies with the method used 
(A) Amount of iDCs and mDCs was evaluated for each method. Number of cells obtained was evaluated as a 
fold of increase compared to the number of cells seeded at day-0. Results are a pool of 5 different experiments. 
(B)  Cells obtained were analyzed by flow cytometry for their expression of CD11c, CD86 and I-A
b MHC 
Class-II molecules. Data is representative of 5 different experiments. 
 
The  quantity  of  iDCs  obtained  using  Son’s  method  was  2.5  fold  higher  compared  to 
Inaba’s  method;  whereas  the  amounts  of  mDCs  obtained  using  both  Inaba’s  and  Son’s 
methods were low.  The yields of iDCs and mDCs obtained when generating DCs using 
Lutz’s method were considerably higher (5 and 2 ½ fold increase respectively) compared to 
the other methods (Figure 3-4/A). Flow cytometric analysis was conducted on both iDCs and 
mDCs obtained with each of the methods. Although the CD11c marker for myeloid DCs was 
highly expressed by all iDCs (85 to 95% expression), its level was lower after maturation 
with LPS for Inaba’s and Son’s mDCs (50% and 70% respectively) whereas it remained 
unchanged when considering mDCs generated according to Lutz’s method (Figure 3-4/B). 
 
iDCs generated according to Inaba’s method expressed low amounts of CD86 (less than 
5%) with 50% of the cells expressing I-A
b molecules. However, further maturation with LPS 
lead to an abrupt drop in the expression levels of all the markers. Similarly, upon maturation, 
the percentage of DCs expressing CD86 and I-A
b MHC Class-II molecules decreases (15% 
and 40% respectively) with the second method.  
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iDCs obtained following Lutz’s method showed a high percentage of cells expressing 
CD11c (90%) and MHC-II (85%) whereas 18 % of the cells expressed the maturation marker 
CD86.  iDCs  matured  overnight  with  LPS  increased  their  expression  of  CD86  and  I-Ab 
molecules (2.5  and 4  fold respectively) with more than 90% of cells still expressing the 
CD11c myeloid marker (Figure 3-4/B).  
 
Since efficient stimulation of antigen-specific CD4
+T cells requires two signals provided 
by mDCs (Anderton et al. 2002; Chapter 1), the generation of BM-DCs following Lutz’s 
method  generated  high  numbers  of  DCs  expressing  high  amounts  of  MHC-II  and 
costimulatory molecules.  
The removal of 75% of the supernatant in Inaba’s method leads to the removal of myeloid 
and  precursor  cells.  The  small  surfaces  of  culture  of  Inaba’s  and  Son’s  method  are 
detrimental as it does not allow for the proper expansion and differentiation of myeloid cells 
into dendritic cells.  
 
3-2-4/ Addition of IL-4 increases the yield but reduces the quality of the 
BM-DCs obtained 
 
Generation  of  DCs  from  human  PBMCs  requires  both  GM-CSF  and  IL-4.  Indeed, 
omission of IL-4 drastically reduces the yield and the DCs generated present an immature 
phenotype, with poor stimulation and antigen presentation capacity (Sallusto et al. 1994). To 
try to further increase the number of cells obtained and their phenotype, IL-4 was added to 
the culture (Figure 3-5). IL-4 enhanced the yield by 350 fold (Figure 3-5/A) with an identical 
expression  of  CD11c,  I-A
b  and  CD86  (Figure  3-5/B).  As  previously  mentioned,  the 
expression of both DEC-205 and CD8α is associated with potent DCs, capable of efficient 
uptake and cross-presentation to generate potent CD4
+ and CD8
+ T cell immune response. 
The addition of IL-4 lead to a reduction of CD8α expression (versus 32% for GM-CSF alone) 
whereas only 35% (versus 95% for GM-CSF) of the cells generated expressed DEC-205 
(Figure 3-5/C).  Interestingly, all BM-DCs expressing CD8α also expressed DEC-205.  
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Figure 3-5: Effect of IL-4 on the generation of BM-DCs 
(A) BM-DCs were generated either with GM-CSF alone or GM-CSF + IL-4 and the yields determined as fold 
increase compared to the original number of cells seeded. (B) BM-DCs generated according to Son’s method 
with or without the addition of IL-4 were stained for CD11c, I-A
b and CD86 and analysed by flow cytometry. 
(C) mBM-DCs were also analysed by flow cytometry for their expression of CD8α and DEC-205. Data is 
representative of two different experiments. 
 
It seemed therefore that the increase in yield obtained with GM-CSF and IL-4 was made 
at the expense of the quality of the cells obtained. This phenomenon has previously been 
observed as DCs generated using GM-CSF and IL-4 showed a significant reduction in the 
expression  of  MHC-II  molecules  (Masurier  et  al.  1999).  I  therefore  decided  not  to 
supplement the culture medium with IL-4 when generating BM-DCs. 
 
3-2-5/ Full maturation of BM-DCs with LPS limits their half-life 
 
DCs are present in two major forms; immature (iDCs) and mature (mDCs). To further 
analyse the different processes leading to the full maturation of iDCs obtained at day 10, we 
assessed the effect of replating (day 11) and addition of maturing agent (day 12) on the 
phenotype of cells obtained following Lutz’s method.  
Replating of iDCs induced further maturation and upregulation of CD86 and MHC-II 
molecules. 96 % of these semi-mature DCs still expressed the myeloid CD11c marker. At this 105 
 
point, semi-mature dendritic cells did not show any major differences in their morphology; 
their  size  (Forward  Scatter  or  FSC)  and  granularity  (Side  Scatter  or  SSC)  remained 
unchanged (Figure 3-6). 
 
Multiple agents have been used to induce the full maturation of dendritic cells in culture. 
However, it is now established that although indirect inflammatory signals such as TNFα or 
IFNα cause the maturation of DCs, these DCs do not trigger the differentiation of T cells and 
their effector functions; these mature but unlicensed DCs promote the proliferation but not 
the full differentiation of CD4
+ T cells. On the other hand, direct  contact with pathogen 
products via TLR receptors ensures that mature DCs are fully licenced to generate, not only 
the  proliferation  of  CD4
+  T  cells,  but  also  to  promote  their  differentiation  and  effector 
functions (Spörri et al. 2005; Heath et al, 2005). Taking this into consideration, I focussed our 
interest on the use of LPS to further mature DCs.  I used LPS from Escherichia Coli (E.Coli) 
as  it  binds  both  CD14  and  TLR4  and  is  potent  at  inducing  the  production  of  key  pro-
inflammatory cytokines TNFα, IL1-β, IL-12 and IFNγ (Netea et al. 2002). 
Throughout culture CD11c expression remained constant at 96 % (Figure 3-6) whereas 
the  size  (FSC)  and  granularity  (SSC)  of  the  cells  increased  with  the  maturation  process, 
reflecting  the  morphological  changes  affecting  DCs  as  previously  reported  (Burns  et  al. 
2004). Similarly, throughout the maturation, the expression of CD86 increases by two fold 
after replating (18% to 36 %) to reach 69% after addition of LPS. 
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Figure 3-6: Replating produce an incomplete maturation of BM-DCs that is only achieved by the addition 
of LPS 
Lutz’s iDCs obtained at day 10 were first replated overnight before LPS was added or complete maturation. 
Cells obtained at the different stages were assessed for the expression of CD11c, I-A
b and CD86 molecules by 
flow cytometry. Keys for the culture recipient are described in the legend of Figure 3-2. Data is representative of 
more than 3 different experiments. 
 
Interestingly, the expression of I-A
b could be detected as two distinct populations: high 
(MHC-II
hi DCs) and low expressors (MHC-II
lo DCs). Although the total amounts of MHC-II
+ 
DCs remained stable during the maturation, the proportion of high expressers increased after 
replating (11% to 30%). Further maturation with LPS stimulation led to 65% of BM-DCs 
expressing high levels of MHC Class-II molecules (increase from 30% DCs). Thus, replating 
of iDCs in Lutz’s method promoted maturation but complete maturation was only achieved 
after the addition of the TLR4 ligand LPS.  
The  differential  expression  of  MHC  Class-II  molecules  was  associated  with  the 
expression of the maturation marker CD86. Indeed, MHC-II
hi DCs also expressed the highest 
levels of CD86 compared to MHC-II
lo DCs. “Lutz’s method” led to the generation of 65% 
MHC-II
hi DCs. These have previously been shown to promote a greater T cell proliferation in 
allogeneic Mixed Leucocyte Reaction (MLR). In addition, MHC-II
hi DCs pulsed with tumor-
antigen are able to provide protection after vaccinating mice with the tumor (Masurier et al. 
1999).  
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To assess the lifespan of mDCs, their phenotype was analysed after they were matured 
with LPS from Escherichia Coli (Figure 3-7). 
 
 
Figure 3-7: Lifespan of mDCs generated according to Lutz’s method 
mDCs obtained after LPS stimulation at day 12 when Lutz’s method was used were left in culture for up to 3 
days. Amount of viable cells as judged by the FSC-SSC profile was evaluated along with the expression levels 
of CD11c, I-A
b and CD86. Data is representative of more than three different experiments. 
 
Upon maturation, 69% of the cells express the co-stimulatory marker CD86 and 65% of 
the cells expressed high amounts of I-A
b MHC Class-II molecules (Figure 3-7). 1 day after 
maturation, although 94% of the cells were still expressing CD11c, the level of expression 
was much lower (4 fold lower) with only 66% of the cells being viable compared to 85 % 
after LPS stimulation. 10% of the cells lost their expression of CD86 whereas about 20% of 
cells reduced their expression of I-A
b (44%).  
After  3  days,  only  46%  of  cells  were  viable  and  the  expression  of  CD11c  had 
dramatically decreased (46% of the cells had extremely low level of expression). 55 % of 
cells still expressed CD86 although at lower levels. This confirmed previous studies showing 
that BM-DCs have a short lifespan when they reach their mature status. This short lifespan 
prevents an unwanted over amplification of the immune response that would be detrimental. 
Indeed, a recent study has found that in certain conditions, mature dendritic cells can switch 108 
 
phenotype to become regulatory and therefore dampen the immune response (Svensson et al. 
2004; Zhang et al. 2004). 
 
3-2-6/  Reduction  of  the  endocytic  activity  of  dendritic  cells  upon 
maturation with a TLR ligand 
 
In figure 3-5, I described that mature mDCs were either DEC-205
+ CD8α
- (62%) or DEC-
205
+  CD8α
+  (32%);  highlighting  their  probable  efficiency  in  antigen  processing  and 
presentation but also their ability to cross-present extracellular antigens on MHC-I molecules. 
The differences in size (FSC) and granularity (SSC) of the cells obtained at day 10 and 12 
(Figure 3-6) prompted me to analyse their morphology by light microscopy. iDCs obtained at 
day 10 displayed some dendritic processes increasing the surface of the cells for potential 
uptake of antigens from the surrounding environment. In contrast, adherent cells presented 
with the typical morphology of macrophages (Figure 3-8). 
 
Upon  maturation  with  LPS,  mDCs  displayed  numerous  dendritic  processes  and 
irregularity in their morphology compared to day 10- adherent cells, thus reflecting the high 
granularity of the cells previously observed by flow cytometry (Figure 3-6). This change in 
morphology observed for mDCs is associated with the formation of podosomes generated 
from  reorganisation  of  the  actin  cytoskeleton  (Burns  et  al.  2004).  The  formation  of 
podosomes is crucial for the migratory capacity of mDCs via cell motility and degradation of 
the extracellular matrix (West et al. 2008; Svensson et al. 2008).  
 
 
Figure 3-8: Maturation using TLR ligand induces a change in morphology of mDCs 
Adherent and non-adherent iDCs obtained at day 10 as well as day 12 mDCs were observed using a light 
microscope (x40 magnification) for their morphology. Arrows highlight the presence of podosomes on iDCs and 
mDCs. Cells were then observed through a fluorescent microscope (magnification: x100). 
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To associate the morphology of the DCs obtained with their ability to uptake exogenous 
materials, day 10 adherent cells, iDCs and mDCs generated following Lutz’s method were 
fed with latex beads for 30 minutes and observed with a fluorescence microscope after being 
stained for the myeloid markers CD11c and MHC Class-II molecules (Figure 3-9). 
 
 
  
Figure 3-9: Maturation reduces the capacities of mDCs to uptake latex beads
The different cell populations obtained at day 10 (non
were incubated with latex beads (blue) for 30 minutes and sta
fluorescence). Cells were then observed through a fluorescent microscope (magnification: x100).
 
9: Maturation reduces the capacities of mDCs to uptake latex beads 
The different cell populations obtained at day 10 (non-adherent iDCs and adherent cells) and 12 (mature DCs) 
were incubated with latex beads (blue) for 30 minutes and stained for CD11c (red fluorescence) and I
fluorescence). Cells were then observed through a fluorescent microscope (magnification: x100).
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adherent iDCs and adherent cells) and 12 (mature DCs) 
ined for CD11c (red fluorescence) and I-A
b (green 
fluorescence). Cells were then observed through a fluorescent microscope (magnification: x100). 111 
 
Adherent cells obtained at day 10 showed a high expression of MHC-II molecules that 
was not associated with the expression of the myeloid marker CD11c or the uptake of latex 
beads, thus confirming their macrophage-like phenotype. iDCs generated at day 10 expressed 
high amounts of CD11c and were efficient in uptaking latex beads while surface expression 
of MHC-II molecules was low (Figure 3-9). Upon maturation with LPS, mDCs displayed 
numerous dendritic processes and expressed high levels of I-A
b at the cell-surface while their 
ability to take-up latex beads was nearly abrogated (Figure 3-9).   
 
3-2-7/  Bone-marrow  derived  dendritic  cells  generated  following  Lutz’s 
method are potent at activating antigen specific T cells 
 
Activation of T cell proliferation is dependent on three signals. The first signal is the 
recognition by the TCR of the MHC:peptide complex present on antigen presenting cells. 
However, this signal needs to be associated with the second costimulatory signals and the 
third signals (from DC- and T- derived cytokines such as IL-2 and IL-12) that allow full 
activation of T cells (Anderton et al. 2002). Failure to provide efficient costimulation leads to 
T cell anergy and a deficient T cell response. I therefore used an assay to evaluate the ability 
of mDCs to deliver strong costimulatory signals to T cells when using an agonistic αCD3 
antibody that mimicked the TCR engagement (Figure 3-10). 
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Figure 3-10: mDCs provide strong costimulatory signals to T cells 
Proliferative  activity  of  T  cells  was  assessed  by  the  measurement  of  (
3H)  thymidine  incorporation.  (A) 
Stimulation of T cells with IL-2, αCD3 and αCD3/28. (B) The costimulatory activity of mDCs was assessed by 
co-cultivating T cells with mDCs generated following the different methods and αCD3. Data are representative 
of more than three different experiments. 
 
The  addition  of  IL-2  to  T  cells  induced  a  low  proliferation.  The  addition  of  αCD3 
antibody increased proliferation. Subsequent addition of αCD28 antibodies provided strong 
costimulatory activity to T cells resulting in a 3.5 fold increase in proliferation (Figure 3-
10/A). To address whether the mDCs generated can provide such a powerful costimulation 
and can therefore be substituted for αCD28 antibodies, we compared the proliferative activity 
of T cells with αCD3 and mDCs obtained using the three different methods. mDCs generated 
following Inaba’s and Son’s methods could provide weak costimulatory signals to T cells 
compared to αCD3/28 (p=*). On the other hand, high costimulatory activity was provided by 
mDCs generated according to Lutz’s method; confirming the mature phenotype previously 
observed (Figure 3-4 and 3-6). 
 
I  then  assessed  the  ability  of  mDCs  to  stimulate  antigen  specific  T  cell  proliferation 
(Figure  3-11).  To  answer  this  question,  we  used  the  TAZ10  mouse  model  which 
spontaneously  develops  destructive  thyroiditis  and  is  characterized  by  the  infiltration  of 
lymphocytes  into  the  thyroid.  These  transgenic  mice  express  a  human  TCR  specifically 
recognizing TPO536-547, a highly stimulatory agonistic cryptic antigen of thyroid peroxidase 113 
 
(TPO).  mDCs were co-cultured with T cells from TAZ10 mice at a DC:T cell ratio of 1:30, 
with increasing concentrations of theTPO536-547 antigen (from 0.01 to 10 µg/mL).  
 
 
Figure 3-11: mDCs generated following Lutz’s method are efficiently activating antigen specific T cells 
from TAZ10 mice 
mDCs were assessed their ability to induce antigen specific T cell proliferation. DCs:T cell ratio was 1:30 and 
the concentration of the antigen (TPO536-547) ranged from 0.01 to 10 µg/mL. T cell proliferation was measured 
by (
3H) thymidine incorporation. Data shown is representative of two different experiments. 
 
Son’s mDCs induced a very low level of T cell proliferation, Inaba’s DCs could induce a 
relatively  strong  T  cell  response.  Lutz’s  mDCs  were  highly  immunogenic  as  they  could 
promote an important T cell proliferation. 
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3-2-8/ Conclusions 
 
IL-10 is an important cytokine produced by tumor cells, which alters  the function of 
dendritic cells and their ability to promote efficient T cell response. IL-10 alters DC functions 
through  different  mechanisms  such  as  the  downregulation  of  costimulatory  molecules 
(Gabrilovitch et al. 2004; Steinbrink et al. 2002) or the blockade of DC maturation (Corinti et 
al. 2001, Morel et al. 1997). 
Beyond this alteration of the maturation of DCs by different soluble factors such as IL-10, 
it is now apparent that the choice of inflammatory signal used to mature DCs is critical to 
ensure an efficient and full T cell response. Indeed, only pathogen products (LPS, CpG etc.) 
signaling through TLR are capable of promoting the generation of mature licensed DCs that 
are  capable  of  inducing  not  only  T  cell  proliferation,  but  also  T  cell  differentiation  and 
effector functions. Maturation of iDCs with the soluble factors released by bystander cells 
upon inflammation, such as TNFα, led to the generation of mature unlicensed DCs that were 
only capable of inducing T cell proliferation (Spörri et al. 2005; Heath et al. 2005). 
 
This study addressed whether the quality of the DCs generated from murine bone-marrow 
was affected by the methodology used. In this respect, I used CT26GM culture supernatant as 
the  unique  source  of  GM-CSF  while  the  plastics  (petri-dishes  and  plates)  used  were 
identically treated and from the same company for all the different methods.  
Both  the  size  of  the  plastic  dish/plate  used  and  the  washing  steps  used  to  add  fresh 
cytokines had an important impact on the quality and yield of iDCs and mDCs obtained. The 
use of petri-dishes in Lutz’s method allowed the efficient expansion of myeloid progenitors 
that would otherwise not be able to expand up to 5-6 fold compared to 2 fold in Son’s method 
or no change  for  Inaba’s method (Figure 3-4).  The washing steps performed in “Inaba’s 
method”  resulted  in  the  loss  of  an  important  amount  of  myeloid  progenitors  that 
differentiated into myeloid DCs when replated in Lutz’s method (Figure 3-3). 
 
Phenotypic  (Figure  3-4  and  3-6)  and  functional  studies  (Figure  3-9,  3-10  and  3-11) 
revealed  that  Lutz’s  method  is  the  most  efficient  technique  to  generate  high  numbers  of 
potent iDCs and highly immunogenic mDCs.  
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3-3/ Results Part 2: Characterization of Myeloid Derived Suppressor 
cells  (MDSCs)  in  TAZ10  mice  with  spontaneous  autoimmune 
thyroiditis 
 
Autoimmune  diseases  (AID)  are  chronic-inflammatory  diseases.  AID  arise  from  a 
breakdown of immunological tolerance to self-antigens and the subsequent activation and 
expansion of self-reactive T cells (Reviewed in Vanderlugt et al. 2002 and Paragraph 1-4/). 
This activation of self-reactive T cells together with the generation of self-reactive B cells, 
the release of soluble factors (pro-inflammatory cytokines such as IL-1β, IL-6 or TNFα or 
nitric-oxide) and the activation of common signaling pathways of inflammation (NF-κB and 
p38 MAPK) are responsible for the destruction of the target tissue.  
Although the initial stimulus leading to these events are unknown, it is now clear that 
mechanisms  of  peripheral  tolerance  fail  to  prevent  the  activation  of  self-reactive  T  cells. 
CD4
+ CD25
+ Foxp3
+ regulatory T cells (Tregs) have been shown to be at the forefront of the 
mechanisms  of  peripheral  tolerance  as  a  deficiency  of  Tregs  has  been  linked  with  the 
development of AID (Sakaguchi et al. 1995; Asano et al. 1996; Suri-Payer et al. 1998).  
 
In the last decade another subset of regulatory cells has been extensively studied. Myeloid 
Derived Suppressor Cells (MDSCs) are cells of the myelomonocytic lineage that have been 
shown to differentiate into cells of the myeloid lineage such as granulocytes, macrophages or 
DCs.  Numerous  studies  have  described  MDSCs  as  expressing  both  the  myelomonocytic 
CD11b  and  Gr1  markers  (Figure  3-12/A  and  3-14/A),  other  markers  have  also  been 
described, such as CD31 or lineage specific markers such as F4/80 (macrophage) and CD11c 
(myeloid DCs) (Bronte et al. 2000).  
MDSCs have been shown to strongly inhibit T cell proliferation (Kusmartsev et al. 2000). 
We assessed the ability of MDSCs from WT mice to inhibit T cell proliferation.  The removal 
of MDSCs (Gr1
+ cells) from WT splenocytes increased the proliferation in response to the 
agonistic αCD3 antibody (Figure 3-12/B). 
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Figure 3-12: MDSCs from WT mice inhibit T cell proliferation in response to αCD3 
(A) Staining of splenocytes from wild-type mice with Gr1 and CD11b reveals the presence of MDSCs. (B) 
Proliferative  activity  of  splenocytes  from  WT  mice  was  assessed  by  (
3H)  thymidine  incorporation  with  or 
without the depletion of Gr1
+ MDSCs. Data is representative of more than three different experiments. 
  
The inability of the immune system to mount an effective anti-tumor response is a crucial 
immunological  problem  limiting  the  effects  of  therapeutic  strategies  in  cancer.  Although 
tumor specific T cells can be found in the blood and tumor (Tumor Infiltrating Lymphocytes 
or TILs) in melanoma, for example, they are rendered unable to effectively mount an anti-
tumor response. Two studies based on the vaccination of melanoma patients using melanoma 
tumor-antigens suggest that this unresponsiveness can be abrogated by the activation and 
expansion of T cells specific for tumor antigens not present in the vaccine (Germeau et al. 
2005; Lurquin et al. 2005). Activation of the few vaccine-specific T cells present leads to a 
change in the local microenvironment of the tumor which allows existing TILs, specific for 
non-vaccine tumor antigens, to be reactivated and new T cells and monocytic cells to be 
recruited. 
Thus,  inefficacies  of  active  immune  strategies  against  cancer  are,  in  part,  due  to 
mechanisms of evasion of the immune system by tumor cells. A recent study on patients with 
prostate  cancer  described  how  the  activity  of  two  enzymes  degrading  L-arginine  was 
involved in rendering TILs inactive at the tumor site (Bronte et al. 2005). Indeed, inhibition 
of nitric-oxide synthase (NOS) and arginase (ARG) was able to abrogate the unresponsive 
status of the TILs. 
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MDSCs  have  been  shown  to  mediate  their  action  on  T  cells  via  the  products  of 
degradation of L-arginine by inducible NOS and ARG (Reviewed in Bronte et al. 2005). 
Studies in tumor-mouse models (Song et  al. 2005; Bunt et al. 2006)  and human cancers 
(Almand et al. 2001) have highlighted an accumulation of MDSCs in tumors and lymphoid 
organs. Indeed, wild-type mice (C57BL/6) had an increase in the amount of MDSCs present 
in the bone-marrow (Figure 3-13/A) and lymphoid tissues (Figure 3-13/B) 7 and 15 days after 
challenge with the melanoma cell-line B16. The presence of MDSCs in the LN not draining 
the original tumor could be explained as B16 tumor quickly metastasizes in the lungs. 
 
 
Figure 3-13: MDSCs accumulate in the spleen of mice injected with the B16 melanoma cell-line  
Accumulation of Gr1+ CD11b+ MDSCs in the bone-marrow (A) and different lymphoid tissues (B) draining 
and  not  draining  the  tumor  in  mice  challenged  with  the  melanoma  B16  tumor  cell-line.  Data  shown  is 
representative of one experiment involving 4 mice (1 control mouse injected with PBS and 3 challenged with 
B16) out of two different experiments. 
 
MDSCs accumulating in tumor mice models and cancer patients inhibit T cell function 
and proliferation and therefore promote tumor growth. These results imply an important role 
of  MDSCs  in  cancer,  I  wanted  to  explore  their  function  in  another  model  of  chronic 
inflammatory disease such as AID. 
 
TAZ10 transgenic mice spontaneously develop autoimmune thyroiditis characterized by 
the activation of self reactive T cells that infiltrate the thyroid triggering its destruction. To 
further  address  the  presence  of  any  other  regulatory  network  in  autoimmune  disease,  we 118 
 
assessed whether MDSCs were present and had any role in the TAZ10 transgenic mouse 
model of autoimmune thyroiditis.  
 
3-3-1/ Myeloid Derived Suppressor Cells accumulate in mice affected by 
an autoimmune pathology 
 
From studies in tumor mouse models, it seemed likely that MDSCs would accumulate in 
TAZ10 mice as a result of ongoing inflammation. As they seemed to be unable to prevent the 
activation of self-reactive T cells leading to the destruction of the thyroid, we hypothesized 
that MDSCs were not present in autoimmune disease or had their function altered in these 
mice.  
 
By three-colour FACS analysis, I investigated whether MDSCs were present in TAZ10 
transgenic mice. In the spleen of TAZ10 mice, a cell population expressing very high levels 
of both Gr1 and CD11b markers was found (Figure 3-14/A). This cell population represented 
3 to 8 % of the total splenic population in TAZ10 mice and was heterogeneous as the CD31 
marker is not equally expressed (Fig 3-14/A). The heterogeneity of these cells was not only 
restricted to the markers expressed but also to their morphology. Indeed, MDSCs present 
with various sizes (FSC) and granularity (SSC) (Fig 3-14/B). 
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Figure 3-14: MDSCs are present in TAZ10 mice and express high levels of Gr1 and CD11b markers  
(A) Splenocytes from TAZ10 transgenic mice were analyzed by three-color FACS analysis for the expression of 
Gr1 and CD11b markers.  The gated Gr1
+ CD11b
+ population was further analyzed for the expression of the 
CD31  marker.  (B)  Analysis  of  the  size  (FSC)  and  granularity  (SSC)  of  Gr1
+  CD11b
+  cells.  Data  is 
representative of more than five different experiments. 
 
Along with Ly6-C, CD31 has been described as a differentiation marker for the myeloid 
lineage and therefore as being a marker characteristic of mature granulo-monocyte precursors 
(Bailey et al. 2006; Zhu et al. 2007). Interestingly I detected a different expression of CD31 
as 27% of MDSCs expressed this marker (Figure 3-14/A). This result confirms the notion 
that MDSCs are composed of precursor cells at different stages of differentiation toward 
granulocytes, macrophages or DCs. From this result, I was confident I could use the Gr1 and 
CD11b markers to describe the population of MDSCs in TAZ10 mice.  
 
I  then  assessed  whether  TAZ10  mice  developing  AID  were  deficient  in  MDSCs 
compared to WT mice, which could explain the development of the disease. Using Gr1 and 
CD11b  markers,  I  investigated  the  distribution  of  MDSCs  in WT  and TAZ10  transgenic 
mice. At the age of 4 months, TAZ10 mice spontaneously develop histological, hormonal and 
clinical changes comparable with human Hashimoto’s autoimmune thyroiditis (Quaratino et 
al. 2004). From 1 to 4 months of age, the destruction of the thyroid by self-reactive T cells is 
such that inflammation would be at its maximum and would therefore be beneficial for the 
function and accumulation of MDSCs. I assessed the proportion of these cells in different 120 
 
tissues  by  flow  cytometry  both  in  WT  and  TAZ10  mice  (1  month  of  age)  affected  by 
autoimmune thyroiditis.  
As shown Figure 3-15/A, MDSCs preferentially accumulated in the spleen of diseased 
mice.  The  number  of  MDSCs  within  the  spleen  showed  a  3  fold  increase.  They  also 
accumulated in the lymph-nodes (LN) draining the thyroid affected by the disease of TAZ10 
mice whereas negligible amounts (0.18%) of MDSCs were detected in the LN of WT mice. 
Analysis of these cells in other tissues (Figure 3-15/B) confirmed this trend as they also 
accumulated in LNs not draining the thyroid.  
 
 
Figure  3-15:  Myeloid  Derived  Suppressor  Cells  accumulate  in  different  lymphoid  and  non-lymphoid 
organs in TAZ10 transgenic mice 
(A) Two-color flow cytometry analysis was performed to assess the percentage of cells expressing Gr1 and 
CD11b  markers  in  the  spleen  and  draining  lymph-node  of  both  wild-type  and  TAZ10  mice.  Result  is 
representative of more than 20 mice. (B) Percentage of Gr1
+ CD11b
+ myeloid suppressor in different organs 
from both wild-type and TAZ10 mice. Data is representative of more than 20 mice.  
 
 
MDSCs are generated from common myeloid progenitor within the bone-marrow and 
normally account for about 30% of the bone-marrow cell population (Bronte et al. 2000). In 
the TAZ10 model, MDSCs accounted for nearly half of the total cell population in the bone-
marrow highlighting an important change in haematopoiesis in these mice (Figure 3-15/B). 
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This finding is in contradiction with the study of another subset of regulatory cells in 
TAZ10 mice. In the last decade, the classic CD4
+ CD25
high CD62L
high Foxp3
+ regulatory T 
cells (Tregs) have been extensively studied both in autoimmune diseases and in cancer. Tregs 
have been shown to play an important role in the prevention of autoimmune diseases and in 
the suppression of anti-tumor responses (Tang et al. 2004). It appeared that there was an 
important reduction of the number of Tregs in the spleen of TAZ10 (2.5%) compared to WT 
(8%)  mice  (Badami  et  al.  2005  and  Badami  E,  Cexus  O,  Londei  M  and  Quaratino  S. 
Manuscript in preparation). Interestingly, the proportion of regulatory T cells in TAZ10 mice 
decreased with time and 6 month-old mice (1.3%) had a reduced amount of Tregs compared 
to younger mice.  
 
3-3-2/ Distribution of Gr1
+ CD11b
+ Myeloid Derived Suppressor Cells in 
the spleen during the course of autoimmunity 
 
In the light of these findings on Tregs, I wanted to evaluate any link between the numbers 
of  MDSCs  and  the  evolution  of  the  disease  in  TAZ10  mice.  We  therefore  assessed  the 
proportion of these cells in the spleen of diseased and WT mice over time. 
 
 
Figure 3-16: In TAZ10 mice, the percentage of MDSCs is higher than WT mice and decrease over time 
FACS analysis was performed on splenocytes using Gr1 and CD11b markers in WT and TAZ10 mice for up to 
6 months of age. Pooled results of more than 20 mice. 
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Although Gr1
+ CD11b
+ MDSCs are present in the spleen of WT mice, their distribution 
suggests  that  they  accumulate  in  the  spleen  of  TAZ10  mice  during  the  acute  phase  of 
inflammation (average of 5% at 1 month of age versus 2% in WT) while they decrease as the 
inflammatory process fades, to remain just above the numbers present in WT mice (2.5% 
from 2 ½ month to 6 months of age) (Figure 3-16).  
Mice below the age of 1 month could not be used to quantify the numbers of MDSCs as 
they were still not weaned. This would raise a question in relation to the amount of MDSCs at 
the onset of the disease. To address this question, current experiments aimed at performing 
adoptive  transfer  of  naïve  TAZ10  T  cells  (TAZ10-TN)  (TCR-Vβ1
+  CD4
+  CD44
lo  CD25
- 
CD62L
hi) into Rag-2 knock-out transgenic mice (Rag2
-/- mice) to mimic the development of 
the disease are underway. From the first results recently obtained, we can hypothesize that the 
onset of the disease in TAZ10 mice is early and occurs in the first few days of life as TAZ10-
TN  proliferate  in  the  thyroid  and  draining  LNs  of  Rag2
-/-  mice  within  a  week  after  the 
adoptive transfer occurred (Paragraph 4-3-3/).  
 
We  have  observed  a  similar  time  course  in  another  model  of  autoimmune  disease 
(arthritis). In the collagen-induced arthritis model (CCIA model), the transgenic mice which 
express  the  TCR-Vβ12  transgene,  develop  chronic  arthritis  which  resembles  rheumatoid 
arthritis  (RA)  after  immunization  with  collagen-type  II  and  Complete  Freund’s  Adjuvant 
(CFA) (Mauri et al. 1997). Immunized mice were culled 40 days after immunization with a 
mean time of onset of disease of 20 days post-immunization. MDSCs peaked at the acute 
phase of inflammation whilst they decreased to the level present in WT mice as the disease 
became chronic (Tan LA, Cexus O et al. Manuscript in preparation). This result, in keeping 
with the present results, suggests a correlation between the numbers of MDSCs and the stage 
of the disease.  
 
In TAZ10 transgenic mice the inflammatory process leads to a progressive destruction of 
the  thyroid  (Quaratino  et  al.  2004).  At  the  time  of  onset  and  during  the  early  stages  of 
thyroiditis, Gr1
+ CD11b
+ MDSCs accumulate in the lymphoid organs of TAZ10 mice. 
These  results  confirmed  the  presence  of  MDSCs  in  a  mouse  model  of  autoimmune 
disease. It is now known that the accumulation of MDSCs is detrimental both in mouse and 
human cancers as they promote a strong inhibition of anti-tumor responses (Almand et al. 
2001; Bunt et al. 2006). However, the accumulation of MDSCs in TAZ10 mice was not able 
to prevent the initiation and development of the destructive thyroid disease by inhibiting the 123 
 
activity of self-reactive T cells. Therefore, I wondered whether the increased numbers of 
MDSCs  in  TAZ10  mice  have  the  same  regulatory  functions  on  T  cells  as  it  has  been 
described in cancer.  
 
3-3-3/  Myeloid  Derived  Suppressor  Cells  display  a  strong  inhibitory 
function on T cells in-vitro. 
 
The  functional  activity  of  MDSCs  was  investigated  by  measuring  their  effect  on  the 
proliferative activity of TAZ10 T cells.  Splenocytes were depleted of MDSCs with anti-
mouse Gr1 microbeads (BD Biosciences, UK). Purity was assessed by flow cytometry using 
anti-mouse  Gr1-FITC  and  anti-mouse  CD11b-PE.  Splenocytes  were  then  stimulated  with 
either  αCD3  or  αCD3/CD28  agonistic  antibodies  and  their  proliferation  measured  by 
quantification of (
3H) thymidine uptake.  
 
 
Figure 3-17: Depletion of Gr1 positive cells remove the population of myeloid derived suppressor cells 
Spleens  from  wild-type  or  TAZ10  mice  were  stained  with  a  FITC  labeled  anti-Gr1  antibody  and  Gr1-
microbeads for further depletion. Efficiency of depletion was assessed by flow cytometry. Data is representative 
of more than 20 different experiments. 
 
The  efficiency  of  the  in-vitro  depletion  of  Gr1  positive  cells  was  assessed  by  flow 
cytometry  after  depletion  using  an  antibody  targeting  the  Gr1  marker  (Clone  RB8-6C5) 
(Figure  3-17).  As  previously  reported  and  observed  in  WT  mice  (Figure  3-12/B),  T  cell 
proliferation  in  response  to  the  agonistic  αCD3  antibody  was  drastically  enhanced  after 
depletion of Gr1
+ cells. Interestingly, the strong stimulation provided by the αCD28 antibody 
was not able to abrogate the strong inhibition on T cells displayed by MDSCs, suggesting a 
suppressor role for these MDSCs (Figure 3-18/A). 
CD4
+  CD25
+  Foxp3
+  Tregs  have  been  shown  to  dampen  the  immune  response  by 
inhibiting the proliferation of effector T cells. Upon depletion of Tregs I could observe a 124 
 
threefold increase in T cell proliferation in response to αCD3 stimulation. However, Tregs 
were  not  able  to  abrogate  the  strong  stimulation  provided  by  both  αCD3  and  αCD28 
antibodies as previously reported (Thornton et al. 1998). This suggested that the suppressive 
functions  mediated  by  Tregs  from  TAZ10  mice  can  be  broken  by  a  strong  stimulation 
provided by αCD3/CD28 (Figure 3-18/B) (Work performed by E. Badami).  
 
In order to assess the ability of MDSCs to suppress T cell suppression, I performed the 
same  assays  as  performed  with  Tregs.  Removal  of  MDSCs  led  to  an  increased  T  cell 
proliferation in response to αCD3 stimulation. However, the suppressive function of MDSCs 
was bypassed by the  addition of αCD28.  As both Tregs  and MDSCs  from TAZ10 mice 
inhibited  T  cell  proliferation  in  response  to  αCD3,  only  MDSCs  abrogated  the  strong 
stimulation provided by αCD3 and αCD28 antibodies. This suggested that MDSCs had an 
important suppressive function on T cells (Figure 3-18/A).  
 
 
Figure 3-18: MDSCs display a stronger inhibitory function on T cell proliferation in response to both 
αCD3 and αCD28 antibodies than CD4
+ CD25
+ regulatory T cells 
Proliferative activity of TAZ10 T cells with or without depletion of MDSCs (A) or regulatory T cells (B) was 
assessed by (
3H) thymidine incorporation assay. Untreated or depleted splenocytes were stimulated with αCD3 
or αCD3-αCD28 antibodies. Data on the effect of the depletion of CD25 cells were generated by Ester Badami 
(B). Data are representative of five different experiments.   
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To  further  investigate  the  inhibitory  functions  of  MDSCs  in  autoimmune  disease  I 
evaluated their ability to inhibit T cell proliferation in response to αCD3 and αCD3  and 
αCD28 antibodies. Addition of MDSCs to splenocytes from TAZ10 mice strongly inhibited T 
cell proliferation to αCD3 antibody. As previously observed, the addition of αCD28 was 
unable to reverse this inhibitory effect (Figure 3-19/A). The action of MDSCs was also dose-
dependent.  While  the  addition  of  MDSCs  to  T  cells,  at  a  MDSC:T  ratio  of  1:2  or  1:5, 
inhibited T cell proliferation in response to αCD3. Only MDSC present at a MDSC:T ratio of 
1:2 were able to abrogate the stimulation provided by αCD3 and αCD28 (Figure 3-19/B). 
 
 
Figure 3-19: Addition of Gr1
+ MDSCs strongly inhibits T cell proliferation in a dose-dependent manner 
(A)  Gr1
+  myeloid  derived  suppressor  cells  were  isolated  and  added  to  splenocytes  from  transgenic  mice 
activated  with  either  αCD3  or  αCD3-αCD28  antibodies.  Proliferation  was  assessed  by  (
3H)  thymidine 
incorporation. (B) Gr1
+ cells were added to activated to T cells either at a T:MDSC ratio of 2:1 or 5:1. Data are 
representative of three different experiments. 
 
MDSCs strongly inhibited T cell proliferation in response to αCD3 and αCD3-αCD28 
antibodies in a dose-dependent manner. I then addressed whether their inhibitory activity 
could be influenced by the ongoing inflammation of the TAZ10 mice. To answer this 
question,  I  used  the  ability  of  mature  bone-marrow  derived  DCs  to  provide  strong 126 
 
costimulatory signals to T cells when cultured in the presence of agonistic αCD3 antibody 
(Figure 3-10).  
 
 
 
Figure 3-20: MDSCs from TAZ10 mice are more inhibitory than WT MDSCs  
The activity of MDSCs from wild-type and TAZ10 mice were assessed for their ability to inhibit a strong T cell 
proliferation induced by the agonistic αCD3 antibody and costimulatory signals provided by mature dendritic 
cells (DCs). Data are representative of three different experiments.  
 
At a T:MDSC ratio of 1 : 1, MDSCs from both WT and TAZ10 mice strongly inhibited T 
cell proliferation in response to αCD3 and mature DCs (Figure 3-20) thus confirming the 
strong  inhibitory  activity  of  MDSCs  on  T  cell  proliferation.  Interestingly  with  the  same 
number  of  cells,  MDSCs  from  TAZ10  mice  were  more  potent  in  inhibiting  T  cell 
proliferation compared to MDSCs from wild-type mice. These results may reflect the context 
of inflammation where MDSCs from TAZ10 mice may present a more stimulated or matured 
phenotype compared to wild-type mice. 
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3-3-4/ Myeloid Derived Suppressor Cells produce nitric-oxide (NO) 
 
MDSCs have been shown to exert part of their inhibitory function on T cell proliferation 
via the products of degradation of L-arginine by inducible nitric-oxide synthase (iNOS) and 
Arginase I (Kusmartsev et al. 2000, Bronte et al. 2005).  
To  assess  the  mechanisms  of  action  of  MDSCs,  I  measured  the  activity  of  iNOS  by 
considering the production of nitric-oxide (NO). The amount of NO in splenocytes freshly 
isolated from both WT and TAZ10 mice was measured by flow cytometry. MDSCs from 
both sets of mice produced NO. In keeping with the previous observations that MDSCs from 
TAZ10 mice might display a stronger inhibitory activity (Figure 3-20), the highest amounts 
of NO were produced by the large Gr1
+ CD11b
+ MDSCs population from transgenic mice 
(Figure 3-21/A). To further evaluate their ability to secrete NO, the amount of NO released in 
the medium with or without MDSCs was measured using the Griess method (Figure 3-21/B). 
In  accordance  with  Figure  3-21/A,  the  amount  of  nitric  oxide  released  from  TAZ10 
splenocytes was much higher than the amount produced by splenocytes from WT mice. In 
both  cases,  MDSCs  were  responsible  for  this  secretion  as  their  depletion  abrogated  the 
release of NO in both wild-type and TAZ10 splenocytes upon stimulation with αCD3 and 
αCD28 (Figure 3-21/B). 
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Figure 3-21: MDSCs from TAZ10 mice produce more nitric-oxide than MDSCs from WT mice 
(A) Three-color FACS analysis was performed to assess the intracellular content of NO in splenocytes from 
both wild-type and transgenic splenocytes. Gated populations were analyzed for their level of expression of Gr1 
and CD11b markers. (B) The amount of NO released into the medium by activated splenocytes (using αCD3 
and αCD28) from WT and TAZ10 mice was measured using the Griess method. Effect of the depletion of Gr1
+ 
MDSCs on the amount of NO released was assessed. Data is representative of more than five experiments. 
 
I  have  therefore  shown  that  MDSCs  are  present  in  autoimmune  disease  and  strongly 
inhibit  T  cell  proliferation  in  response  to  αCD3  and  αCD3/CD28  agonistic  antibodies. 
Although more work need to be performed, we could suggest that this action is partially 
mediated via the release of nitric oxide. Results in figure 3-20 suggest that the inflammatory 
status of TAZ10 mice was able to promote the activity of TAZ10 MDSCs probably through 
the  cytokine  environment.  This  strong  suppressive  function  on  T  cells  along  with  their 
accumulation in TAZ10 mice (Figure 3-15) did not explain why MDSCs could not prevent 
the activation of self-reactive T cells as TAZ10 mice still developed the disease. 
 
3-3-5/ MDSCs from TAZ10 mice inhibit antigen-specific T cells in-vitro 
 
Stimulation of T cells using αCD3 and αCD28 does not represent the situation in-vivo 
where TAZ10 T cells are activated upon recognition of the TPO536-547 cryptic epitope when 
presented in the context of MHC Class-II molecules (Quaratino et al. 2004).  129 
 
The  activity  of  MDSCs  has  been  linked  to  the  level  of  cytokines  present  in  the 
microenvironment. For instance Th1 cytokines such as IFNγ will promote the transcription of 
iNOS and the subsequent production of NO whereas Th2 like-cytokines (such as IL-4 or IL-
13)  will  induce  the  activation  of  ARG1  and  the  generation  of  urea  amd  polyamines 
(Reviewed  in  Bronte  et  al.  2005).  We  therefore  hypothesized  that  the  strong  inhibition 
previously  observed  was  due  to  the  stimulation/maturation  of  MDSCs  by  the  important 
release of cytokines resulting from the activation and proliferation of T cells induced by 
αCD3 and αCD28. 
 
I first evaluated the ability of MDSCs to inhibit the proliferation of TAZ10 T cells in 
response to the cognate TPO536-547 peptide (Figure 3-22). 
Although T cells did proliferate when the peptide was presented by antigen-presenting 
cells, the addition of MDSCs at a T: MDSC ratio of 5:1 did not inhibit T cell proliferation. 
On the other hand, addition of MDSCs at a higher T: MDSC ratio of 1:1 led to a strong 
inhibition of T cell proliferation down to background levels. At this stage I had to ascertain 
that MDSCs were not capable of presenting the peptide to TAZ10 T cells and promoting their 
proliferation.  I  could  rule  out  that  MDSCs  might  induce  the  proliferation  of  Ag  specific 
TAZ10 T  cells  (Figure  3-22). However, this result could not exclude the possibility that 
MDSCs were not expressing MHC Class-II molecules nor costimulatory molecules required 
for the full induction of T cell proliferation as shown for DCs (Chapter 3-2). This lack of 
inhibition at a T:MDSC ratio of 5:1 was then investigated as I wondered whether MDSCs 
were unable to inhibit antigen specific T cell proliferation or if they were not efficiently 
potentiated by the cytokine “milieu” as suggested from the results obtained when stimulating 
T cells with αCD3 and αCD28.  
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Figure 3-22: Effect of MDSCs on the proliferation of T cells in response to the TPO536-547 cognate peptide 
MDSCs were added to the culture of APCs and T cells at different T:MDSC ratio (5:1 and 1:1) to assess their 
inhibitory capacity. Effect of the pre-activation of MDSCs using αCD3/28 or IFNγ was evaluated (pre-activated 
MDSCs). Proliferation of T cells was measured by (
3H) thymidine incorporation. Data are representative of two 
different experiments. 
 
To  mimic  the  same  stimulatory  environment,  MDSCs  were  either  purified  from 
splenocytes activated for three days with αCD3/28 or pre-activated for 3 days with IFNγ 
(200U/mL). After purification, pre-activated MDSCs were then added to the assay at a T: 
MDSC ratio of 5:1. Addition of pre-activated MDSCs strongly inhibited T cell proliferation 
to  background.  Therefore,  the  inability  of  MDSCs  to  inhibit  T  cell  proliferation  at  a  T: 
MDSCs ratio of 5:1 was more due to a lack of activation by cytokines (IFNγ or cytokines 
secreted by splenocytes upon stimulation with αCD3 and αCD28 antibodies) rather than an 
intrinsic inability to inhibit antigen specific T cell proliferation (Figure 4-10). 
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3-3-6/  Rush  judgment  on  MDSCs:  Highly  inhibitory  MDSCs  cannot  be 
used in-vivo for the treatment of autoimmune disease  
 
The  ability  of  MDSCs  from  TAZ10  mice  to  strongly  inhibit  T  cell  proliferation  in 
response to αCD3 associated or not with αCD28 or costimulatory molecules, displayed by 
mature DCs suggested that they could be ideal candidates as a therapeutic tool to dampen the 
activation of T cells in autoimmune disease. As a matter of fact, numerous studies have taken 
advantage of the inhibitory activity of MDSCs on both NK and T cells (Li et al. 2009). 
Indeed, in-vivo depletion of MDSCs using the anti-Gr1 antibody clone RB6-8C5 abrogated 
the development of tumor cells in tumor bearing-mice. Similarly, it has been shown that the 
adoptive transfer of purified Gr1
+ CD11b
+ MDSCs promotes tumor-growth via an increased 
inhibition of NK cell activities (Li et al. 2009). 
 
To assess whether MDSCs could dampen the onset and development of the disease when 
injected into TAZ10 mice, Gr1
+ MDSCs were purified using magnetic beads and adoptively 
transferred  into  TAZ10  transgenic  mice.  Surprisingly,  despite  their  inhibitory  function 
displayed in-vitro, the adoptive transfer of MDSCs worsened the disease as all mice died 
within  50days  after  the  injections  (Figure  3-23;  Experiments  performed  by  Delphine 
Labrousse). 
 
Figure 3-23: Adoptive transfer of MDSCs fails to prevent the development of the disease in TAZ10 mice 
TAZ10 mice were adoptively transferred with purified GR1
+ MDSCs and their survival assessed over a period 
of  50  days.  Data  are  representative  of  two  independent  experiments  involving  3  control  mice  and  6  mice 
injected with Gr1
+ cells. (Experiments performed and kindly donated by Delphine Labrousse). 
 
This result prompted us to consider the fact that MDSCs are myeloid precursors and have 
therefore the ability to differentiate to DCs, macrophages or granulocytes according to the 132 
 
microenvironment. I consequently analyzed MDSCs ex-vivo for the expression of various 
markers of antigen presenting cells (APCs) such as CD11c, F4/80, CD86 and I-A
b (Figure 3-
24) to assess whether MDSCs from TAZ10 and WT mice display a different phenotype. 
 
 
Figure 3-24: MDSCs from TAZ10 mice express markers of professional antigen presenting cells (APCs) 
MDSCs from the splenocytes of TAZ10 mice were assessed for the expression of markers specific of APCs 
such as CD11c and F4/80 (A). The expression of maturation markers such as CD86 and MHC-II molecules I-A
b 
was  also  evaluated  by  flow  cytometry  (B).  Data  are  representative  of  two  independent  experiments. 
(Experiments performed and kindly donated by Delphine Labrousse). 
 
Interestingly, MDSCs from TAZ10 transgenic mice showed an increased proportion of 
cells expressing F4/80 and CD11c of over twofold compared to WT mice (Figure 3-24/A). 
This was associated with a higher proportion of cells expressing maturation markers such as 
CD86 (over threefold increase) or I-A
b molecules (about 1.5 fold increase). Together with 
previous  results,  we  could  hypothesize  that  the  inflammatory  status  of  TAZ10  mice 
modulating both MDSCs’ functions (Figure 3-20) and phenotype (Figure 3-24). 
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3-3-7/ Conclusions 
 
The inhibitory effect of MDSCs has been extensively described both in tumor-mouse 
models and human cancers (Gabrilovitch. 2004). Inspired by these studies, I assessed whether 
MDSCs could play  a role in other chronic inflammatory  conditions such as  autoimmune 
diseases. To answer this question it was important to establish the presence of MDSCs in a 
spontaneous  model  of  autoimmune  disease,  where  no  adjuvant  was  used.  We  therefore 
investigated  TAZ10  mice,  a  humanized  mouse  model  that  spontaneously  develops 
autoimmune  hypothyroidism  with  the  same  clinical  signs  of  disease  as  patients  with 
Hashimoto’s thyroiditis (Quaratino et al. 2004).  
I detected an accumulation of MDSCs in different tissues in these mice depending on the 
status of inflammation. Young mice presenting acute inflammation (1 month old) showed 
greater amounts of MDSCs whereas the number decreased with age as the inflammatory 
processes faded, and became more chronic. The accumulation of MDSCs was detected both 
in the natural niche (the bone-marrow) but also in the spleen, non-draining LNs and LNs 
draining the thyroid.  
As MDSCs have been characterized in cancer, where they strongly inhibit T cells, we 
assessed their functionality in our model. MDSCs strongly inhibited T cell proliferation in 
response to both αCD3 and αCD3/28 agonistic antibodies. We found that these actions were 
dose dependent. Of interest was the comparison with CD4
+ CD25
+ regulatory T cells whose 
inhibitory functions were abrogated when T cells were stimulated with αCD3/28 antibodies. 
Although MDSCs inhibited T cells in response to α-CD3, the addition of αCD28 could not 
abrogate their inhibitory function.  
 
I have established that the activity of MDSCs depends on the microenvironment and, 
more precisely, on the level of cytokines as their activity is enhanced upon stimulation with 
IFNγ.  
The factors leading to the recruitment of MDSCs to peripheral lymphoid organs upon 
inflammation  remain  largely  unknown.  G-CSF  has  been  shown  to  promote  both  the 
recruitment  and  proliferation  of  myeloid  precursors  in  mouse  and  human  cancer  via  the 
down-regulation of CXCR4 on myeloid cells, thus removing a factor of retention in the bone-
marrow (Kim et al. 2006; Gabrilovitch. 2004). Tumour cells secreting IL-1β, a major pro-
inflammatory cytokine, promote the mobilization of MDSCs via the release of soluble factors 
by bystander cells (Song et al. 2005; Bunt et al. 2006; Tu et al. 2008). From the role of IL-1β 134 
 
in  inducing  the  recruitment  of  MDSCs  in  cancer,  we  suggest  that  the  inflamed  status  of 
TAZ10 mice, shown by the activation of self-reactive T cells and their infiltration in the 
thyroid, explain why MDSCs accumulate at the peak of inflammation when the levels of pro-
inflammatory cytokines are high.  
 
The paradoxical situation whereby strongly inhibitory MDSCs accumulating in TAZ10 
mice are unable to prevent the activation of TAZ10 self-reactive T cells and therefore the 
development of the disease, prompted us to address the full phenotype of MDSCs. MDSCs 
from TAZ10 mice expressed higher levels of markers specific for professional APCs such as 
CD11c and F4/80 but also the maturation markers CD86 and MHC-II molecule I-A
b. As 
MDSCs  from  TAZ10  mice  were  more  inhibitory  than  MDSCs  from  WT  mice,  I  could 
hypothesized that the acquisition of these markers was linked with an increased inhibitory 
function associated with the increased release of nitric oxide. The results obtained in-vivo in 
TAZ10 mice were in sharp contrast with the study of Proinsulin-NOD (PI-NOD) transgenic 
mice model of diabetes (Steptoe et al. 2005). Indeed, adoptive transfer of MDSC generated 
from bone-marrow cells cultured with a combination of GM-CSF and TGF-β were able to 
suppress  autoimmune  diabetes  in  these  mice.  This  phenomenon  was  associated  with  the 
differentiation of injected MDSCs into resting DCs (CD11c
+ MHC-II
lo CD86
lo). However the 
generation of MDSCs from bone-marrow precursors with GM-CSF and TGF-β could not 
reflect the real phenotype and functions of MDSCs present in the spleen or lymph-nodes of 
these mice with autoimmune diabetes. 
 
The analysis of MDSCs in mice using only Gr1 and CD11b markers is therefore not 
appropriate as it does not reflect the phenotype of this inhibitory network. Although different 
factors such as G-CSF or All-Trans retinoic Acid (ATRA) have been used to study the effect 
of MDSCs in diseases such as cancer, by promoting the accumulation of MDSCs, the action 
of these drugs on other cellular subsets such as T cells is detrimental. On the other hand, the 
depletion of MDSCs in-vivo using the depleting antibody clone RB6-8C5 has its limits as it 
also depletes other cellular subsets such as granulocytes or neutrophils. 
The recent acquisition of the B6-eYFP mouse model that expresses eYFP ubiquitously 
will be an important tool in the study of the kinetics of accumulation of MDSCs at the onset 
of chronic inflammatory diseases. Indeed, combining the generation of Rag2
-/- bone-marrow 
chimeric mice reconstituted with the bone-marrow from B6-eYFP mice, with the adoptive 
transfer  of  naïve  T  cells  in  a  Rag2
-/-  model  represents  the  ideal  tool  to  unravel  the 135 
 
mechanisms leading to the recruitment, accumulation and differentiation of MDSCs from the 
onset until the late chronic stages of the disease. 
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3-4/ Results Part 3: Characterisation of CD34
+ cells and MDSCs in 
human  patients  with  Rheumatoid  Arthritis  (RA)  and  Systemic 
Lupus Erythematosus (SLE) 
 
Although MDSCs have been largely described in tumor mouse models, their role in other 
chronic inflammatory diseases remains elusive. We previously highlighted the presence and 
inhibitory functions displayed by MDSCs in a mouse model of spontaneous thyroiditis. The 
study of MDSCs in human chronic inflammatory diseases is however incomplete with regard 
to cancer and absent in autoimmune diseases. This is in part due to the more complex nature 
of hematopoiesis in humans compare to mice. Also, no studies have attempted to completely 
describe the phenotype of MDSCs. Indeed, the markers used to characterize human MDSCs 
vary considerably between the different groups involved (I will discuss this issue Paragraph 
3-4-4/).  
In the light of our finding about MDSCs in the TAZ10 mouse model of autoimmune 
thyroiditis, we embarked on the characterization of human MDSCs. In this chapter, I will 
progressively dissect the phenotype and functions of MDSCs in patients with Rheumatoid 
Arthritis (RA) and Systemic Lupus Erythematosus (SLE) versus controls. These two different 
chronic  inflammatory  diseases  were  chosen  as  they  differed  in  the  level  and  anatomical 
localization of inflammation. Indeed, RA is essentially located in the joints and scoring of the 
disease  using  the  DAS28  score  accurately  represents  the  stage  of  the  disease 
(http://www.rheumatology.org/publications/classification /index.asp#ra and Appendix 1). On 
the other hand, patients affected by SLE present multiple sites of inflammation such as renal, 
neurological,  hematologic  or  immunological  disorders 
(http://www.rheumatology.org/publications/classification/index.asp#other and Appendix 2).  
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3-4-1/  Patients  with  Rheumatoid  Arthritis  and  Systemic  Lupus 
Erythematosus have a reduced population of monocytes 
 
Before embarking on the description of human MDSCs, we first assessed the levels of 
monocytes  in  patients  with  RA  and  SLE.  Monocytes  were  characterised  using  their 
morphological features by flow cytometry (Figure 3-25/A): the size (FSC or Forward Scatter) 
and  the  granulocity  (SSC  or  Side  Scatter)  of  the  cells.  By  analysing  Peripheral  Blood 
Mononuclear Cells (PBMCs) obtained by passing the blood through a Ficoll Gradient, we 
observed that controls had ~5% monocytes whereas patients with RA and SLE both showed 
less than 2% (Figure 3-25/B).  
 
 
Figure 3-25: Reduction of the amount of monocytes in PBMCs from patients with Rheumatoid Arthritis 
(RA) and Systemic Lupus Erythematosus (SLE) 
(A)  Level  of  monocytes  in  PBMCs  from  controls  and  patients  with  RA  and  SLE  was  assessed  by  flow 
cytometry using their their size (FSC) and granulocity (SSC). (B) Amounts of monocytes in patients with RA 
(n=8), SLE (n=10) or controls (n=5) was assessed by flow cytometry as a percentage of the PBMC population. 
(C) Evaluation of the amount of monocyte for a White Cell Count of 1x10
9/L (WCC) for each patient. The 
violet rectangle symbolizes the ratio for the controls. Statistics were done using the unpaired Student’s t-test. 
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We then compared the level of monocytes in PBMCs with the White Cell Count (WCC) 
of controls, RA and SLE patients. The WCC includes neutrophils, eosinophils, basophils, 
lymphocytes and monocytes and is expressed per litre of blood. We found that although RA 
patients had a WCC falling within the normal range (4 to 11 x10
9/L), the majority of SLE 
patients had a low WCC (~ 5 x10
9/L) with 5 patients having a WCC below 4 x10
9/L. From 
this result we evaluated the ratio of the amount of monocytes present in PBMCs and the 
WCC to obtain the amount of monocytes for a WCC of 1x10
9/L (Figure 3-25/C). Although 
the difference between the group of RA patients and controls was not significant, they ranged 
from 6 to 12 in RA patients compared to ~8.5 in controls. Interestingly, for the same WCC, 
SLE patients presented a decreased number of monocytes. Therefore, SLE and RA patients 
presented  less  monocytic  cells  in  the  PBMCs  compared  to  controls  while  the  amount  of 
monocytic cells in SLE patients was severely decreased (Figure 3-25/).  
 
I then focused on establishing a relationship between the disease activity in RA patients 
using the DAS28 score, and the amount of monocytes in PBMCs. The DAS28 score allows 
the segregation of patients into different categories as described Figure 3-26/A (Prevoo et al. 
1995). This method allows the scoring of the disease activity according to various criteria: the 
number of swollen and tender joints for a total of 28 joints (Refer to Appendix 1); the amount 
of C-reactive protein; the scoring of the Overall well-being of the patient on a scale from 1 to 
100 (1 being the best imaginable health state and 100 the worst imaginable health state). 
Below a DAS28 score of 2.6, patients are considered to be in remission. Between 2.6 and 3.2, 
the  disease  is  considered  to  have  a  low  activity  whereas  patients  having  a  DAS28  score 
between 3.2 and 5.1 have a moderate disease activity. Finally, a patient presenting a DAS28 
score over 5.1 present a highly chronic disease activity. This DAS28 score is essential for the 
establishment of therapeutic treatments. Indeed, between 2.6 and 5.1, patients can have up to 
3 rounds of treatment  with non-specific anti-inflammatory drugs such  as methotrexate or 
mycophenolate. Patients presenting a DAS28 score over 5.1 and fail to respond to all the 
previous  anti-inflammatory  treatments  are  put  on  anti-TNFα  therapy  (Adalimumab, 
Etanercept or Infliximab). Failure to respond to these three separate treatments means that the 
patient will be put on the waiting list for treatment with Rituximab which is a monoclonal 
antibody targeting CD20 and that leads to the depletion of B cells (Reviewed in Smolen et al. 
2007).  
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Figure 3-26: Evolution of the amount of monocytes in patients with rheumatoid arthritis with the severity 
of the disease (DAS28) 
Description of the DAS28 scoring system in rheumatoid arthritis (A). The score reflects the disease activity on a 
scale from 0 to 10. RA patients with a DAS28 score below 2.6 were in remission whereas DAS28 score above 
5.1 presented a high disease activity. (B) The relation between the DAS28 score and the amount of monocytes 
in PBMCs was assessed for patients with rheumatoid arthritis. Statistical analysis performed using the Unpaired 
Student’s t-test. 
 
As described in figure 3-26/B, there seemed to be no correlation between the severity of 
the disease and the amount of monocytes present in patients with RA. As for patients with 
SLE, no relation could be established between the severity of the disease and the amount of 
monocytes. 
 
3-4-2/ CD34
+ cells are present in patients with SLE and RA 
 
MDSCs have been largely described in  cancer  where they strongly inhibit anti-tumor 
responses (Bronte et al. 1998 and 2000; Almand et al. 2000). Numerous studies in patients 
with head and neck cancer have highlighted an increased level of peripheral CD34
+ cells with 
inhibitory activity on T cell proliferation (Almand et al, 2000) where the CD34 marker is 
specific for hematopoietic progenitors.  
Before embarking on the study of MDSCs, I first analysed whether CD34
+ cells were 
present in patients with RA and SLE and if they displayed the same inhibitory function on T 
cell proliferation in response to αCD3 as has been described in cancer. I analysed 8 patients 140 
 
with RA, 9 with SLE and 6 controls. The majority of the SLE patients studied at the time 
were  receiving  anti-inflammatory  drugs  (such  as  methotrexate)  except  one  patient  not 
receiving any specific treatment. Among RA patients, 3 were recently diagnosed and were 
not receiving any treatments when the blood was taken, while one patient was on the anti-
TNF therapy Etanercept. These specific cases will be further mentioned where appropriate.  
 
I analysed the peripheral distribution of CD34
+ cells in patients and controls by flow 
cytometry (Figure 3-27/A). The proportion of CD34
+ cells in controls ranged from 0.1 to 
0.2% of the total cell population. Although some patients with RA and SLE presented an 
increased amount CD34
+ cells in PBMCs (0.4 and 0.5% in RA and 0.5% in SLE), differences 
were overall non significant.  
 
 
Figure  3-27:  Purification  and  quantification  of  CD34
+  cells  in  PBMCs  in  PBMCs  from  controls  and 
patients with RA and SLE 
(A) FACS analysis was performed to assess the expression of the CD34 marker in PBMCs. (B) Amounts of 
monocytes  as  a  %  of  monocytic  cells  in  RA  and  SLE  patients  compared  to  controls.  Statistical  analysis 
performed using the Unpaired Student’s t-test. 
 
I then further explored the distribution of CD34
+ cells in RA and SLE patients to assess 
whether there was a correlation between the amount of CD34
+ cells and the stage of the 
disease (Figure 3-28). I showed that RA patients in remission (DAS28 less than 2.6) and with 
low disease activity (DAS28 score between 2.6 and 3.2) presented a similar proportion of 
CD34
+ cells as controls. RA patients with moderate to high disease activity (DAS28>3.2) 
presented  an  increased  amount  of  CD34
+  cells.  Although  we  had  only  one  patient  on 
Etanercept, they presented with a significant reduction in the amount of CD34
+ cells down to 
the levels of controls. This specific patient had a high DAS28 score of 6.91 (high disease 
activity),  did  not  show  any  response  to  the  ongoing  treatment  and  failed  to  respond 141 
 
previously  to  the  two  other  anti-TNF  therapy  treatments  available  (Adalimumab  and 
Infliximab).  
 
 
Figure 3-28: Effect of the disease activity on the amount of CD34
+ cells 
Analysis of the amount of CD34
+ cells in patients with rheumatoid arthritis and systemic lupus erythematosus 
by flow cytometry. Amounts varied in relation to the disease activity and the treatmen received. Statistical 
analysis performed using the Unpaired Student’s t-test. 
 
SLE patients had from 0.1 to 0.2% of CD34
+ cells in the monocyte population with two 
patients having no CD34
+ cells. Interestingly, one SLE patient who was diagnosed in 2005, 
but was not under any treatment at the time of the study, had a high amount of CD34
+ cells 
(0.5%). Patients with RA presented an increased amount of CD34
+ cells with the severity of 
the disease cells whereas no correlation could be established in SLE patients between the 
amount of CD34
+ cells and the disease activity.  
 
3-4-3/ CD34
+ cells lose their suppressive activity in patients with RA and 
SLE 
 
In order to perform some functional assays, CD34
+ cells were isolated from 50mLs of 
blood  from  each  patient  and  controls  using  anti-CD34  antibody  coated  magnetic  beads 
(Myltenyi Biotech). In order to isolate this cell population representing only 0.1% of total 
PBMCs, the buffers and incubation times had to be optimized in order to obtain a high rate of 142 
 
purity of the CD34
+ cell population. After purification, no cells expressing CD34 could be 
detected  in  the  CD34  depleted  PBMC  population  (Figure  3-29)  and  the  purity  reached 
between 75 and 90%. 
 
 
Figure 3-29: Purification of CD34
+ cells from PBMCs of controls and patients with RA and SLE 
CD34
+ cells were purified from PBMCs using magnetic beads conjugated to anti-CD34 antibodies (Miltenyi 
Biotec). Efficiency of the purification of CD34
+ cells was assessed by flow cytometry. Data is representative of 
all patients and controls. 
 
CD34
+ cells were then tested for their ability to inhibit T cell proliferation in response to 
agonistic anti-CD3 antibodies (αCD3, Clone OKT-3) and evaluated per 0.1% of CD34
+ cells. 
T cell proliferation was assessed using (
3H) thymidine incorporation assay.  
Depletion  of  CD34
+  cells  resulted  in  an  important  increase  of  T  cell  proliferation  in 
response  to  αCD3  (Figure  3-30/A)  in  control  individuals.  To  ascertain  the  inhibitory 
functions  on  T  cells  displayed  by  CD34
+  cells,  we  assessed  the  proliferative  activity  of 
PBMCs in response to αCD3 by adding CD34
+ cells. Addition of CD34
+ cells to PBMCs 
significantly reduced T cell proliferation to αCD3 (Figure 3-30/B). Generally, and as reported 
in cancer (Pak et al. 1995; Young et al. 1997 and Garrity et al. 1997), CD34
+ cells displayed a 
suppressive activity on T cells in control individuals of about 40% and ranging from 25 to 
60% (Figure 3-30/C). 
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Figure 3-30: CD34
+ cells from controls inhibit T cell proliferation upon stimulation with αCD3   
(A)  Effect  of  the  depletion  of  CD34
+  cells  on  PBMCs  from  controls  and  patients  with  RA  and  SLE  was 
measured by T cell proliferation upon stimulation with αCD3 using (
3H) thymidine incorporation. (B) Pooled 
results of the inhibitory activity of CD34
+ cells. (C) Pooled results of the inhibitory activity of CD34
+ cells on T 
cell proliferation in response to αCD3. Data on (A) and (B) are from one individual and representative of all 
controls. Statistical analysis performed using unpaired Student’s t-test. 
 
The  amount  of  CD34
+  cells  was  similar  between  controls  and  RA  patients  with  low 
disease activity (DAS28 score inferior to 3.2) whereas RA patients with high disease activity 
had an increased amount of CD34
+ cells (Figure 3-28). I evaluated whether CD34
+ cells from 
RA patients could inhibit T cell proliferation as shown in controls. Removal of CD34
+ cells 
resulted  in  an  increased  T  cell  proliferation  in  response  to  αCD3  (Figure  3-31/A). 
Interestingly,  this  suppressive  function  on  T  cells  in  RA  patients  was  lower  than  the 
inhibition provided by CD34
+ cells from controls (Figure 3-31/B) and ranged from 10 to 
40%. No correlation between the DAS28 score and the inhibitory activity of CD34
+ cells 
could be observed. RA patients had reduced amounts of monocytes compared to controls and 
SLE patients (Figure 3-25/C). The amount of CD34
+ cells recovered after purification was 
unfortunately too low to perform  any experiments where CD34
+ cells  could be added to 
PBMCs to ascertain their inhibitory functions as described Figure 3-34/C. 144 
 
 
 
Figure 3-31: CD34
+ cells from patients with rheumatoid arthritis have a reduced inhibitory activity on T 
cell proliferation in response to αCD3  
(A)  Effect  of  the  depletion  of  CD34
+  cells  on  PBMCs  from  patients  with  RA  was  measured  by  T  cell 
proliferation upon stimulation with αCD3 by (
3H) thymidine incorporation. (B) Pooled results describing the 
inhibitory activity of CD34
+ cells. 5 controls and 5 patients with rheumatoid arthritis were used. Statistical 
analysis performed using unparired Student’s t-test. 
 
The same experiments described in figure 3-30 and 3-31 were performed on PBMCs from 
SLE  patients.  Unexpectedly,  the  removal  of  CD34
+  cells  was  detrimental  to  T  cell 
proliferation to αCD3 as proliferation was reduced down to background levels (Figure 3-
32/A).  We  could  confirm  the  activatory  function  of  the  CD34
+  cells  as  their  addition  to 
PBMCs resulted in an increased T cell proliferation in response to αCD3. No correlation 
between  the  stage  of  the  disease  and  the  activatory  activity  of  CD34
+  cells  could  be 
described. 
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Figure 3-32: CD34
+ cells from patient with SLE display an activatory activity on T cells upon stimulation 
with αCD3 
(A) Effect of the depletion and addition of CD34
+ cells on PBMCs from SLE patients was measured by T cell 
proliferation  in  response  to  αCD3  using  (
3H)  thymidine  incorporation.  (B) Pooled  results  of  the  inhibitory 
activity of CD34
+ cells from SLE patients on T cell proliferation upon αCD3 stimulation compared to RA 
patients and controls. Data in (A) is from one patient and representative of all SLE patients. Statistical analysis 
performed using unpaired Student’s t-test. 
 
As described in figure 3-32/B, CD34
+ cells from one SLE patient had no effect on T cell 
proliferation to αCD3. The activatory function displayed by CD34
+ cells from other SLE 
patients ranged from 40% to nearly 100%. The impact of CD34
+ cells on T cell proliferation 
upon stimulation with αCD3 was important when considering their low presence in PBMCs 
(0.1 to 0.5% of monocyte population). Compared to controls (Figure 3-25 and 3-26), CD34
+ 
cells  from  RA  patients  had  a  reduced  inhibitory  activity  on  T  cell  proliferation  upon 
stimulation with αCD3. Interestingly, SLE patients present multiple sites of inflammation and 
autoimmune disease such as psoriasis. In this context of intense inflammation, CD34
+ cells 
lost their inhibitory function on T cells and displayed an activatory phenotype. 
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3-4-4/ Definition and phenotype of MDSCs in patients with Rheumatoid 
arthritis and controls 
 
From these results, I wanted to address whether MDSCs had a different phenotype in 
patients with RA compared to controls. Although MDSCs in mice could be characterized by 
Gr1 and CD11b markers (Figure 3-12 and 3-14), their phenotype in humans is still not clearly 
defined and varies between research groups (Figure 3-33). In all these studies and despite the 
different phenotypes, the cells were always called MDSCs. 
 
 
Figure 3-33: Markers used to characterize the phenotype of human MDSCs 
Description of the different markers used to characterize the phenotype of MDSCs in human. Lineage regroups 
the markers for mature cells (CD3 for T cells, CD19 for B cells, CD56 for NK cells, CD14 for monocytes and 
CD15 for granulocytes). Boxes are grey when the specific marker is not mentioned in the studies. + and – means 
that the MDSCs were considered to express or not express the specific marker respectively. 
 
First reports on the existence of progenitors of the myeloid lineage are from studies in the 
bone-marrow where CD34
+ CD33
+ cells were designed as Natural Suppressor Cells; with 
CD34 as a marker specific for stem-cell hematopoietic precursors and CD33 a marker only 
expressed by cells of the myeloid lineage (Schmidt-Wolf et al. 1992; Sugiura et al. 1998). I 
therefore  investigated  whether  the  amounts  of  CD34
+  CD33
+  cells  varied  depending  on 
autoimmune disease. I analysed the proportion of CD33
+ cells within the CD34
+ population 
by flow cytometry in controls, RA and SLE patients (Figure 3-34). Control individuals had 
between 30 and 35% CD33
+ cells within the CD34
+ population while it was decreased in 
patients with RA (from 2 to 20%). Taking into account the results in figure 3-25/C, where RA 147 
 
patients presented less monocytes than SLE patients and controls, we could conclude that 
patients with RA presented an overall reduction in the pool of monocytes, CD34
+ and CD34
+ 
CD33
+ cells. Although CD33
+ cells represented between 3 and 32% of CD33
+ cells in SLE 
patients, no correlation with the disease activity could be established (Figure 3-34).  
 
 
Figure 3-34: Distribution of CD34
+ CD33
+ cells in controls and patients with Rheuamatoid Arthritis (RA) 
or Systemic Lupus Erythematosus (SLE) 
Proportion of CD33
+ cells within CD34
+ cells in controls, RA and SLE patients was assessed by flow cytometry 
using CD33 and CD34 cell-surface markers. Statistical analysis performed using unpaired Student’s t-test. 
 
Although  first  studies  in  mice  excluded  the  expression  of  lineage  specific  markers  by 
MDSCs, it is now largely admitted that they do express specific markers of APCs such as 
CD11c or F4/80 and markers of maturation such as MHC-II molecules and CD86 (Figure 3-
24).  As  described  in  previous  studies,  I  considered  that  human  MDSCs  could  therefore 
express lineage markers such as CD15 (Zea et al. 2005; Srivastava et al. 2008) and CD14 
(Filipassi et al. 2007; Hoechst et al. 2008).  
 
In humans, the loss of CD34 has been linked with the maturation of CD34+ cells into cells 
of the myeloid lineage (Salati et al. 2007) such as DCs (Bernhard et al. 1995; Garrity et al. 
1997) or CD15
+ cells (Tao et al. 2004; Goussetis et al. 2006). We further analysed MDSCs 
by analysing the levels of expression of CD15, CD14, CD11b and HLA-DR as a maturation 
marker. CD15 is expressed in about 90% of circulating human granulocytes and 30 to 60% of 
circulating monocytes. CD14 is preferentially expressed on monocytes and macrophages; it 
binds  LPS binding protein and has recently been shown to recognize  apoptotic cells. As 148 
 
CD11b was commonly used to characterise MDSCs, we included this marker in our panel. 
CD11b is considered as a marker of inflammation (Davis et al. 2006) and is most highly 
expressed on neutrophils and monocytes / macrophages where it operates as a phagocytic 
receptor and has an important role in myeloid cell transmigration. 
 
By  analysis  of  CD34
+  CD33
+  cells  in  control  patients  (Figure  3-35/A),  we  could 
distinguish 5 major populations according to the expression of CD14 and CD15 (Figure 3-
35/C).  
Indeed, 16% of CD34
+ CD33
+ expressed high levels of CD15 (Population P1) but did not 
express CD11b (95% are CD11b
- and HLA-DR
-). This progenitors would therefore acquire 
markers specific of granulocytes. The down-regulation of CD15 is a marker of maturation in 
granulocytes (Sackel et al. 1991; Oehler et al. 1998) and 7% of CD34
+ CD33
+ cells expressed 
low levels of CD15 (population P2). The low expressors of CD15 did not express HLA-DR 
whereas 35% upregulated the expression of CD11b.  
1% of CD33
+ CD34
+ cells expressed markers of mature neutrophils; CD14, CD15, CD11b 
and HLA-DR (Population P5). 
Finally, 12% of the cells expressed low levels of CD14 (Population P4) and were negative 
for the expression of HLA-DR and CD11b. This corresponded to the acquisition of markers 
of non-activated monocytes. On the other hand, the majority of CD34
+ CD33
+ (62%) neither 
expressed CD14 nor CD15 (Population P3) and the majority lacked the expression of HLA-
DR (90%).  
 
Interestingly, in all 3 controls analysed, among a small population expressing high levels 
of  the  CD34  marker  85%  of  the  cells  also  expressed  CD33  molecules  (Population  P6). 
Among these cells, that all expressed CD14 and CD15, the majority (90%) did not express 
either HLA-DR or CD11b.  
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Figure 3-35: Phenotypic analysis of MDSCs from control individuals 
(A) PBMCs from the blood of control individuals were analyzed for the expression of CD34 and CD33 by flow 
cytometry. CD34
hi CD33
+ (B) and CD34
+ CD33
+ cells (C) were analyzed for the expression of CD14 and 
CD15. Each populations revealed by CD14 and CD15 was further analyzed using CD11b and HLA-DR. Data is 
representative of all control individuals. For Figure 3-35/C, please see overleaf  
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In all 3 controls analysed, we established that the description of MDSCs using CD33 and 
CD34 markers was ideal as CD34 is a marker for hematopoietic progenitor and CD33 a 
marker  specific  for  cells  of  the  myeloid  lineage.  This  phenotype  correlates  with  that  of 
natural suppressor cells described in the bone-marrow (Schmidt-Wolf et al. 1992). I observed 
that MDSCs from WT mice expressed the expression of markers specific for APCs (such as 
CD11c  and  F4/80)  and  maturation  markers  (CD86  and  MHC-II  molecules).  Increased 
expression  was  observed  in  a  context  of  inflammation  in  the  TAZ10  mouse  model  of 
autoimmune thyroiditis. In human controls, although the majority of cells did not express any 
markers of differentiated monocytes, CD34
+ CD33
+ cells acquired markers of neutrophils 
(1%),  undifferentiated  and  differentiated  granulocytes  (16%  and  7%  respectively)  and  of 
monocytes (12%).  
 
To assess whether human MDSCs upregulated the expression of markers of mature cells 
of  the  myeloid  lineage,  in  models  of  autoimmune  diseases,  I  assessed  the  phenotype  of 
CD34
+ CD33
+ cells in patients with RA. Unfortunately, we did not have any SLE patients to 
perform a full phenotypic analysis on PBMCs. 
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Figure 3-36: Altered phenotype of MDSCs from patient with rheumatoid arthritis 
(A) PBMCs from the blood of patient with rheumatoid arthritis were analyzed for the expression of CD34 and 
CD33 by flow cytometry. CD34
+ CD33
+ cells (B) were analyzed for the expression of CD14 and CD15. Each 
populations  revealed  by  CD14  and  CD15  was  further  analyzed  using  CD11b  and  HLA-DR.  Data  is 
representative of all patients with rheumatoid arthritis.  
 
Only  15%  of  CD34
+  cells  were  expressing  CD33  (Figure  3-36/A)  showing  a  twofold 
reduction compared to control individuals. Also, no cells expressing high levels of CD34 
could be observed. Further analysis of CD34
+ CD33
+ revealed a lack of expression of CD14 
and CD15. Indeed the populations of CD14
- CD15
hi, CD14
+ CD15
+ and CD14
+ CD15
- cells 
were not present in the PBMCs of patients with RA compared to controls. As observed in 
control individuals, about 60% of CD34
+ CD33
+ (Population P3) were lacking the expression 
of CD14 or CD15 and about 10% of the cells also expressed HLA-DR. The rest of the cells 
(Population P2 - 28%) expressed low levels of CD15 with 25% expressing CD11b and 10% 
expressing CD11b and HLA-DR. 
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3-4-6/ Conclusions 
 
In this section,  I analysed whether MDSCs were present in patients with autoimmune 
diseases such as RA and SLE. One major obstacle in this study was the undefined phenotype 
of MDSCs in humans as it differs between laboratories, studies and diseases.  
 
The common expression of CD34 and CD33 ensured that the cells analysed would express 
the marker of hematopoietic progenitors (CD34) while expressing the common markers of 
the myeloid lineage (CD33). I excluded the sole use of CD33 as a marker as it does not 
reflect  properly  the  definition  of  “progenitor”  cells  of  the  myeloid  lineage.  This  idea  is 
important and was the focus of three consecutive communications that were published in 
Cancer Research (Krystal et al. 2007; Yang et al. 2007 and Gabrilovitch et al. 2007).  In a 
study on melanoma patients (Filipazzi et al. 2007), the authors excluded the use of the CD34 
marker as the cells were considered to have too low a frequency in the blood. Instead, they 
considered  CD14
+  CD11b
+  cells  as  the  population  of  MDSCs.  There  were  discrepancies 
between the different studies with regard to the use of markers of differentiated myeloid cells 
(included in the lineage markers); numerous studies considered MDSCs as not expressing any 
lineage  specific  markers.  However,  in  a  couple  of  studies,  the  markers  for  granulocytes-
neutrophils CD15, mature myeloid cells CD13 or monocytes CD14 were included in the 
panels  of  markers  used  to  describe  the  phenotype  of  MDSCs.  It  seemed  clear  from  our 
analysis of PBMCs from controls and patients with RA that these markers needed to be 
included in order to specifically describe the nature of MDSCs that acquire markers of mature 
myeloid cells upon maturation / differentiation in the inflammatory context. Surprisingly, 
patients  with  RA  were  deficient  in  CD34
+  CD33
+  cells  expressing  the  CD14  and  CD15 
markers compared to controls. I suggested that the lack of inhibition displayed by CD34
+ 
cells  from  RA  patients  could  result  from  the  reduced  population  of  CD34
+  cells  and  of 
specific subsets of CD34
+ CD33
+ MDSCs.  
The study of the phenotype of CD34
+ CD33
+ MDSCs in SLE patients would be of great 
interest as CD34
+ cells displayed a strong activatory function on T cells upon stimulation 
with αCD3. 
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3-5/ Summary 
 
In this chapter, I have described the role and functions of MDSCs both in mouse and 
human chronic inflammatory diseases. Gr1
+ CD11b
+ MDSCs accumulate in a mouse model 
of autoimmune thyroiditis and display an inhibitory function on T cells upon stimulation with 
αCD3, αCD3-αCD28 or the cognate peptide. Despite their inhibitory activity on T cells in-
vitro, MDSCs were not capable of preventing the development of the disease in mice and 
their use as therapeutic strategies in TAZ10 mice was detrimental, resulting in the death of 
the mice 50 days after adoptive transfer. By studying different methods to generate bone-
marrow  derived  DCs,  we  showed  that  the  manipulation  of  myeloid  progenitors  could 
influence the quality and yield of the DCs population obtained and therefore their use in 
cancer vaccines.  
 
Although MDSCs from TAZ10 mice were more immunosuppressive in-vitro than from 
WT mice, the CD34
+ progenitor populations in RA patients had a reduced inhibitory function 
on T cells upon stimulation with αCD3 compared to controls. Interestingly, the population of 
CD34
+  cells  in  a  more  severe  chronic  inflammatory  disease  than  RA,  SLE,    lost  their 
inhibitory  activity  on  T  cells  upon  αCD3  stimulation  to  acquire  a  more  stimulatory 
phenotype. We showed that patients with RA presented a reduced amount of CD34
+ CD33
+ 
MDSCs with an altered phenotype as revealed by the lack of expression of the CD14 marker 
and the important decreased expression of CD15. 
 
Studies of MDSCs in both mice and humans highlighted the limitations in using only the 
Gr1 and CD11b markers (mouse) and the CD33 and CD34 markers (human). The definition 
of MDSCs as progenitors of the myeloid lineage implies that they  acquire or upregulate 
markers specific for more mature myeloid cells such as CD11c and F4/80 (mouse) or CD14 
and CD15 (human). I indeed established that human MDSCs could be detected as CD34
+ 
CD33
+  cells.  However,  only  the  addition  of  specific  lineage  markers  could  allow  the 
complete study and understanding of the function of MDSCs both in mouse and human. 
 
Interestingly, we highlighted the fundamental differences between chronic inflammatory 
diseases in mice and humans. MDSCs upregulate markers of professional APCs and display 
stronger inhibitory activity on T cells in a mouse model of autoimmune disease compared to 
MDSCs from WT mice. On the contrary, human MDSCs expressed fewer markers of cells of 155 
 
the myeloid lineage in RA patient compared to controls. Indeed CD34
+ cells had a decreased 
inhibitory  activity  on  T  cells  upon  αCD3,  whereas  CD34
+  cells  from  SLE  patients  were 
highly activatory. 
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4/ Spreading of TPO cryptic epitopes 
initiates autoimmune disease in a 
spontaneous mouse model of autoimmune 
thyroiditis 
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4-1/ Introduction 
  
Autoimmune diseases are chronic inflammatory diseases mediated by self-reactive T and 
B cells following a breakdown of tolerance to self-antigens. These self-reactive T cells are 
found in the inflamed tissues of patients with autoimmune diseases where they play a pivotal 
role  in  the  destruction  of  the  target  tissue  (Giordano  et  al.  1996;  Stassi  et  al.  2000). 
Regulatory cells such as Tregs are at the forefront of peripheral mechanisms that prevent the 
activation of self-reactive T cells and the development of AID (Sakaguchi et al. 1995; Asano 
et al. 1996).  
We previously described the paradoxal role displayed by cells of the myeloid lineage in 
modulating the activation of self-reactive T cells (Chapter 3). Despite their strong inhibitory 
function  on  T  cell  proliferation,  MDSCs  accumulate  in  TAZ10  mice  with  autoimmune 
thyroiditis and fail to prevent the activation of self-reactive T cells and the development of 
AID. Precursors of cells of the myeloid lineage, MDSCs can give rise to DCs, macrophages 
or granulocytes depending on the microenvironment. Indeed, we showed that MDSCs from 
TAZ10 mice acquire markers specific of antigen presenting cells such as DCs (Paragraph 3-
1).  Differentiation  of  bone-marrow  cells  also  revealed  that  the  manipulation  of  myeloid 
precursors  influence  the  ability  of  mDCs  to  efficiently  activate  self-reactive  T  cells 
(Paragraph 3-2). 
 
However,  the  initial  mechanisms  leading  to  the  break  of  tolerance  and  the  evasion  of 
mechanisms of peripheral tolerance in autoimmune disease are still elusive.  
 
To answer this question, I used the TAZ10 mouse model of autoimmune thyroiditis in 
which self-reactive T cells have been shown to be involved in the intitiation and pathogenesis 
of disease (Quaratino et al. 2004). TAZ10 transgenic mice express a human T cell receptor 
(Vβ1/Vα15)  isolated  from  the  thyroid  infiltrating  T  cell  clone  37  from  a  patient  with 
Hashimoto’s thyroid disease (Quaratino et al. 2004). The immunodominant T cell clone 37 is 
specific for thyroid peroxidase (TPO) TPO535-551 (N-LDPLIRGLLARPAKLQ-C) (Quaratino 
et al. 1996). Within this autoantigen, T cell clone 37 recognizes the highly stimulatory cryptic 
epitope TPO536-547 (N-DPLIRGLLARPA-C) generated upon endogenous processing of TPO 
by thyroid epithelial cells (Quaratino et al. 1996). Interestingly, this TCR also recognizes the 
naturally  occurring  antagonistic  epitope  TPO537-548  (N-PLIRGLLARPAK-C),  an  altered 158 
 
peptide ligand (APL) of TPO536-547. The antagonistic epitope induces anergy of T cell clone 
37 when presented by DCs upon processing of exogenous TPO (Quaratino et al. 2000).  
 
Although T cell clone 37 recognizes the TPO epitopes in the context of DQ6 in human, 
transgenic T cells from TAZ10 mice also recognize the murine equivalent of TPO536-547: 
TPO524-535 (N-DPIVRGLLARAA-C). Indeed, the homologous mouse TPO cryptic epitope 
induces  the  specific  activation  of  TAZ10  transgenic  T  cells  when  presented  by  H2-A
k 
(Quaratino et al. 2004) and H2-A
b (Unpublished results). TAZ10 transgenic T cells display 
an activated phenotype in-vivo. TAZ10 mice spontaneously develop destructive autoimmune 
thyroiditis  sharing  the  same  clinical  signs  (gain  of  weight),  hormonal  changes  (increased 
amounts  of  serological  TSH  and  decreased  levels  of  T4)  and  histological  modifications 
(destruction of the thyroid associated with mononuclear cellular infiltrates) as patients with 
Hashimoto’s thyroiditis (Quaratino et al. 2004). 
 
Studies in TAZ10 mice allowed the understanding of the crucial role  played by self-
reactive T cells in autoimmune diseases. Interestingly, TAZ10 mice spontaneously develop 
thyroiditis  in  an  environment  devoid  of  environmental  insults.  In  this  chapter,  I  will 
investigate how the generation of the cryptic TPO524-535 epitope by thyroid epithelial cells 
promotes the activation of TAZ10 T cells and the initiation of thyroiditis in TAZ10 mice. 
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4-2/  Results  Part  1:  Thyroid  epithelial  cells  (TEC)  as  non-
professional  antigen  presenting  cells  under  inflammatory 
conditions 
 
TAZ10 transgenic mice develop destructive thyroid disease characterized by infiltration 
of  monocytic  cells  (Quaratino  et  al.  2004).  Thyroid  autoimmune  disorders  have  been 
extensively studied over the last decades and separate mechanisms involved in the destruction 
of the thyroid have been described such as the suicide or fratricide killing of thyroid epithelial 
cells  (Stassi  et  al.  2002).  The  potential  role  of  IFNγ  and  the  upregulation  of  MHC-II 
molecules  in  the  pathogenesis  of  the  disease  are  also  controversial  (Fang  et  al.  2007). 
However no studies have investigated the role played by epithelial cells in the initiation of 
autoimmune  thyroiditis.  I  first  assessed  the  role  played  by  thyrocytes  in  promoting  the 
activation of TAZ10 self-reactive T cells. To answer this question, I evaluated the ability of 
TEC to modulate the activation of self-reactive T cells from TAZ10 mice upon inflammation. 
 
4-2-1/ Characterization of thyroid epithelial cells in culture 
 
To assess the effect of inflammation on the function and survival of thyroid epithelial 
cells (TECs) in TAZ10 transgenic mice, it was first important to optimize their culture in-
vitro and to ensure that the preparation would not be contaminated with other cell types 
(fibroblasts, macrophages, dendritic cells etc.) that could alter the results obtained in further 
experiments. Indeed, the majority of experiments performed in this chapter required the use 
of thyroids from 40 to 80 wild-type or transgenic mice.  
 
After  being  isolated  from  WT  or  TAZ10  mice,  thyroid  lobes  were  isolated  from  the 
trachea and cut into small pieces using a scalpel. The preparation was then digested with 
Collagenase I and Dispase II for 45 minutes at 37° C with gentle agitation every 10 minutes. 
The  digestion  mix  obtained  was  gently  centrifuged  for  2  minutes  at  200g  as  previously 
described (Jeker et al. 1999). The digestion leads to the release of partially digested thyroid 
lobules. The step of centrifugation is important to ensure that only partially digested thyroid 
lobules  are  isolated  and  cultured  whereas  free  thyrocytes  and  cells  (fibroblasts,  dendritic 
cells,  etc.)  are  discarded  in  the  supernatant.  I  first  assessed  the  morphological  changes 
affecting  partially  digested  lobules  by  light  microscopy  during  the  culture.  The  culture 
medium was changed after the first day and then every two days to ensure the constant supply 160 
 
of the soluble factors (such as somatostatin and glycyl-L-histidyl-L-lysine acetate) that are 
essential for the growth and function of TEC. Thyroid lobules could be seen in the culture 
after  digestion  (day  0).  After  three  days  of  culture,  thyroid  lobules  lost  their  three-
dimensional structure and flattened to form a layer of cells (Figure 4-1). Thyroid epithelial 
cells  were  proliferating  by  growing  out  from  the  flattened  initial  thyroid  lobule  partially 
digested. This result confirmed previous studies on the culture of thyrocytes (Jeker et al. 
1999) and is similar to the description of primary culture of other epithelial cells such as 
colonocytes (Follmann et al. 2000; Birkner et al. 2004).   
 
 
Figure 4-1: Morphological analysis of primary culture of mouse thyrocytes (TEC) from wild-type (WT) 
mice  
Thyroid lobes from WT mice were separated from the trachea and digested in collagenase and dispase for 45 
minutes at 37°C. They were then seeded in specific complete Ham’sF12-Nu Serum IV medium. Medium was 
changed the day after the start of the culture (day 0) and then every two days. The morphology of thyroid 
lobules after digestion of the thyroid and 3 days of culture was assessed using a light microscope (magnification 
X 40). Data shown is representative of two different experiments. 
 
To ascertain that the culture was only constituted of TECs, it was important to assess the 
level  of  expression  of  markers  specific  of  epithelial  cells.  Fluorescence  microscopy  on 
thyrocytes  from  WT  mice  grown  for  3  days  was  done  using  a  pan-cytokeratin  antibody. 
DAPI was used to counterstain the nucleus. As revealed at magnification of X40 (Figure 4-2), 
the  expression  of  cytokeratin  was  ubiquitous  and  was  associated  with  the  DAPI  nuclear 
staining.  Some  patches  of  high  intensity  could  be  seen  especially  at  the  edge  of  the 
monolayer. Observation of the cells at higher magnification (X100) confirmed this as some 
cells  showed  intense  expression  whereas  others  only  had  low  cytokeratin  staining. 
Furthermore, the expression of cytokeratin was generally not diffused within the cytoplasm 
but more concentrated into focal points. These focal points could represent an accumulation 
of actin filament of cytokeratin to create the multiple tight-junctions and desmosomes as 161 
 
previously observed in the primary culture of thyrocytes (Hishinuma et al. 1992; Bechtner et 
al. 1996) and colonocytes (Follmann et al. 2000). 
 
 
Figure 4-2: Primary culture of mouse thyrocytes (TEC) from wild-type (WT) mice 
Thyroid lobes from WT mice were separated from the trachea and digested in collagenase and dispase for 45 
minutes at 37°C. They were then seeded in specific complete Ham’sF12-Nu Serum IV medium. Medium was 
changed the day after the start of the culture and then every two days. Thyroid lobules were grown for three 
days and assessed for the presence of the epithelial marker cytokeratine. Immunofluoresent staining was done 
using a polyclonal pan-cytokeratin antibody (green) and cells were counterstained with DAPI (blue) to reveal 
the nucleus. Pictures were taken using a fluorescence microscope (magnification x40 and x100). Data shown is 
representative of two different experiments. 
 
Studies have highlighted the loss of function of thyrocytes in culture over time. Unless 
mentioned, TECs were normally not cultured for more than 4 days to preserve the expression 
of thyroid peroxidase (TPO), the main thyroid antigen at the centre of our study (Chazenbalk 
et al. 1987; Bocanera et al. 1999). 
 
4-2-2/ Thyroid epithelial cells express major histocompatibility complex 
(MHC) II molecules in the presence of pro-inflammatory cytokines  
 
Induction of an adaptive immune response requires the recognition of a peptide fragment 
in the groove of MHC molecules by T cells via the T cell receptor. In thyroiditis and other 
pathological  conditions,  epithelial  cells  that  normally  do  not  express  MHC-II  molecules, 
aberrantly express these molecules suggesting their potential ability to present antigens to T 
cells.  Indeed,  early  studies  have  highlighted  the  ability  of  TECs  expressing  MHC-II
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molecules to present viral antigens to T cells (Londei et al. 1984). T cells cloned from the 
thyroid of patients with autoimmune thyroiditis were shown to be capable of recognizing 
autologous thyrocytes expressing MHC-II molecules (Londei et al. 1985). Following these 
results, Quaratino et al demonstrated that a T cell clone from a patient with autoimmune 
thyroiditis was capable of recognizing thyroid peroxidase (TPO), a major thyroid autoantigen 
(Quaratino et al. 1996). The T cell clone was capable of recognizing TPO-transfected EBV 
cell-line but not EBV cell-line pulsed with soluble TPO. Interestingly, this T cell-clone also 
recognized  autologous  TECs  aberrantly  expressing  MHC-II  molecules.  These  results 
suggested that cryptic epitopes endogenously generated by non-professional APCs (TECs) 
were playing a central role in autoimmune disease. 
 
In TAZ10 transgenic mice, T cells express a human TCR specific for the human cryptic 
TPO epitope (TPO536-547). TAZ10 T cells also recognize the murine TPO cryptic epitope 
TPO524-535 (Quaratino et al. 2004). To assess the role that TEC could play at the onset of the 
disease, we first investigated whether TEC from TAZ10 mice could present the TPO524-535 
to TAZ10 T cells in the context of MHC-II molecules.  
 
I first quantitated the expression of MHC-II molecules on thyroid epithelial cells by the 
staining of partially digested thyroid lobules with a specific antibody to H2-A
b. (Thyroiditis 
leads to the death of thyrocytes and the destruction of thyroid follicles in nearly 100% of 
mice at the age of 4 months (Quaratino et al. 2004)). Thyroids from young TAZ10 mice were 
used (2 months old) to ensure that the thyroid was not already too damaged by the ongoing 
inflammation. At this age the weight gain was low and similar to WT mice. ~75% CD8
+ and 
CD4
+ T cells presented a naïve phenotype (high levels of CD62L and no CD69) in young 
TAZ10 mice (Badami et al. 2005). Indeed, the extent of expression of MHC-II molecules 
would vary among TAZ10 mice according to their age and thereafter to the damaged inflicted 
on the thyroid. Thyroid from old TAZ10 mice should have a lower or no expression of MHC-
II  molecules  compared  to  young  TAZ10  mice,  whereas  TEC  from  WT  mice  devoid  of 
inflammation in the thyroid should not express any MHC-II molecules. 
 
Thyroid lobules from 2 months old TAZ10 mice naturally expressed high levels of MHC-
II molecules as revealed by fluorescence microscopy (Figure 4-3). The neo-expression of 
MHC-II molecules by epithelial cells is a sign of tissue inflammation and demonstrates the 
important level of inflammation occurring in the thyroid of TAZ10 transgenic mice. Also, 163 
 
compared to the round and follicular morphology of the partially digested thyroid lobules 
from wild-type mice (Figure 4-1), thyroid lobules isolated from TAZ10 mice did not show a 
follicular morphology hence highlighting the tissue damage that occurs in TAZ10 mice.  
 
 
Figure 4-3: Thyroid epithelial cells from TAZ10 transgenic mice naturally express high levels of MHC-II 
molecules 
Thyroid from  young TAZ10  mice (2  months old)  were isolated and digested as previously described. The 
morphology of the thyroid lobule was observed with a light microscope (magnification x40). Thyroid lobules 
were stained using a monoclonal antibody against the MHC-II molecule H2-A
b (Green). Pictures were taken 
using  a  fluorescence  microscope  (magnification  x40).  Data  shown  is  representative  of  two  different 
experiments. 
 
Because IFNγ has been shown to promote the expression of MHC-II molecules both in 
mouse and human epithelial cells via the induced expression of the class-II transactivator 
gene CIITA (Caturegli et al. 2000), we explored the effect of IFNγ on the expression of H2-
A
b molecules by cultured TECs from wild-type mice. Thyroids from wild-type mice were 
cultured for 3 days with or without  IFNγ at 200U/mL and expression of H2-A
b MHC-II 
molecules assessed by fluorescence microscopy. As expected, TECs from WT mice did not 
express H2-A
b naturally whereas its expression was greatly enhanced when cultured with 
IFNγ. Expression was not uniform across the whole population as some expressed more H2-
A
b molecules than others (Figure 4-4/A).  
By flow cytometry, we compared the level of expression of MHC-II molecules between 
freshly digested thyroid epithelial cells from transgenic mice and cultured TECs from wild-
type mice with or without stimulation with IFNγ (Figure 4-4/B). Addition of IFNγ increased 
the levels of expression of MHC-II molecules at the cell-surface in cultured TECs from wild-
type mice; its expression was nearly similar to that displayed by freshly isolated TECs from 
TAZ10 transgenic mice (Figure 4-4/B). It was interesting to see that in this experiment, not 
all epithelial cells from transgenic mice expressed MHC-II molecules. Some cells showed 164 
 
low or no expression of MHC-II molecules. This potentially highlighted that the damages 
inflicted on TECs and the subsequent destruction of the thyroid had already occurred in the 
young TAZ10 mice investigated. 
 
 
Figure 4-4: Thyroid epithelial cells from wild-type mice express MHC-II molecules H2-A
b upon exposure 
to pro-inflammatory cytokines 
 A/ Thyroid from wild-type (WT) mice were harvested and digested as previously described. Thyrocytes were 
grown on poly-L-Lysine coated coverslips for one day in complete medium and for a further 3 days with or 
without  IFNγ  at  (200U/mL),  TNFα  (20ng/mL)  and  IL-1β  (20ng/mL).  Cells  were  then  stained  using  a 
monoclonal  antibody  against  MHC-II  molecule  H2-A
b  and  analyzed  using  a  fluorescence  microscope 
(magnification X 40). Thyrocytes grown with IFNγ and a mix of IFNγ, TNFα and IL-1β expressed H2-A
b 
molecules (A). The expression of H2-A
b by thyrocytes from WT mice when cultured with IFNγ for three days 
was confirmed by flow cytometry. Interestingly, the level of expression was similar to that of fresh thyrocytes 
from  young  TAZ10  transgenic  mice  (Tg  Thyroid)  (B).  Data  shown  is  representative  of  two  different 
experiments. 
 
The important infiltration of the thyroid by monocytic and T cells has been demonstrated 
both  in  patients  with  Hashimoto’s  thyroiditis  (Giordano  et  al.  1997;  Stassi  et  al.  2000), 
Grave’s  disease  (Stassi  et  al.  2000)  and  in  TAZ10  mice  (Quaratino  et  al.  2004).  This 
infiltration would be likely to lead to release of pro-inflammatory cytokines including IFNγ. 
We assessed whether a combination of pro-inflammatory cytokines such as IFNγ, TNFα and 
IL-1β would also be able to promote the neo-expression of MHC-II molecules by thyroid 
epithelial cells from wild-type mice in-vitro. Indeed, this combination of pro-inflammatory 
cytokines was able to promote the neo-expression of MHC-II molecules (Figure 4-4/A).  165 
 
4-2-3/ TECs provide costimulatory signals to T cells in the presence of 
pro-inflammatory cytokines 
 
As  we  previously  described  in  Chaper  3,  dendritic  cells  must  display  costimulatory 
molecules to efficiently activate T cells (Figure 3-10). The constitutive expression of H2-A
b 
MHC-II molecules by thyroid epithelial cells in TAZ10 mice prompted me to investigate 
whether  TECs  could  promote  the  proliferation  of  T  lymphocytes.  We  first  assessed  the 
costimulatory activity displayed by freshly isolated TECs from TAZ10 mice to CD4
+ T cells 
from both TAZ10 and wild-type mice in the presence of the agonistic αCD3 antibody (Figure 
4-5). 
 
Both CD4
+ T cells purified from the spleen of WT and TAZ10 mice proliferated strongly 
to  αCD3  and  mature  bone-marrow  derived  DCs  as  antigen  presenting  cells  (black  bars; 
Figure 4-5). Interestingly, T cells did not proliferate in response to αCD3 and TEC from WT 
mice (blue bars; Figure 4-5). I could exclude that this was due to the lack of expression of 
MHC-II  molecules  by  TEC  from  WT  mice  as  previously  shown  (Figure  4-4)  as  αCD3 
bypassed  the  presence  of  MHC-II  molecules.  However,  T  cells  from  TAZ10  mice 
proliferated in the presence of αCD3 and TECs from TAZ10 mice (red bars; Figure 4-5). 
CD4
+ T cells from WT mice strongly proliferated when co-cultured with TECs from TAZ10 
mice in the presence of αCD3. From this result, I could rule out that the proliferation of 
TAZ10  T  cells  previously  observed  was  due  to  its  transgenic  nature  or  any  eventual 
activation by thyroid antigens presented by TECs from TAZ10 mice (Figure 4-5). 
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Figure 4-5: Costimulatory activity of TECs from TAZ10 transgenic mice on T cells 
The proliferation of T cells from WT and TAZ10 mice assessed by (
3H) thymidine incorporation was used as 
readout of the costimulatory activity of TECs from TAZ10 transgenic mice. TECs were digested and directly 
co-cultured  with purified CD4
+T cells from  wild-type and TAZ10  mice. The addition of  αCD3 antibodies 
mimicked the TCR:MHC engagement  whereas TECs  would eventually provide co-stimulatory signals to T 
cells. The level of costimulation provided by TEC was assessed by measuring the T cell proliferative activity 
using (
3H) thymidine incorporation. Statistics were performed using the unpaired Student’s t-test. Data shown is 
representative of two different experiments 
 
Thyrocytes from WT mice were unable to provide costimulatory activity to CD4
+ T cells 
from both WT and TAZ10 mice (Figure 4-5). As we previously showed that TECs from WT 
mice express high levels of MHC-II molecules upon stimulation with IFNγ (Figure 4-4), we 
wondered whether IFNγ could also promote the expression of costimulatory molecules. TEC 
from TAZ10 mice provided costimulatory signals to T cells from WT mice (red bars, Figure 
4-6) whereas TEC from WT mice did not (blue bars, Figure 4-6). Stimulation of TEC from 
WT  mice  with  IFNγ  led  to  an  increased  proliferation  of  WT  T  cells  in  the  presence  of 
agonistic αCD3 antibody (green bars, Figure 4-6). We could rule out that IFNγ was involved 
in  the  activation  of  T  cells  as  TECs  were  thoroughly  washed  with  medium  prior  to  the 
addition of T cells from WT and TAZ10 mice. The costimulatory activity displayed by TEC 
from WT mice upon stimulation with IFNγ was however inferior to the one provided by 
TECs from TAZ10 mice.  167 
 
 
Figure 4-6: TECs from WT mice provide costimulatory signals to T cells upon stimulation with IFNγ 
TECs were digested and cultured for 3 days in the presence or absence of IFNγ. CD4
+T cells from wild-type 
mice  were  added  to  the  culture  and  the  costimulatory  activity  of  TECs  was  assessed  by  (
3H)  thymidine 
incorporation. The addition of αCD3 antibody was mimicking the TCR:MHC engagement whereas TECs would 
eventually provide co-stimulatory signals to T cells. Statistics were performed using the unpaired Student’s t-
test. Data presented is representative of two different experiments. 
 
Although I have not identified the costimulatory molecules expressed by thyrocytes, this 
result is consistent with previous studies showing that TECs upregulate the expression of 
costimulatory molecules such as B7-1 (Battifora et al. 1998) and B7-2 (Peterson et al. 1999) 
in an inflammatory context (Reviewed in Salmaso et al. 2002). Alongside the high level of 
expression  of  MHC-II  molecules  by  TECs  from  TAZ10  mice,  this  result  highlights  the 
potential that the inflammatory environment in the thyroid of TAZ10 mice has to induce a T 
cell response via TECs. 
 
The ability of epithelial cells to upregulate the expression of MHC-II and costimulatory 
molecules  suggest  they  can  act  as  non-professional  antigen  presenting  cells.    We  then 
wondered whether TECs from TAZ10 mice and TECs from WT mice challenged with IFNγ 
were able to present the TPO cryptic epitope to transgenic T cells. 
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4-2-4/  Thyroid  epithelial  cells  from  TAZ10  transgenic  mice  expressing 
MHC  II  molecules  present  the  cryptic  TPO524-535  epitope  to  TAZ10 
transgenic T cells. 
 
TAZ10  T  cells  proliferate  in  response  to  the  human  and  mouse  TPO  cryptic  epitope 
(respectively TPO536-547 and TPO524-535) when presented by antigen presenting cells in the 
context of MHC-II molecules (Quaratino et al. 1996, Quaratino et al. 2004). Interestingly, the 
T cell clone 37 isolated from the thyroid of the patient with thyroiditis could recognize the 
cryptic epitope presented by allogeneic thyroid epithelial cells. I wanted to assess whether 
thyroid epithelial cells from TAZ10 mice could present the TPO524-535 cryptic epitope to 
TAZ10 T cells bearing the same TCR than the human T cell clone 37. 
 
 Thyroid  lobes  were  isolated  from  young  TAZ10  mice  to  ensure  they  would  not  be 
destroyed and would express high levels of MHC-II and costimulatory molecules (Figure 4-3 
and 4-5). Thyroid lobules were digested in collagenase and dispase as previously described 
and partially digested thyroid lobules washed and co-cultured with CD4
+ T cells from TAZ10 
or WT mice.  
Although  I  previously  demonstrated  that  thyroid  epithelial  cells  from  TAZ10  mice 
naturally  express  MHC-II  molecules  (Figure  4-3),  we  evaluated  its  expression  using  the 
superantigen  Staphylococcus-aureus  Enterotoxin  D  (SED)  at  10ng/mL.  In  human,  SED 
promotes the proliferation of T cells by the simultaneous binding of TCR through the Vβ3 
region (Choi et al. 1989) and the binding of dimerized MHC-II molecules induced by SED 
(Chintagumpala et al. 1991; Al-Daccak et al. 1998). T cells from TAZ10 mice bearing the 
TCR  from  the  human  T  cell  clone  37  (Vβ1),  also  proliferate  in  response  to  SED  in  the 
presence  of  murine  H2-A
b  MHC-II  molecules  whereas  T  cells  from  WT  mice  do  not 
(Unpublished results).  
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Figure 4-7: Thyroid epithelial cells (TECs) from TAZ10 transgenic mice present the TPO524-535 cryptic 
epitope to T cells from TAZ10 mice 
The ability of TECs from TAZ10 transgenic mice to present the TPO cryptic epitope to T cells was assessed by 
(
3H) thymidine incorporation. Purified CD4
+ T cells from TAZ10 or WT mice were co-cultured with TECs from 
TAZ10 mice for 3 days. Proliferation of TAZ10 T cells in response to the superantigen SED (Staphylococcus 
aureus Enterotoxin D) was taken as readout for the expression MHC-II molecule as SED is only recognized by 
T cells from TAZ10 mice. Statistics were done using the unpaired Student’s t-test. Data shown is representative 
of two different experiments. 
 
T cells from TAZ10 mice proliferated in response to the superantigen SED (blue bars, 
Figure 4-7), thus confirming the aberrant expression of MHC-II molecules by TECs from 
TAZ10 mice. Transgenic T cells were able to proliferate when cocultured with TEC from 
transgenic  mice  in  the  absence  of  the  superantigen  SED.  CD4
+  T  cells  from  WT  mice 
however slightly proliferate, thus suggesting that TECs from transgenic mice presented the 
TPO524-535 cryptic epitope to TAZ10 T cells (white bars, Figure 4-7).  
 
From these results, I wanted to assess whether TECs from WT mice were able to present 
the  TPO  cryptic  epitope  to  transgenic  T  cells  when  expressing  MHC-II  molecules  upon 
stimulation with IFNγ. 
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4-2-5/ In a context of inflammation, thyroid epithelial cells from wild-type 
mice  can  present  the  cryptic  TPO  epitope  to  transgenic  T  cells  from 
TAZ10 mice 
 
I  previously  showed  that  TECs  from  TAZ10  mice  naturally  expressing  MHC-II 
molecules are efficient in activating TPO-specific transgenic T cells. TECs from WT mice 
exposed to IFNγ strongly upregulated the expression of MHC-II molecules. TECs from WT 
mice  also  provided  costimulation  to  T  cells  when  pre-exposed  to  IFNγ.    I  wanted  to 
determine  whether  presentation  of  the  endogenous  TPO524-535  cryptic  epitope  can  be 
initiated by IFNγ in TEC from WT mice.  
 
To optimize the results, I needed to carefully titer the numbers of TAZ10 T cells for the 
number of TEC after the thyroid lobules were  partially  digested. The  major problem we 
encountered was that in order to count the cells, TECs had to be harvested using EDTA and 
trypsin. Unfortunately, after re-seeding, the majority of thyroid epithelial cells died within 2 
days. I also avoided harvesting TECs before co-culturing them with T cells so as to prevent 
the  removal  of  eventual  peptides  present  at  the  surface  of  the  cells.  Indeed,  the  thyroid 
preparation was seeded in term of volume and not in term of cell-number directly in wells of 
96 well-plates. I estimated that in a volume of 25µL of partially digested thyroid lobules, we 
had 60,000 thyroid epithelial cells. 
  
TECs  from  WT  mice  were  cultured  with  or  without  IFNγ  for  3  days.  To  assess  the 
eventual presentation of the TPO cryptic epitope by TECs,  2x10
5 CD4
+ T cells from TAZ10 
mice were co-cultured with TECs from WT mice and their proliferation assessed by (
3H) 
thymidine incorporation 3 days later (Figure 4-8). 
 
As expected, the proliferation of TAZ10 T cells was negligible when co-cultured with 
TECs from WT mice previously cultured for 3 days in medium (blue bars; Figure 4-8).  
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Figure 4-8: Titration of the ratio WT TECs:T cells from TAZ10 mice  
TECs from WT mice were digested and seeded at different concentration for 3 days with or without IFNγ at 200 
units/mL. CD4
+ T cells from TAZ10 mice were seeded at 2x10
5 per well for 3 days and their proliferation 
assessed by (
3H) thymidine incorporation. Statistics were performed using the unpaired Student’s t-test. 
 
The addition of IFNγ to the thyroid culture strongly enhanced the proliferation of T cells 
from TAZ10 mice when 12.5µL of the digested TEC was used as APCs (red bars; Figure 4-
8). Lower T cell proliferations were detectable when using 5 and 25µL of partially digested 
thyroid lobules. As a result, in all subsequent experiments, 40 thyroids (80 thyroid lobes) 
were digested and resuspended in 8.8mL of medium. From this mix 12,5µL was used per 
well of a 96 well-plate and TECs were co-cultured with 2x10
5 CD4
+ T cells from TAZ10 or 
wild-type mice. 
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Figure 4-9: Thyroid epithelial cells from WT mice act as non-professional APCs when stimulated with 
IFNγ γ γ γ 
Thyroids from WT mice were digested and TECs seeded in 96 well-plates for 3 days with or without IFNγ at 
200 units/mL. CD4
+ T cells from TAZ10 or wild-type mice were co-cultured with TEC for a further 3 day and 
their proliferation assessed by (
3H) thymidine incorporation. Addition of the superantigen (SED) was used as 
readout for the expression of MHC-II  molecule and is only recognized by TAZ10 T cells. Data shown is 
representative of two different experiments. Statistics performed using the unpaired Student’s t-test. 
 
I wanted to ascertain that the proliferation of TAZ10 T cells observed Figure 4-8 was the 
result  of  the  recognition  of  the  TPO  cryptic  epitope  presented  by  MHC-II  molecules  to 
transgenic  T  cells.  We  assessed  the  proliferative  activity  of  CD4
+  T  cells  from  WT  and 
TAZ10 mice when co-cultured with TECs from WT mice with or without stimulation with 
IFNγ. The proliferation of T cells was assessed by (
3H) thymidine incorporation. 
 
The vigorous proliferation of T cells from TAZ10 mice in the presence of SED confirmed 
that TECs from WT mice stimulated with IFNγ expressed high levels of MHC-II molecules. 
TECs from WT mice grown without IFNγ did not express MHC-II molecules and therefore 
were not able to induce the proliferation of the TAZ10 T cells in response to SED. This result 
confirmed the upregulation of MHC-II molecules upon inflammation as previously obtained 
by fluorescence microscopy and flow cytometry (Figure 4-4).  
TECs from TAZ10 transgenic mice promote the proliferation of T cells from TAZ10 
mice (Figure 4-9). CD4
+ T cells from wild-type mice did not proliferate in the presence of 
TECs from WT mice pre-stimulated or not with IFNγ. T cells from TAZ10 mice were not 
able to proliferate when co-cultured with TECs from WT mice not challenged with IFNγ. The 
upregulation of MHC-II and costimulatory molecules induced by IFNγ on WT TECs allowed 173 
 
TAZ10 T cells to proliferate. We could conclude that the cryptic epitope TPO524-535 was 
therefore presented to TAZ10 T cells in the context of MHC-II molecules by TECs from 
TAZ10 mice and TECs from WT mice challenged with IFNγ (Figure 4-7). 
  
IFNγ was therefore capable of partially mimicking the effect of the general inflammation 
occurring in the thyroid of the diseased mice;  at least at the levels of MHC-II molecule 
expression and presentation of the TPO cryptic epitope. 
 
The  effects  of  IFNγ  on  the  induction  of  the  ability  of  thyrocytes  to  display  antigen 
presenting capacities to T cells are confirmed by other studies on various cell types such as 
mesenchymal  stem  cells  (Chan  et  al.  2006),  Schwann  cells  (Kingston  et  al.  1989)  and 
bronchial epithelial cells (Suda et al. 1995). 
The  upregulation  of  MHC-II  molecules  by  the  combination  of  pro-inflammatory 
cytokines (IFNγ, TNFα and IL-1β) suggest that cytokines secreted by activated T cells or 
antigen presenting cells present at the site of inflammation could trigger the up-regulation of 
MHC-II molecules and the subsequent antigen presenting function of thyroid epithelial cells. 
This phenomenon however was independent of the recognition of thyroid epithelial cells by T 
cells from TAZ10 mice.  
 
I highlighted the central role played by IFNγ in the induction of the antigen presenting 
capacities of thyrocytes. A study on Schwann cells (SC) confirmed the important role of 
IFNγ (Kingston et al. 1989). If IFNγ alone could induce the expression of MHC-II molecules 
in  50%  of  SC,  the  addition  of  TNFα  had  a  synergetic  effect  as  80%  of  the  cells  were 
expressing MHC-II molecules. Also, addition of activated T cells was capable to promote the 
neo-expression of MHC-II molecules by SC and their ability to promote a T cell response. 
This phenomenon was abrogated by the blocking of IFNγ, suggesting the important role of 
this pro-inflammatory cytokine in the upregulation of MHC-II by epithelial cells. Although I 
excluded the presence of APCs such as DCs and macrophages in TEC culture in-vitro, I 
wondered whether APCs that are not TEC could present the cryptic epitope from exogenous 
source of TPO antigens. This will be explored Paragraph 4-3/. 
 
The  destruction  of  thyrocytes  by  cytotoxic  MHC-I  molecule  restricted  -  CD8
+  T 
lymphocytes has been shown in autoimmune diseases and thyroiditis (Sugihara et al. 1995). 174 
 
However, in TAZ10 mice, CD8
+ T cells are not MHC-I restricted and recognize the TPO 
cryptic epitope when presented in the context of MHC-II molecules (Quaratino et al. 2004). 
Therefore, we could rule out any role played by CD8
+ TAZ10 T cells in the recognition and 
killing  of  thyrocytes.  Indeed,  we  hypothesized  that  activated  TAZ10  T  cells  initially 
infiltrating the thyroid would induce thyrocyte damage by the release of pro-inflammatory 
cytokines.   
 
4-2-6/ Control of the survival of T cells and thyrocytes in inflammation 
 
Although  thyrocytes  from  patients  with  Grave’s  disease  do  not  undergo  apoptosis, 
Hashimoto’s thyroiditis is characterized by the death of thyrocytes and the destruction of 
thyroid follicules. Both CD95 (Fas) and CD95L (Fas-L) are involved in the destruction of 
thyrocytes by apoptosis (Stassi et al. 2000). The destruction of thyroid epithelial cells in 
autoimmune thyroiditis has been described and includes the direct lysis of TECs by CD8
+ 
CTLs, thyrocytes fratricide or suicide (Reviewed in Stassi et al. 2002). To address the effect 
of pro-inflammatory cytokines on the induction of apoptosis in TECs, thyrocytes from WT 
mice were grown with or without a combination of pro-inflammatory cytokines:  IFNγ at 
(200U/mL), TNFα (20ng/mL) and IL-1β (20ng/mL) for 3 days. Staining for TUNEL showed 
that TECs grown in medium only did not undergo cell-death. If TECs challenged with IFNγ 
showed some cell-death, the combination of IFNγ, TNFα and IL-1β drastically enhanced the 
amount of thyrocytes undergoing apoptosis (Figure 4-10).  
 
Figure 4-10: Thyroid epithelial cells from WT mice undergo apoptosis upon inflammation 
Thyroid  from  wild-type (WT)  mice  were  harvested and digested as previously described. Thyrocytes  were 
grown on poly-L-Lysine coated coverslips for one day in complete medium and for a further 3 days with or 
without IFNγ (200U/mL), TNFα (20ng/mL) and IL-1β (20ng/mL). Apoptosis was detected by TUNEL (green) 
staining  using  a  fluorescent  microscope  and  nucleus  was  counterstained  with  DAPI  (blue).  Data  shown  is 
representative of two different experiments. 175 
 
Interestingly, staining with TUNEL was not immediate and only occurred after 2- days of 
exposure  with  pro-inflammatory  cytokines  highlighting  that  thyrocytes  are  particularly 
resistant to apoptosis (Stassi et al. 2000).  
The  role  of  nitric-oxide  (NO)  has  been  largely  documented  in  chronic  inflammatory 
diseases  and is  associated with tissue destruction.  Indeed, increased production of  NO is 
associated with myelin damage in multiple sclerosis (Hill et al. 2004) and is associated with 
the destruction of pancreatic islets in a mouse model of diabetes (non-obese diabetes mouse 
model or NOD mice) (Lakey et al. 2001; Suarez-Pinzon et al. 2001). 
I measured the amounts of NO released by thyrocytes upon challenge with IFNγ and a 
combination  of  IFNγ,  TNFα  and  IL-1β  (yellow  bars;  Figure  4-11).  Thyrocytes  grown  in 
medium did not release NO. Addition of IFNγ led to a 5 fold increase of the production of 
NO while IFNγ, TNFα and IL-1β increased NO concentration by 20 fold. I then assessed 
whether there was any link between the amount of nitric-oxide secreted and the survival of 
thyrocytes using the MTT assay. In all cases, the iNOS inhibitor L-NMMA abrogated the 
release of NO by TECs. L-NMMA was able to decrease the apoptosis of TECs induced by 
IFNγ (blue bars; Figure 4-11) and to prevent the apoptotic effect on TEC mediated by IFNγ, 
TNFα and IL-1β. Together, these results confirm a small number of studies performed on 
human thyrocytes (Kasai et al. 1995; van den Hove et al. 2002). 
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Figure 4-11: Thyroid epithelial cells from WT mice undergo apoptosis upon inflammation: Role of nitric-
oxide (NO) 
Thyroid  from  wild-type (WT)  mice  were  harvested and digested as previously described. Thyrocytes  were 
seeded in 96 well-plates for one day in complete medium and for a further 3 days with or without a combination 
of  IFNγ  (200U/mL),  TNFα  (20ng/mL)  and  IL-1β  (20ng/mL).  Cell  survival  was  detected  by  mitochondrial 
respiration or MTT assay (blue bars). Amounts of NO released in the supernatant were measured using the 
Griess method (yellow bars). The cell viability in medium only was taken as the reference (100%). Data shown 
is representative of two different experiments.  
 
Studies in experimental mice of autoimmune uveitis (EAU) have also highlighted the 
important role played by NO. Indeed, treatment of the mice with the iNOS inhibitor (L-
NAME) delayed the onset while reducing the clinical signs of the disease (Hoey et al. 1997). 
This mechanism was IFNγ dependent. Interestingly, the apoptosis of cells from the retina by 
NO was shown to be mediated by Fas/Fas-L interactions and signaling pathways (Liversidge 
et al. 2002). I therefore assessed whether there was any link between the amount of NO 
released by thyroid epithelial cells and the levels of expression of Fas and Fas-L by flow 
cytometry analysis (Figure 4-12). 
 
Constitutive expression of  FasL on thyrocytes in human (Giordano et al. 1997; Stassi et 
al. 1999 and 2000) confers an immune privileged status to the thyroid by promoting the 
deletion of Fas-expressing activated T cells (Stassi et al. 1999). Therefore, the expression of 
Fas-L  by  human  thyrocytes  prevents  the  occurrence  of  autoimmune  diseases.  In  mice 
however, although thyrocytes express high amounts of FAS mRNA (Tang et al. 2000; Wei et 
al. 2001 and 2003), they do not express either Fas or Fas-L at the protein level (Batteux et al. 177 
 
1999, 2000; Tourneur et al 2001; Wang et al. 2002; Wei et al. 2001, 2003, 2004). Indeed, the 
transgenic expression of Fas-L on thyrocytes in mice restores immune privilege and prevents 
the  occurrence  of  autoimmune  thyroiditis  (Batteux  et  al.  1999  and  2000;  Tourneur  et  al. 
2001). Therefore, the thyroid in mouse is not an immune-privileged tissue. I first assessed 
whether primary culture of TECs from WT mice expressed Fas and Fas-L. 
 
In WT mice, I found that the majority of thyrocytes did not express Fas and Fas-L (Figure 
4-12) molecules. 20% of TEC did however express Fas in-vitro (red histograms; Figure 4-12) 
and  I  suggested  that  the  expression  was  the  result  of  stress  imposed  on  TEC  during  the 
culture. The majority of the cells did not however expressed Fas-L (blue histograms; Figure 
4-12) and did not undergo apoptosis as described Figure 4-10 and 4-11.  
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Figure  4-12:  Upregulation  of  Fas  and  Fas-L  by  TEC  upon  challenge  with  IFNγ  is  dependent  in  the 
production of nitric oxide (NO) 
Thyroids from wild-type (WT) mice were harvested and digested as previously described. Thyrocytes were 
seeded in 96 well-plates for one day in complete medium and for a further 3 days with or without a combination 
of IFNγ  at 200U/mL. The level of expression of Fas was assessed by flow cytometry analysis (red histograms). 
Fas
+  and  Fas
-
  TECs  were  further  analysed  for  their  expression  of  Fas-L  (blue  and  green  histograms 
respectively). To assess the role of nitric oxide we used L-NMMA, an inhibitor of NO synthase (5µM). Data 
shown is representative of two different experiments. 
 
Upon challenge with IFNγ, 52% of TECs expressed high levels of Fas and Fas-L markers. 
Inhibition of the production of NO by TECs using the NOS inhibitor L-NMMA strongly 
decreased the expression of Fas by TECs down to 32%. This was associated with a decreased 
staining for Fas-L. 
 
The destruction of thyrocytes by suicide or fratricide has been shown to be mediated by 
Fas / Fas-L interaction (Giordano et al. 1997; Stassi et al. 2000). Expression of Fas-L by 
TECs  in  human  thyroid  is  the  basis  of  the  definition  of  immunoprivilege.  Indeed  Fas 179 
 
molecules  expressed  by  activated  T  cells  binding  Fas-L  expressed  by  TECs  leads  to  the 
deletion  of  the  activated  T  cells;  thus  preventing  the  occurrence  of  AID.  We  wondered 
whether the increased expression of Fas and Fas-L led to an increased death of T cells from 
TAZ10 and WT mice (Scwab et al. 2005). Thyroid epithelial cells were cultured with or 
without IFNγ for three days and washed with medium to remove any traces of IFNγ. Target 
cells (CD4
+ T cells from TAZ10 mice) were labeled with the membrane dye PKH26 and co-
cultured with TECs for 6 hours. At the end of the assay, the cells were harvested and labeled 
with the DNA probe YO-PRO at 1µM for 30 minutes on ice. Unlike the Chromium release 
assay, PKH26 stained both proliferating and non-proliferating cells. YO-PRO penetrated cells 
demonstrating some permeability and could therefore label dying and dead cells. These cells 
would not be all detected using the classical staining using AnnexinV (AnV) and propidium-
iodine (PI). A second population expressing high amounts of YO-PRO was considered as 
dead cells that would be double positive for PI and AnV. Samples were analysed by flow 
cytometry. T cells were distinguished from TECs by their staining with PKH26 (Figure 4-
13/A). We could exclude any contamination of TEC cells with PKH26 labelled T cells. CD4
+ 
T cells did not contain detectable amounts of dying cells (Figure 4-13/A) thus excluding a 
potential involvment of T cell suicide or T cell / T cell fratricide that have been previously 
described (Reviewed in Stassi et al. 2002).  
 
Although histology analysis excluded the expression of Fas and Fas-L by murine TECs, 
the primary culture was leading to an increased expression of Fas by TEC. Indeed, after 6 
hours of incubation, about 2.3-2.5% of WT and TAZ10 T cells stained for moderate levels of 
YO-PRO-1  demonstrating  that  TECs  could  induce  the  death  of  T  cells  within  hours. 
Interestingly, TECs challenged with IFNγ for 3 days increased importantly the amount of 
dying T cells to 3% and 4.1% for WT and TAZ10 T cells respectively (Figure 4-13/B and C). 
We did not detect the death of thyrocytes after 6 hours thus confirming that they are more 
resistant to cell death than T cells (Stassi et al. 2000). 
We  showed  that  TECs  upregulating  Fas  and  Fas-L  when  challenged  with  pro-
inflammatory cytokines are able to trigger the depletion of activated T cells. However, the 
expression of Fas and Fas-L by TECs leads to fratricide and thyrocyte destruction. 
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Figure 4-13: Thyrocytes promote the death of T cells from wild-type and transgenic mice 
Thyroid  from  wild-type (WT)  mice  were  harvested and digested as previously described. Thyrocytes  were 
seeded in 96 well-plates for one day in complete medium and for a further 3 days with or without a IFNγ at 
200U/mL. CD4
+ T cells from WT and TAZ10 mice were stained with PKH26 (A) and added to TECs for 6 
hours. At the end of the assay, thyrocytes and T cells were harvested and apoptotic cells revealed by the staining 
with the nuclear probe YO-PRO (C). TECs and T cells alone were used as negative controls (A). Data were 
analysed by flow cytometry and analysed with BD FACS Diva software. Graphic representation of the evolution 
of the percentage of apoptotic T cells (C). Data shown is representative of two different experiments. 
 
We  could  observe  an  important  infiltration  of  TAZ10  T  cells  in  the  thyroids  of  3-4 
months  old  TAZ-10  mice.  Similarly,  thyrocytes  had  undergone  extensive  apoptosis  as 
revealed by the important TUNEL staining. The death of TAZ10 T cells was however not 
observed  in  histology  in  TAZ10  mice  of  4  months  of  age  (Quaratino  et  al.  2004)  thus 
suggesting that the induction of T cell death in the thyroid could have occurred earlier in the 
development of thyroiditis. Indeed, these TAZ10 mice had extensive thyroid damage as the 
majority of TEC had undergone apoptosis.  
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4-3/ Results Part 2: Initiation of the T cell response in TAZ10 mice 
in-vivo 
 
Transgenic  T  cells  from  TAZ10  mice  recognize  the  human  self  peptide  TPO535-551 
(Quaratino et al. 2004). Within this peptide, two different epitopes can be recognized by the 
transgenic TCR; the agonist epitope TPO536-547 (Quaratino et al. 1996) and the antagonist 
Altered Peptide Ligand (APL) TPO537-548 (Quaratino et al. 1995). The agonist epitope TPO536-
547 is the cryptic epitope resulting from the endogenous processing of the TPO protein and is 
processed and presented by TECs expressing MHC-II molecules (Quaratino et al. 1996). The 
antagonist epitope TPO537-548 induces T cell-anergy and is generated by dendritic cells having 
uptaken TPO (Quaratino et al. 1995). 
TAZ10 trangenic T cells also recognize the murine cryptic epitope TPO524-535 and the 
antagonist TPO525-536 APL (Quaratino et al. 2004).  In  a context of inflammation, thyroid 
epithelial cells are capable of presenting the TPO524-535 cryptic epitope to transgenic T cells 
(Figure 4-7 and 4-9). However, I still wondered if TECs naturally produce the cryptic epitope 
from endogenous processing.  
 
4-3-1/ Dendritic cells that have captured necrotic thyroid epithelial cells 
induce proliferation of both TAZ10 and wild-type T cells 
 
To answer this question,  I used the  ability of professional antigen presenting cells to 
efficienty  uptake,  process  and  present  exogenous  antigens  in  the  context  of  MHC-II 
molecules  (Chapter  3-2).  I  first  assess  whether  iDCs  can  mature  when  stimulated  with 
necrotic TECs from WT mice. Semi-mature DCs obtained at day 11 using “Lutz’s method” 
(Figure 3-2) were stimulated with LPS from E.Coli or necrotic TECs from WT mice at a 
DC:TEC of 2:1. 
 
 The addition of LPS increased the levels of expression of MHC-II and CD86 molecules 
(Figure 4-14/A) and the MHC-II
hi DCs  represented 30% of all CD11c expressing mDCs 
(Figure 4-14/B). Interestingly, challenge of semi-mature DCs with necrotic TECs induced a 
much  stronger  maturation  as  MHC-II
hi  DCs  expressing  high  levels  of  the  costimulatory 
molecule CD86 represented half of the CD11c+ DCs (Figure 4-14/A and B). Indeed, necrosis 
results in the release of proinflammatory signals such as dsDNA or HSP molecules able to 
activate an immune response via Toll-like receptors (Vabulas et al. 2001 and 2002). MHC-II
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DCs promote an efficient T cell response compared to MHC-II
lo DCs (Masurier et al. 1999). 
The large population of MHC-II
hi DCs obtained after maturation of semi-mature DCs using 
necrotic TECs from WT mice, led us to investigate their ability to induce the activation of 
transgenic T cells from TAZ10 mice. 
 
 
Figure 4-14: Necrotic thyroid epithelial cells (TEC) induce the full maturation of dendritic cells  
Thyroid  lobes  from  WT  mice  were  digested  as  previously  described  and  partially  digested  thyroid  lobules 
seeded in 96 well-plates for 3 days.  Plates were then spundown for 5 minutes at 1300 rpm and supernatant 
quickly harvested before they were stored for a couple of days at -80°C to mimick necrosis. mDCs generated as 
described previously following the “Lutz’s method”. Replated iDCs (semi-mature DCs) were matured overnight 
in the presence of LPS from E.Coli (0.5 µg/mL) or necrotic TECs at a DC:TEC ratio of 2:1. Cells were stained 
for H2-A
b and CD86 and analysed by flow cytometry (A). Analysis of the proportion of CD86
+ H2-Ab
+ (green 
population) and CD86
hi H2-Ab
hi (blue population) populations (B). Statistics were performed using the unpaired 
Student’s t-test. 
 
To assess the ability of dendritic cells to activate TAZ10 T cells after taking-up necrotic 
TECs, bone-marrow derived mDCs were fed overnight with necrotic thyroid epithelial cells 
from WT mice. CD4
+ T cells from WT and TAZ10 mice were added to the culture for a 
further three days and their proliferative activity measured by (
3H) thymidine activity (Figure 
4-15). 183 
 
DCs matured with necrotic TECs induced the proliferation of CD4
+ T cells from WT 
mice  suggested  the  presence  of  a  population  of  self-reactive  T  cells  in  WT  mice.  This 
response was inhibited when TECs were challenged with a combination of pro-inflammatory 
cytokines  prior  to  the  necrosis  being  induced  (Figure  4-15).  Indeed,  several  studies  have 
highlighted the presence of self-reactive T and B cells in the T cell repertoire of a wild-type 
mouse where resolution of apoptosis is deficient and leading to secondary necrosis.  
 
Transgenic CD4
+ T cells from TAZ10 mice proliferated when co-cultured with DCs fed 
with necrotic TECs. This response was further enhanced when TECs had previously been 
challenged  with  IFNγ  (200U/mL),  TNFα  (20ng/mL)  and  IL-1β  (20ng/mL)  prior  to  the 
induction of necrosis (Figure 4-15). I could rule out that the proliferation of T cells from both 
WT and TAZ10 mice could be triggered by the necrotic TECs or DCs matured with LPS 
from E.Coli as they could not.  
 
 
Figure  4-15: Mature  dendritic  cells  (mDCs)  present  the  TPO  crypic  epitope  to  TAZ10  T  cells  while 
activating the proliferation of T cells from WT mice 
TECs from WT mice were digested and seeded in 96 well-plates for 3 days with or without a combination of 
IFNγ at (200U/mL), TNFα (20ng/mL) and IL-1β (20ng/mL).  Plates were then spundown for 5 minutes at 1300 
rpm and supernatant harvested before they were stored for a couple of days at -80°C to mimic necrosis. mDCs 
generated  as  described  previously  following  the  “Lutz’s  method”.  Replated  iDCs  (semi-mature  DCs)  were 
matured overnight in the presence of LPS from E.Coli (0.5 µg/mL) or necrotic TECs at a DC:TEC ratio of 2:1. 
CD4
+ T cells from WT and TAZ10 mice were added to the culture for a further 3 days and T cell proliferation 
was assessed by (
3H) thymidine incorporation for the last 8 hours of culture. Statistics were performed using the 
unpaired Student’s t-test. 
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 Although I demonstrated the ability of TECs to present the cryptic TPO epitope to T cells 
upon inflammation and subsequent upregulation of MHC-II and costimulatory molecules, the 
origin of the generation of the cryptic epitope remained elusive. The proliferation of TAZ10 
T cells when co-cultured with mDCs matured with necrotic TECs from WT mice suggested 
that mDCs had presented the cryptic TPO524-535 epitope to TAZ10 T cells. From this result, 
we showed that the cryptic TPO524-535 is naturally produced by TECs. Therefore, the ability to 
induce  the  proliferation  of  TAZ10  T  cells  depends  on  the  level  of  MHC-II  molecules 
expressed in inflammatory conditions by TECs. This allowed mDCs to uptake dying TECs 
and present their antigens (including TPO524-535) to T cells from WT and TAZ10 mice. 
  
DCs taking-up necrotic TECs could be expected to take-up TPO protein and therefore to 
generate the antagonistic TPO525-536 epitope to T cells (Quaratino et al. 1996). However, DCs 
were still able to induce the proliferation of TAZ10 T cells. Quantitative analysis of the two 
TPO peptides is under-way to correlate the forces present of anergy versus activation. This 
latest point will be considered and more detailed in the summary (Paragraph 4-4). Although 
TECs challenged with pro-inflammatory cytokines displayed antigen-presenting capacities, it 
seemed that IFNγ also enhanced the ability of TECs to generate the cryptic TPO524-535 epitope 
as T cells from TAZ10 mice proliferated more.  
 
In Chapter 3, we described the distribution of MDSCs in the spleen of TAZ10 and WT 
mice over time. Unfortunately, as mice were not weaned before 1 month of age, we could not 
evaluate the level of MDSCs in TAZ10 mice at the onset of the disease. This raised the 
question on the development of the disease and we needed to establish when TAZ10 T cells 
are  activated,  promote  the  destruction  of  the  thyroid  and  the  generation  of  autoimmune 
thyroiditis. Although the results previously obtained on the origin of the TPO cryptic epitope 
were  encouraging,  it  was  important  to  assess  in-vivo  the  anatomical  locations  where  the 
cryptic epitope is present in WT mice. This would allow the characterization of the triggers in 
TAZ10 mice models of autoimmune thyroiditis.  
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4-3-2/ The cryptic epitope TPO524-535 is present in the thyroid and lymph-
nodes draining the thyroid in WT mice 
 
We first investigated whether we could define where the cryptic TPO524-535 epitope was 
in wild-type mice. Indeed, it was important to assess whether the first activation of TAZ10 T 
cells occurred in the thyroid, the lymph-nodes draining the thyroid or other lymphoid or non 
lymphoid tissues. The thyroids, LN draining and not draining the thyroid, spleen and other 
tissues such as the trachea or the gut were isolated from 80 WT mice. After tissues were 
passed through a cell-strainer, cells were lysed in formic acid and boiled. Lysis-mixes were 
centrifuged to pellet the membranes and supernatant was passed through a 30 kDa cutoff 
filter by centrifugation.  The different peptide extracts obtained were then tested for their 
ability to promote the proliferation of TAZ10 T cells with BM-DCs  generated  following 
“Lutz’s method” used as APCs (Figure 4-16). 
 
The peptide extraction requiring both lysis of the cells and the use of a 30 kDa Cutoff 
filter, we assessed the level of the TPO cryptic peptide that would be lost in the process. The 
Caco-2 colon carcinoma cell line was used as a control cell line and peptide extracts were 
done with or without the addition of the cryptic epitope at 1µg/mL. The proliferation of T 
cells from TAZ10 mice was assessed by (
3H) thymidine incorporation (black and blue bars; 
Figure  4-16/A  and  4-17).  During  the  peptide  extraction,  we  lost  some  peptide  as  the 
proliferation decreased from about 60 to 80 % between mDCs pulsed with 1µg/mL of TPO 
peptide  and  mDCs  pulsed  with  the  peptide  extracts  of  CaCo-2  cells  supplemented  with 
1µg/mL of TPO peptide. 
The  presence  of  the  cryptic  epitope  was  then  assessed  in  peptide  extracts  from  the 
spleens,  thyroids  and  LN  draining  the  thyroid.  As  expected  from  the  results  previously 
obtained (Figure 4-15), TAZ10 T cells proliferated in response to mDCs pulsed with the 
peptide extract from the thyroid. Interestingly, extracts from the draining lymph-nodes also 
revealed the presence of the cryptic epitope thus confirming our previous results (Figure 4-
15) that mDCs uptaking dying TEC and migrating to the peripheral lymphoid tissue were 
presenting the TPO cryptic epitope (Figure 4-16/A; red bars). 
Although we could not exclude that intra-thyroidal APCs uptaking dying TECs would 
generate the antagonistic TPO peptide (Quaratino et al. 1996), these results confirmed that 
the TPO cryptic epitope is naturally generated by thyroid epithelial cells. To further assess 
the  amount  of  the  TPO  cryptic  epitope  present  in  the  thyroids  or  DLN,  I  evaluated  the 186 
 
proliferation of TAZ10 T cells per 1,000,000 cells used in the peptide extracts (Figure 4-
16/B). For the same number of cells used to generate peptide extracts, thyroid cells did not 
induce a stronger proliferation of TAZ10 T cell than cells from the DLN.  
 
Figure  4-16:  The  cryptic  epitope  TPO524-535  is  present  in  the  thyroid  and  lymph-nodes  draining  the 
thyroid of wild-type (WT) mice 
Thyroids, cervical lymph-nodes draining the thyroid and spleens mice were isolated from up to 80 WT mice and 
peptides extraction performed. Proliferation of CD4
+ T cells from TAZ10 mice in response to the peptide extract 
was assessed by (
3H) thymidine incorporation. Mature bone-marrow derived dendritic cells from WT mice 
(mDCs) and expressing high levels of MHC-II molecules mice were used as APCs. Peptide extracts from Caco-
2 and Caco-2 cells supplemented with the cryptic epitope at 1µg/mL were used as controls (A). Proliferation of 
CD4
+ T cells from TAZ10 mice was evaluated per 1x10
6 cells used to extract peptides (B). Statistics were 
performed using the unpaired Student’s t-test. Data shown is representative of two different experiments. 
 
To  ascertain  that  the  proliferation  of  TAZ10  T  cells  I  observed  Figure  4-16  was  in 
response to the cryptic TPO epitope and not the result of non-specific activation, I assessed 
the proliferative activity of TAZ10 T cells in response to mDCs pulsed with peptide extracts 
from the trachea and gut of WT mice (Figure 4-17). TAZ10 T cells did not proliferate in 187 
 
response to mDCs pulsed with peptide extracts from spleens, guts and tracheas from WT 
mice thus demonstrating the specific T cell response to TPO524-535 observed Figure 4-16. 
 
Figure 4-17: The cryptic epitope TPO524-535 is not present in the gut and trachea of WT mice 
Spleens, trachea and guts from 80 wild-type (WT) mice were harvested and peptides extraction performed. 
Proliferation  of  CD4
+  T  cells  from  TAZ10  mice  in  response  to  the  peptide  extract  was  assessed  by  (
3H) 
thymidine  incorporation.  Mature  bone-marrow  derived  dendritic  cells  from  WT  mice  were  used  as  APCs. 
Peptide extracts from Caco-2 and Caco-2 cells supplemented with the cryptic epitope at 1µg/mL were used as 
controls. Statistics were performed using the unpaired Student’s t-test. 
 
In light with the results obtained previously on the origin of the cryptic TPO epitope, we 
ascertained that the cryptic epitope is generated by thyroid epithelial cells and presented to 
TAZ10 T cells by thyroid epithelial cells upon challenge with pro-inflammatory cytokines 
and by dendritic cells having taken up dying TECs. It therefore seemed that the physiological 
turnover of thyroid epithelial cells and their clearance by dendritic cells allows the spreading 
of the TPO cryptic epitope to cervical lymph nodes draining the thyroid.  
Although the cryptic TPO524-535 epitope is naturally present in the thyroid and cervical 
lymph-nodes of WT mice, we wondered whether this epitope spreading naturally mediated 
by APCs could trigger the activation of TAZ10 T cells and the development of autoimmune 
thyroiditis. 
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4-3-3/ Spontaneous activation of self-reactive T cells in-vivo 
 
TAZ10 T cells are reactive to the cryptic epitope TPO524-535 present in the thyroid and 
cervical LN draining the thyroid of WT mice. We transferred CFSE labeled naïve T cells 
(CD4
+ CD62L
hi) from TAZ10 mice (TAZ10-TN) into Rag2
-/- mice. Rag2
-/- mice were used as 
recipient as they are devoid of any lymphocytes and would allow for the important expansion 
of the CD4
+ T cells that may encounter the cryptic epitope TPO524-535. Naïve T cells from 
WT mice (WT-TN) were used as a control and transferred into Rag2
-/- mice. 
Seven days after adoptive transfer occurred, blood, spleen, thyroids, DLN and NDLN 
were  analysed  for  the  presence  of  donor  T  cells  and  CFSE  dilution  (Figure  4-18). 
Interestingly, T cells from WT mice could still be seen in the blood whereas transgenic T 
cells  from  TAZ10  mice  were  absent.  This  suggested  that  TAZ10-TN  had  all  migrated  to 
peripheral lymphoid organs where they would be activated. Indeed even if T cells from WT 
and  TAZ10  mice  were  detected  in  the  spleens,  DLN  and  NDLN  of  recipient  mice,  only 
transgenic T cells strongly proliferated as shown by the important CFSE dilution. However, a 
bigger number of transgenic T cells were proliferating in the DLN compared to NDLN and 
spleens. Transgenic T cells were present in the thyroid of Rag2
-/- recipient after adoptive 
transfer with TAZ10-TN while no T cells from wild-type mice could be detected (Figure 4-
18). 
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Figure 4-18: Naïve CFSE-labeled TAZ10 T cells proliferate in lymphoid organs of Rag2
-/- mice 
Rag2
-/- mice were immunized with 2x10
6 naïve T cells from WT and TAZ10 mice. 7 days after the adoptive 
transfer occurred, thyroids, spleens, lymph-nodes draining and not draining the thyroid were isolated from the 
mice. Cells were stained for CD4, Vβ1 and analysed for the presence of T cells expressing CFSE by flow 
cytometry. Data shown is representative of 7 and 4 different mice for the adoptive transfer of naïve T cells from 
TAZ10 and WT mice respectively. 
 
Interestingly, T cells from TAZ10 mice were detected in tissues other than the thyroid 
and DLN, suggesting that not all primarily activated CD4
+ T cells migrated to the thyroid but 
instead redistributed to TPO cryptic epitope-free lymphoid organs (Figure 4-16 and 4-17) 
such as the spleen and NDLN. This phenomenon suggested that the generation of memory 
TAZ10 T cells occurs early after initiation of the antigen immune response. This is consistent 
with other studies which have shown that CD8
+ T cell expansion can be detected as early as 3 
to 4 days after the initiation of the immune response (Brinkman et al. 2008).  
  
I then explored whether TAZ10-TN and WT-TN presented an activated phenotype by the 
analysis of the CD25 activation marker (Figure 4-19). T cells from wild-type mice that did 
not proliferate in recipient mice (Figure 4-18) did not express CD25 thus confirming their 
naïve  phenotype  (Figure  4-19).  Upregulation  of  the  CD25  marker  indicated  that  the 
transgenic T cells present in peripheral lymphoid organs (Spleen, DLN and NDLN) had an 
activated phenotype (25 to 50%). Interestingly, the expression of CD25 on Transgenic T cells 190 
 
was higher in DLN than NDLN (Figure 4-19/B) in all Rag2
-/- recipient mice (7 in total) that 
had received TAZ10-TN.  
 
  
Figure 4-19: TAZ10 trangenic T cells have an activated phenotype in the thyroid and lymphoid organs of 
Rag2
-/- mice 
Rag2
-/- mice were immunized with 2x10
6 naïve T cells from WT and TAZ10 mice. 7 days after the adoptive 
transfer occurred, thyroids, spleens, lymph-nodes draining (DLN) and not draining (NDLN) the thyroid were 
isolated from the mice. Cells were stained for CD4, TCR-Vβ1 and analyzed for the levels of expression of 
CD25 by T cells expressing CFSE by flow cytometry. Data shown is representative of 7 and 4 different mice for 
the adoptive transfer of naïve T cells from TAZ10 and WT mice respectively (A). Cumulative result showing 
the percentage of T cells expressing CD25 in the different tissues 7 days after adoptive transfer. Statistics were 
performed using the unpaired Student’s t-test (B). 
 
The absence of CFSE
+ cells in the thyroid suggested that WT-TN cells did not migrate to 
the thyroid (Figure 4-18). Only seven days after adoptive transfer, T cells from TAZ10 mice 
were present in the thyroid of Rag2
-/- mice where they had clearly proliferated according to 
CFSE dilution. Interestingly, the lower fluorescence intensity of CFSE displayed by TAZ10 
T cells from the thyroid suggested they did not migrate directly to the thyroid to proliferate. 
From this result, we could suggest that the activation of TAZ10-TN occurred primarily in the 
cervical lymph nodes draining the thyroid where the cryptic epitope TPO524-535 is present. 
Activated transgenic T cells would then migrate to the thyroid where they undergo intensive 
proliferation. We previously demonstrated that the TPO cryptic epitope was present both in 191 
 
the  thyroid  and  cervical  LN  draining  the  thyroid  (Figure  4-16  and  4-17).  We  could 
hypothesize that the spreading of the TPO cryptic epitope that occurs first in the thyroid 
allows the activation of TPO self-reactive T cells and the initiation of thyroiditis in TAZ10 
mice 
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4-4/ Summary 
 
In this chapter, we investigated the initial events leading to the activation of self-reactive 
T  cells  in  the  TAZ10  mouse  model.  Interestingly,  this  model  spontaneously  develops 
autoimmune thyroiditis in an environment devoid of any environmental insults (Quaratino et 
al. 2004). This point is of importance as infectious agents are sometimes considered as key in 
the  development  of  autoimmune  diseases  by  molecular  mimicry,  bystander  activation, 
epitope spreading or crypticity (Paragraph 1-5/; Vandergult et al. 2002).   
 
4-4-1/  Physiological  turnover  of  TECs  and  epitope  spreading  initiate 
autoimmune thyroiditis 
 
We  first  established  the  origin  of  the  TPO524-535  cryptic  epitope  homologous  to  the 
human cryptic epitope TPO536-547. Although TECs from TAZ10 mice and TECs from WT 
mice challenged with IFNγ could induce the specific activation of T cells from TAZ10 mice, 
we did not know whether TECs were naturally generating the TPO524-535 cryptic epitope. 
 
The role of IFNγ in the pathogenesis of thyroiditis is controversial (Fang et al. 2007). 
Indeed, G-EAT mice with a defect in IFNγ develop thyroiditis characterized by an important 
eosinophil infiltration while G-EAT mice with functional IFNγ genes show no involvement 
of  eosinophils  when  developing  the  disease  (Tang  et  al.  1998).  WT  mice  constitutively 
expressing IFNγ in the thyroid also develop hypothyroidism (Caturegli et al. 2000). This 
resulted from the lack of expression of the sodium iodide transporter gene induced by IFNγ 
and  confirmed  previous  studies  showing  that  IFNγ  downregulates  thyroid  specific  genes 
(Mori-Aoki et al. 2000; Tang et al. 1995; Gerard et al. 2006). 
However,  constitutive  overexpression  of  IFNγ  in  NOD.H-2h4  mice  susceptible  to 
thyroiditis upon immunization with mouse thyroglobulin, promoted the expression of Class-II 
molecules  by  TECs  without  the  development  of  the  disease.  IFNγ
-/-  NOD.H2h4  mice 
immunized  with  mouse  thyroglobulin  had  a  suppressed  B  and  T  cell  response  that  was 
restored with blockade of IFNγ in-vivo using a monoclonal Ab (Barin et al. 2003). Despite 
this negative effect on lymphocytes, the action of IFNγ on thyrocytes was essential for the 
development  of  the  disease  in  NOD.H-2h4  mice  upon  immunization  with  mouse 
thyroglobuline (Yu et al. 2006). 193 
 
Histological studies have highlighted the presence of IFNγ expressing lymphocytes in the 
thyroid of patients with thyroiditis (Hamilton et al. 1991). IFNγ induces the expression of 
MHC-II molecules in epithelial cells such as hepatocytes (Herkel et al. 2003), bronchial cells 
(Suda et al. 1995), mesenchymal stem cells (Chan et al. 2006), scwann cells (Kingston et al. 
1989) and thyrocytes (Todd et al. 1995; Maile et al. 2000). Transgenic mice constitutively 
expressing MHC-II molecules in the thyroid do not develop thyroiditis (Li et al. 2004). This 
suggested that the expression of MHC-II molecules was not sufficient to induce the disease 
but increased the severity of the disease after onset (Kinura et al. 2005).  
 
TECs  from  WT  mice  do  not  express  MHC-II  molecules  whereas  TECs  from  young 
TAZ10 mice do. We could induce the expression of MHC-II molecules by TECs from WT 
mice upon challenge with IFNγ or a combination of IFNγ, TNFα and IL-1β. This suggested 
that  MHC-II  upregulation  was  a  secondary  phenomenon  resulting  from  the  presence  of 
activated lymphocytes secreting cytokines in the thyroid of TAZ10 mice (Yue et al. 1998). If 
the induction of the antigen-presenting capacities of TECs by IFNγ was necessary for the 
efficient stimulation of transgenic T cells from TAZ10 mice, TECs constitutively generate 
the  cryptic  epitope  TPO524-535  (Figure  4-20/A).    We  could  confirm  this  as  T  cells  from 
TAZ10  mice  could  proliferate  to  peptide  extracts  from  the  thyroids  of  WT  mice  when 
presented  by  dendritic  cells  in  the  context  of  MHC-II  molecules.  In  a  context  of 
inflammation,  TECs  upregulate  the  expression  of  costimulatory  and  MHC-II  molecules 
allowing  the  presentation  of the cryptic  epitope TPO524-535 to T cells from TAZ10 mice 
(Figure 4-20/B). 
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Figure 4-20: Thyrocytes naturally generate the cryptic epitope TPO524-535 
(A) Thyroid epithelial cells (TECs) express TPO at their apical membrane. Turnover of the TPO protein leads to 
its degradation  where the cryptic TPO epitope TPO524-535 (red dots) is  generated. The absence of MHC-II 
molecules by TECs does not allow the cryptic epitope to be presented to T cells from TAZ10 mice. (B) Upon 
challenge with pro-inflammatory cytokines such as IFNγ, TECs express MHC-II molecules in the endoplasmic 
reticulum (ER) before being exported to the lysosomes/MHC-II rich compartment via the trans-Golgi network 
(TGN).  MHC-II  molecules  exchange  the  CLIP  peptide  (black  triangle)  with  the  cryptic  epitope.  MHC-II 
molecules associated with the cryptic epitope are exported at the cell surface where they are recognized by T 
cells from TAZ10 mice. 
 
Several studies have stressed the role of dendritic cells in the development of the disease. 
Immunization of mice models of thyroiditis with dendritic cells loaded with necrotic TEC 
have been shown to considerably accelerate the disease (Ma et al. 2005; Li et al. 2006). It is 
now established that immature dendritic cells are present in healthy thyroid and they regulate 
the growth of TECs via different cytokines such as IL-6, IL-1β or TNFα. This cross-talk 
between TECs and DCs has also been shown to be important in maintaining DCs in their 
immature state (Croizet et al. 2000 and 2001; Mooij et al. 1994, Simons et al. 1998). We 
suggested that the physiological turnover of TECs in the thyroid results in the engulfment of 
dying TECs by intra-thyroidal DCs. The break of the cross-talk between TECs and DCs 
resulting from the death of thyrocytes would lead to the maturation and the migration of 
dendritic cells to the cervical DLN. mDCs would then present the cryptic epitope and process 
the glycoprotein TPO that are naturally present in dying TEC (Figure 4-21).  
Because  wild-type  mice  do  not  develop  thyroiditis,  the  essential  difference  with  the 
transgenic model was the presence of T cells expressing the TCR specific for the TPO cryptic 
epitope.  Interestingly,  the  presence  of  TPO524-535  was  also  detected  in  the  cervical  LN 195 
 
draining the thyroid but not in the non-draining lymph-nodes, the spleen or other tissues such 
as the gut or the trachea of WT mice. We could suggest that TECs dying as a result of 
physiological turnover were taken-up by intra-thyroidal dendritic cells that would present the 
cryptic epitope to T cells after migrating to the cervical lymph-nodes.  
 
 
Figure 4-21: Dendritic cells taking-up dying thyrocytes present the antagonistic epitope TPO525-536 and 
the cryptic epitope TPO524-535 in the context of MHC-II molecules 
Dying  thyroid  epithelial  cells  (TECs)  containing  the  cryptic  epitope  TPO524-535  (red  dots)  and  the  TPO 
glycoprotein are engulfed by resident dendritic cells. These dendritic cells migrate to the lymph node draining 
the thyroid (DLN) where they present the cryptic epitope to TAZ10 T cells promoting their differentiation and 
proliferation. DCs also process the TPO glycoprotein to generate the antagonistic epitope TPO525-536 (brown 
square). 
 
 
Dendritic cells migrating to the DLN allow the spreading of the TPO cryptic epitope to 
induce the activation and proliferation of T cells from TAZ10 mice. Activated transgenic T 
cells expressing high levels of CD25 then migrate to the thyroid where they undergo high 
proliferation. Although we are currently investigating the different subsets of helper T cells 
generated  following  the  initial  priming  of  naïve  transgenic  CD4
+  T  cells,  the  vigorous 
proliferation  of  transgenic  T  cells  is  associated  with  the  important  release  of  pro-
inflammatory cytokines. In this environment, TECs express high levels of Fas and Fas-L 
leading to the fratricide and suicide of TECs via in part on the release of nitric-oxide (Wang 
et al. 2002; Bretz et al. 1999; Hoey et al. 1997). TECs expressing Fas-L also promote the 196 
 
death  of  the  activated  lymphocytes  (expressing  high  levels  of  Fas  molecules)  that  have 
infiltrated the thyroid. 
 
Histological analysis of the thyroid in 4 months old TAZ10 mice reveals the extensive 
damages inflicted on the thyroid. All TECs have undergone apoptosis and thyroids present an 
important infiltrate of CD4
+ and CD8
+ T cells (Quaratino et al. 2004). The absence of T cells 
undergoing apoptosis in these mice does not exclude that this phenomenon does not occur in 
the  first  few  weeks  after  transgenic  T  cells  are  first  invading  the  thyroid.  We  still  need 
however to assess the level of the antagonistic versus cryptic epitope present in the thyroid 
and DLN to clearly define the forces of anergy versus activation facing transgenic T cells.  
 
4-4-2/  Mechanisms  of  peripheral  tolerance  fail  to  prevent  the 
development of autoimmune thyroiditis 
 
Naïve T cells from TAZ10 mice showed extensive proliferation 7 days after Rag2
-/- mice 
were  immunized.  The  rapid  spontaneous  development  of  AID  in  TAZ10  mice  raises  the 
question on the failure of mechanisms of peripheral tolerance to prevent the activation of self-
reactive T cells from TAZ10 mice.  
 
No detrimental effects on the expression of the cryptic epitope TPO524-535 by TEC upon 
challenge by IFNγ was observed in our assays as TECs from WT mice challenged with IFNγ 
could present the cryptic TPO epitope to T cells from TAZ10 mice. While the activation of 
CIITA  following  stimulation  with  IFNγ  promoted  the  expression  of  MHC-II  and 
costimulatory molecules (Figure 4-4 and 4-6) it has been reported that IFNγ also suppressed 
the expression of thyroid specific genes such as TSH-R, thyroglobulin and TPO both in-vitro 
(Mori-Aoki et al. 2000; Tang et al. 1995; Gerard et al. 2006) and in-vivo (Caturegli et al. 
2000,  Gerard  et  al.  2006).  TAZ10  mice  have  been  shown  to  have  increased  serological 
amounts of TSH that was associated with a decreased amount of T4 (Quaratino et al. 2004). 
In contrast to IFNγ, TSH has been shown to decrease the expression of MHC-I and MHC-II 
molecules while promoting the expression of thyroid specific genes (Tang et al. 1995. Gerard 
et al. 2006). Interestingly, the upregulation of TPO mediated by TSH can be inhibited by 
IFNγ (Ashizawa et al. 1989; Asakawa et al. 1992) and other pro-inflamatory cytokines such 
as  IL-1β  and  IL-6  (Chiovato  et  al.  1991).  These  mechanisms  would  therefore  have  a 
protective role to control the presentation of self-antigens to T cells in the context of both 197 
 
MHC-I  and  MHC-II  molecules;  thus  highlighting  its  importance  for  the  maintenance  of 
peripheral tolerance in the thyroid. 
 
However, this process is not immediate and human thyroid epithelial cells have been 
shown to co-express for some time both MHC-II molecules and TPO thus promoting the 
presentation of cryptic epitope in the context of MHC II molecules (Chiovato et al. 1994). 
Indeed, we have shown that infiltration, proliferation and activation of T cells from TAZ10 
mice occur in the thyroid within a week of the adoptive transfer of naïve T cells from TAZ10 
mice. Also, within three weeks of age, TAZ10 mice had a high serological concentration of 
TSH; this was abolished by the in-vivo depletion of CD4
+ Tcells (Ester Badami PhD Thesis, 
University of Southampton, UK). 
The  control  of  expression  of  both  MHC-II  molecules  and  TPO  by  epithelial  cells  in 
relation to the increased concentration of TSH and inflammatory cytokines such as IFNγ in 
TAZ10 mice has therefore two consequences. During the early stages of the disease TECs 
would express both MHC-II molecules and TPO thus favoring the presentation of the cryptic 
epitope  to  T  cells  thereby  promoting  the  inflammatory  process.  This  mechanism  would 
however fade away with the concentration of pro-inflammatory cytokines (such as  IFNγ) 
increasing in the thyroid as a result of the important infiltration of the thyroid with activated 
transgenic  T  cells.  Increased  concentration  of  pro-inflammatory  molecules  favors  the 
expression of MHC-II molecules by TECs while abrogating the TSH induced up-regulation 
of TPO expression. However, we do not yet know the impact of these mechanisms on the 
development of thyroiditis in TAZ10 mice. 
 
In human, the thyroid is considered to be an immune-priviledged tissue. Indeed human 
thyrocytes  constitutively  expressing  Fas-L  molecules  induce  the  apoptosis  of  infiltrating 
activated self-reactive T cells that express Fas (Stassi et al. 1999). Thyrocytes in mouse do 
not constitutively express Fas or Fas-L (Batteux et al. 1999, 2000; Tourneur et al 2001; Wang 
et al. 2002; Wei et al. 2001, 2003, 2004). We showed that TECs from WT mice stimulated 
with  IFNγ  upregulate  Fas  and  Fas-L  and  induce  the  death  of  T  cells  from  TAZ10  mice 
(Figure  4-13).  This  however  implies  that  the  activation  of  self-reactive  T  cells  and  their 
migration to the thyroid have previously occurred. Furthermore, the death of thyrocytes is 
significant when challenged with pro-inflammatory cytokines such as IFNγ, TNFα and IL-1β 
(Figure 4-10). Histological analysis of the thyroid of 4-months old TAZ10 mice reveals that 
T cells are not in contact with TECs and do not undergo apoptosis in 4 months-old TAZ10 198 
 
mice (Quaratino et al. 2004). This suggest that the induction of apoptosis of T cells from 
TAZ10 mice has occurred earlier but could not overcome the strong accumulation of highly 
activated self-reactive T cells. 
 
We previously showed that highly inhibitory MDSCs accumulate in TAZ10 mice with 
thyroiditis  (Chapter  3).  Although  we  are  still  investigating  whether  the  recruitment  of 
MDSCs in the DLN occurs as soon as T cells from TAZ10 mice are activated in the DLN or 
at the first signs of thyroid damage, MDSCs are not capable of preventing the activation of 
self-reactive T cells. It could be possible that the inhibitory activity on T cells displayed by 
MDSCs  is  overpowered  by  the  strong  activation  of  T  cells  from  TAZ10  mice  upon 
recognition of the cryptic epitope.  
 
Previous work (Badami et al. 2005 and Badami E, Cexus O, Londei M and Quaratino S. 
Manuscript in preparation) has revealed that CD4
+ CD25
hi Foxp3
+ Tregs are not present at 
the site of inflammation (the thyroid) and the cervical lymph nodes. Indeed, Tregs die by 
AICD upon recognition of TPO epitopes when presented by mature DCs. Interestingly, only 
mDCs pulsed with the TPO protein could induce the death of Tregs. mDCs pulsed with the 
TPO cryptic epitope resulted in the loss of expression of Foxp3 that was not associated with 
the  death  of  the  cells.  It  was  therefore  suggested  that  mDCs  unmasking  the  antagonistic 
TPO525-536 epitope would induce the conversion of Tregs into Teff. This phenomenon has 
been  previously  observed  with  the  reprogrammation  of  antigen-specific  Foxp3
+  Tregs  to 
Th17 cells effector cells (Radhakrishnan et al. 2008). Interestingly mDCs uptaking dying 
TECs from WT mice previously challenged with IFNγ are able to present the TPO524-535 
cryptic epitope to T cells from TAZ10 mice. This was confirmed as we showed that the 
cryptic epitope TPO524-535 is naturally present in the thyroid and cervical lymph nodes of WT 
mice but not in other tissues. However, it is likely that mDCs fed with dying TECs generate 
the antagonist epitope TPO525-536 along with the cryptic epitope TPO524-535 (Quaratino et al. 
1996; Quaratino et al 2000). Therefore mDCs  migrating from the thyroid to the cervical 
lymph-nodes could either induce the death or Tregs or induce their convertion to Teff. To 
prove this, we need to assess the levels of both TPO524-535 and TPO525-536 both in the thyroid 
and DLN by functional assays and mass-spectometry on peptide extracts from thyroids and 
DLN. 
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5-1/ Introduction 
 
I  have  previously  highlighted  the  important  role  played  by  professional  and  non-
professional  antigen  presenting  cells  in  the  pathogenesis  of  thyroiditis  in  the  TAZ10 
transgenic mouse model spontaneously developing autoimmune thryoiditis (Chapter 4). The 
physiological turnover of TECs is at the origin of the development of autoimmune thyroiditis 
in  the  DLN.  Indeed,  professional  APCs  are  responsible  for  the  spreading  of  the  cryptic 
epitope  TPO524-535  from  the  thyroid  to  the  DLN  resulting  in  the  strong  activation  of 
transgenic T cells from TAZ10 mice. The infiltration of the thyroid with highly proliferative 
activated transgenic T cells promotes the death of thyrocytes. Activated lymphocytes in the 
thyroid  releasing  pro-inflammatory  cytokines  such  as  IFNγ  trigger  the  destruction  of  the 
thyroid that is achieved in almost 100% of TAZ10 mice at 4 months of age (Quaratino et al. 
2004). 
 
It  is  now  established  that  an  impaired  clearance  of  apoptotic  cells  by  APCs  such  as 
macrophages is an important factor involved in the pathogenesis of autoimmune diseases 
such as SLE (Gaipl et al. 2007). I previously highlighted the important role played by MFG-
E8  in  the  engulfment  of  apoptotic  bodies  by  APCs.  Indeed  impaired  MFG-E8  function 
promotes the activation of self-reactive T and B cells associated with the production and 
deposition  of  antibodies  to  dsDNA  into  the  kidney  and  the  development  of  autoimmune 
diseases (Hanayama et al. 2002 and 2004; Asano et al. 2004). Interestingly a recent study 
showed that MFG-E8 binds tissue transglutaminase 2 (TG2) (Toth et al. 2009), a pleiotropic 
enzyme  expressed  in  many  cell-types  and  upregulated  upon  inflammation  (Lorand  et  al. 
2003; Ientile et al. 2007). Indeed, the formation of a complex between TG2 and MFG-E8 is 
necessary for the efficient recognition and phagocytosis of apoptotic bodies by macrophages 
(Toth et al. 2009) 
TG2  has  been  linked  with  the  development  and  resolution  of  apoptosis  in  normal 
physiological conditions. TG2 promotes the formation of apoptotic bodies by cross-linking 
cytoplasmic actin (Nemes et al. 1997; Melino et al. 1994) and the exposure of phosphatidyl-
serine by apoptotic cells (Sarang et al.2007). TG2 also has an important role in regulating the 
anti-inflammatory response (Falasca et al. 2005) while being involved in the engulfment of 
apoptotic bodies by macrophages (Szondy et al. 2003; Toth et al. 2009). 
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In this respect, treatment with the TG2 inhibitor cystamine (Jeitner et al. 2005) has been 
shown to be beneficial in the NZB/W F1 mouse model of SLE. The downregulation of TG2 
activity in treated mice was coupled with a reduced expression of pro-inflammatory cytokines 
such as TNFα involved in the pathogenesis of SLE (Hsu et al. 2007). Mice injected with 
cystamine  also  presented  a  reduced  activity  of  matrix  metalloproteinase  9  (MMP-9)  and 
decreased  level  of  autoantibodies  in  the  serum  (Hsu  et  al.  2007).  Treatment  of  NZB/W 
F1mice with cystamine led to a reduction of apoptosis in the liver and the brain which was 
associated with a decreased expression of important pro-inflammatory proteins such as COX-
2 or iNOS (Hsu et al. 2008; Tzang et al. 2008; Wang et al. 2009). 
  
These results prompted me to start analyzing the potential role played by TG2 in TAZ10 
transgenic  mice  characterized  by  the  destruction  of  thyrocytes  (Quaratino  et  al.  2004).  I 
previously highlighted the role of pro-inflammatory cytokines such as IFNγ in inducing the 
apoptosis of thyrocytes via the release of NO and the induced-expression of Fas and Fas-L 
(Figure  4-9,  4-10  and  4-11).  By  fluorescence  microscopy,  I  analyzed  the  impact  of 
inflammation on the expression and activity of TG2 by thyrocytes. TECs from WT mice 
presented a basal expression level of TG2 in-vitro. Upon challenge with IFNγ for 3 days, 
TECs presented an increased TG2 expression (Figure 5-1/A) and activity. To ascertain this, 
we analyzed the expression of TG2 mRNA in different tissues from WT and TAZ10 mice 
(Figure 5-1/C). If no difference in the expression of TG2 mRNA could be detected in the 
lungs, guts and brains of WT and TAZ10 mice, thyroids from TAZ10 mice showed a higher 
TG2 mRNA expression compared to WT mice (Figure 5-1/B). 
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Figure  5-1:  Increased  expression  and  activity  of  tissue  transglutaminase  (TG2)  by  TECs  upon 
inflammation  
(A) Thyroids were isolated from wild-type (WT) mice and digested as previously described. Thyrocytes were 
grown on poly-L-Lysine coated coverslips for one day in complete medium and for a further 3 days with or 
without IFNγ at 200U/mL. Cells were then stained for tissue transglutaminase (TG2, green). (B) The effects of 
IFNγ on the activity of TG2 was assessed by the incorporation of biotin monodansyl-cadaverine revealed with 
streptavidin-Alexa488 (green). (A, B) Slides were analyzed by fluorescence microscopy (magnification x40 and 
x100). DAPI (blue) was used to counterstain the nucleus. (C) The relative expression of TG2 mRNA versus β-
actin mRNA was measured in wild-type and 2 months-old TAZ10 mice. Data shown are representative of two 
different experiments. 
 
TECs from TAZ10 mice were able to present the cryptic TPO epitope to T cells from 
TAZ10  mice  (Figure  4-6).  The  ability  of  TECs  from  WT  mice  stimulated  with  IFNγ  to 
present the TPO cryptic epitope to transgenic T cells was associated with the neo-expression 
of MHC-II molecules (Figure 4-3 and 4-8). While I suggested that this phenomenon was not 
involved at the onset of the disease, we wondered whether the upregulation of TG2 by TECs 
upon  challenge  with  IFNγ  had  any  effect  on  the  expression  of  MHC-II  molecules.  We 
therefore assessed the expression of MHC-II molecules (H2-A
b) by thyrocytes co-cultured 
with IFNγ in the presence or absence of the TG2 specific inhibitor cystamine. As observed by 
fluorescence microscopy, cystamine was able to reduce the effect of IFNγ-induced MHC-II 
expression by thyrocytes (Figure 5-2). 
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Figure 5-2: Inhibition of TG2 controls the upregulation of MHC-II molecules on thyrocytes induced by 
IFNγ  
Thyroids were isolated from wild-type (WT) mice and digested as previously described. Thyrocytes were grown 
on poly-L-Lysine coated coverslips for one day in complete medium and for a further 3 days with or without 
IFNγ at 200U/mL. Cells were then analysed for the level of expression of MHC-II molecules (H2-A
b, green). 
The effect of TG2 on the expression of MHC-II molecules by thyrocytes was assessed using the TG2 specific 
inhibitor cystamine. Slides were analyzed using a fluorescence microscope (magnification x40 and x100). DAPI 
(blue) was used to counterstain the nucleus. Data shown are representative of two different experiments. 
 
I  then  decided  to  measure  the  impact  of  the  inhibition  of  TG2  on  inflammation  by 
assessing the proliferative activity of T cells from the spleen of TAZ10 mice treated daily 
with cystamine for 7 only days. As expected, T cells from untreated TAZ10 mice strongly 
proliferated in response to αCD3. Surprisingly, the treatment of TAZ10 mice with cystamine 
led  to  a  dramatic  reduction  of  T  cell  proliferation  in  response  to  αCD3  (Figure  5-3/A). 
Indeed, if αCD3 increased T cell proliferation by about 750 fold compared to unstimulated 
splenocytes, treatment with cystamine led to a dramatic reduction of the ability of T cells to 
proliferate in response to αCD3 down to about 70 fold (Figure 5-3/B).  
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Figure  5-3:  Treatment  of  TAZ10  mice  with  the  TG2  inhibitor  cystamine  abrogate  the  proliferative 
activity of splenic T cells  
6 TAZ10 mice were treated for 7 days with 100µL of 0.01M daily injection of cystamine dihydrochloride 
dissolved in PBS. Spleens were isolated and the proliferative activity of splenocytes in response to αCD3 was 
assessed using (
3H) thymidine incorporation (cpm). 3 untreated TAZ10 mice were used as controls. Data in (A) 
represents one mouse of each group representative of all the mice in the same group. (B) Pooled analysis on the 
effect of αCD3 on the proliferation of transgenic T cells assessed as a percentage of increase compared to the 
basal proliferation of splenocytes in  medium only (no αCD3). Statistical analysis  was performed using the 
unpaired Student’s t-test. 
 
I previously showed that MDSCs efficiently inhibit the proliferation of TAZ10 T cells in 
response to the cognate peptide (Figure 3-22) or strong stimuli such as αCD3 (Figure 3-18) 
and accumulate in  lymphoid and non-lymphoid organs in TAZ10 mice (Figure 3-15). As 
MDSCs accumulate in peripheral organs in response to inflammation and proinflammatory 
cytokines such as IL-1β (Gabrilovitch. 2004; Song et al. 2005; Bunt et al. 2006 ; Kim et al. 
2006; Tu et al. 2008), I wondered whether TAZ10 mice treated with cystamine would present 
an altered distribution of MDSCs that could explain the results previously obtained (Figure 5-
3).  
 
By flow cytometry analysis, I revealed that Gr1
+ CD11b
+ MDSCs accumulated in the 
spleen of  cystamine-treated TAZ10 mice from  about 2.5% to 4% of the total splenocyte 
population (Figure 5-4/A, left panel). Although this accumulation of MDSCs in cystamine 
treated splenocytes could explain the decreased proliferation of T cells from TAZ10 mice, it 
did not confirm the increased accumulation of MDSCs in inflammation I observed in TAZ10 
mice (Chapter3/). I then investigated the proportion of MDSCs in the DLN of TAZ10 mice. 
Indeed we previously showed that LN from WT mice do not contain MDSCs (Figure 3-13/B 
and 3-15/B) while they accumulate in a context of cancer (Figure 3-13/B) or autoimmune 
disease (Figure 3-15/B). Surprisingly, the amount of Gr1
+ CD11b
+ MDSCs was nearly halved 205 
 
in  the  DLN  of  cystamine-treated  mice  (Figure  5-4/A,  right  panel);  thus  confirming  the 
beneficial effects of the treatment in TAZ10 mice. 
 
I also took this opportunity to analyse the proportion of effector CD4
+ T cells in the 
tissues previously analysed. Effector T cells were characterized by the lack of expression of 
CD62L (L-selectin) and CD127 (α subunit of the IL-7 receptor) (Stemberger et al. 2007) by 
flow cytometry. To our surprise, we also found a significant reduction in CD4
+ Vβ1
+ CD62L
-
 
CD127
-
 effector T cells both in the spleen (Figure 5-4/B, left panel) and the DLN (Figure 5-
4/B, righ panel) of TAZ10 mice treated for 7 days with cystamine. We could rule out that this 
difference was due to a reduction in the pool of CD4
+ T cells in these tissues (Figure 5-4/C). 
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Figure 5-4: Treatment of TAZ10 mice with the TG2 inhibitor cystamine alters the proportion of MDSCs 
and CD4
+ effector T cells 
(A) 6 TAZ10 mice were treated for 7 days with 100µL of 0.01M daily injection of cystamine dihydrochloride 
dissolved in PBS. Spleens (left panel) and draining lymph nodes (right panel) were isolated and cells analysed 
for the presence of Gr1
+ CD11b
+ MDSCs. The proportions of CD4
+ T cells (C) and CD4
+ CD62L
- CD127
- 
effector T cells were assessed in the spleens (left panel) and draining lymph nodes (right panel) of cystamine-
treated and untreated TAZ10 mice (B). Blue and red dots represent untreated and cystamine-treated TAZ10 
mice respectively. Statistical analysis was performed using the unpaired Student’s t-test. Red and blue bars 
represent SEM. 
 
Although experiments are still being performed to study in depth the mechanisms by 
which the inhibition of TG2 activity seems to reduce inflammation in TAZ10 mice with 
spontaneous thyroiditis, the results obtained are encouraging.  
 
Chronic inflammatory diseases affect a significant percentage of the population and are 
the cause of considerable suffering as well as large economic burden. Spanning from cancer 
to  autoimmune  diseases  (such  as  thyroiditis,  rheumatoid  arthritis  or  systemic  lupus 
erythematosus) and chronic disorders of the gut (celiac disease) or the lung (cystic fibrosis), 
chronic  inflammatory  diseases  have  in  common  the  infiltration  of  tissues  by  monocytic 
immune cells, the release of soluble factors such as cytokines (IL-1β, IL-6, TNFα) or nitric-207 
 
oxide and the activation of p38 MAPK and NF-κB. Interestingly, patients with autoimmune 
thyroiditis have an increased chance of developing celiac disease and vice versa (Naiyer et al. 
2008; Duntas, 2009). In celiac disease (CDis), TG2 is the main autoantigen recognized by 
autoantibodies (Dieterich et al. 1997; Marsh, 1997). TG2 also plays a fundamental role in the 
pathogenesis of the disease by operating a crucial deamidation of glutamine to glutamic acid 
of immunodominant gliadin epitopes that drive the adaptive immune response (van de Wal et 
al. 1998; Arentz-Hansen et al. 2000). 
 
However, a recent study has highlighted a new unexpected role of TG2 in celiac disease 
where  the  inhibition  of  TG2  activity  controlled  the  activation  of  gliadin-specific  T  cells. 
While the non-immunodominant gliadin peptide p31-43 induced the death of epithelial cells 
of the gut via Fas engagement (Maiuri et al, 2001; Maiuri et al. 2003), these effect were 
abrogated by incubating the cells with a monoclonal antibody blocking TG2 expressed at the 
cell-surface (Maiuri et al. 2005). Our close interactions with pediatric endoscopists provided 
an  opportunity  to  investigate  the  role  of  TG2  in  inflammatory  bowel  diseases  (such  as 
Crohn’s and celiac disease) as well as cystic fibrosis (CF) with a view to establishing whether 
other chronic inflammatory diseases in humans might share common mechanisms with other 
autoimmune pathologies such as that displayed in the TAZ10 transgenic mouse model of 
thyroiditis.  
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5-2/ Human CFTR-defective airway epithelial cells are constitutively 
stressed 
 
In Cystic Fibrosis, persistent infections produce a state of chronic inflammation in the 
lungs that is associated with biliary and pancreatic disorders (Didierlaurent et al. 2007; Ratjen 
et al. 2003). The inability of the clearance of infections such as Pseudomonas Aeruginosa in 
these patients is exacerbated both by the inactivation of neutrophils in the lungs (Hartl et al. 
2007) and the failure to efficiently clear the mucus from the airways. The impaired function 
of  the  CFTR  channel  consequential  to  mutation(s)  of  the  CFTR  gene,  results  in  reduced 
chloride permeability and an increased sodium and water absorption (Boucher et al. 1988; 
Reddy et al. 1999). This consequently leads to the cilia being unable to efficiently clear the 
thickened mucus (Ratjen et al. 2003). While few studies have suggested that the decreased 
airway  mucociliary  clearance  and  airway  mucosal  inflammation  occur  before  any  airway 
infection (Zahm et al. 1997), the impact of CFTR mutations on lung epithelial cells is still 
elusive. 
 
5-2-1/ Upregulation of the common markers of inflammation in CF airway 
epithelial cells  
 
I investigated the consequences of CFTR mutations in the human CF bronchial cell line 
bearing the common ∆F508/W1282X CFTR mutation (IB3-1 cell-line) and the isogenic C38 
cell-line  rescued  with  functional  CFTR  (Egan  et  al.  1992).  I  first  assessed  the  level  of 
activation of the two-different cell-lines in sterile tissue culture. To ensure that our system 
was free of any infections,  I regularly carried out RT-PCR to assess for the presence or 
absence  of  mycoplasma.  Culture  media  were  also  supplemented  with  antibiotics  and  low 
endotoxin  FCS  was  used.  By  fluorescence  microscopy,  we  evaluated  the  level  of 
phosphorylated tyrosines, a marker of inflammation in airway epithelial cells upon challenge 
with LPS (Raia et al. 2005). As shown Figure 5-5/A, IB3-1 cells showed a high staining for 
phospho-tyrosine compared to the control C38 cells thus highlighting that the cells present 
displayed some level of inflammation and cellular signaling.  
NF-κB has been shown to be at the centre of inflammatory responses by inducing the 
expression  of  pro-inflammatory  genes  such  as  IL-1β,  TNFα  or  COX-2  (Li  et  al.  2002; 
Youssef et al. 2006; van Loo et al. 2006). By fluorescence microscopy, I could see that IB3-1 
cells bearing the defective CFTR protein presented a higher amount of the phosphorylated 209 
 
form of p65 subunit of NF-κB that was mainly colocalizing in the nucleus whereas staining 
for C38 cells was scarce (Figure 5-5/B). This confirms previous studies describing that NF-
κB translocation to the nucleus is important in airway epithelial cells of CF patients (Tabary 
et al. 1999). 
 
To assess the impact of this increased NF-κB activation, I evaluated the expression of IL-
1β and TNFα at messenger (mRNA) and protein levels. CF cells presented high amounts of 
IL-1β and TNFα mRNAs while their expression in C38 cells was negative and very low 
respectively (Figure 5-5/C). By ELISA, I could see that IB3-1 cells secreted high amounts of 
TNFα and IL-1β cytokines (Figure 5-5/D) compared to C38 cells. This confirmed previous 
results highlighting a marked increase in the expression of pro-inflammatory cytokines such 
as IL-1β, TNFα, IL-6 or IL-17 associated with the CF phenotype (Osika et al. 1999). 
 
 
Figure 5-5: Up-regulation of inflammatory markers in human CFTR-defective airway epithelial cells  
Presence  of  phospho-tyrosine  residues  (A)  (green)  and  the  phosphorylated  form  of  p65  subunit  of  NF-κB 
(green) (B) in human CFTR-defective cell-line (IB3-1 cells) and the isogenic cell-line rescued with functional 
CFTR (C38 cells). DAPI was used to counterstain the nucleus. Cells were analysed by fluorescence microscopy 
(magnification x40). (C) mRNA profile of C38 and IB3-1 cell-lines for TNFα and IL-1β. mRNA expression for 
β-actin was used as control. (D) Amount of TNFα and IL-1β secreted by C38 and IB3-1 cell-lines by ELISA. 
Data shown are representative of at least two different experiments. 
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Lungs of patients with CF are characterized by the recruitment of neutrophils (Ratjen et 
al. 2003; Downey et al. 2009). Both ICAM-1 (Inter-Cellular Adhesion Molecule 1) and IL-8 
have  been  shown  to  be  important  factors  involved  in  the  recruitment  and  activation  of 
neutrophils (Nathan et al. 2006, Downey et al. 2009). 
 
Prompted by the expression of TNFα, IL-1β and the phospho-p65 subunit of NF-κB, we 
evaluated the levels of expression of ICAM-1 and IL-8 by fluorescence microscopy analysis 
and ELISA respectively. IB3-1 cells expressed high levels of ICAM-1 while this expression 
was weak in C38 cells (Figure 5-6/A). This was associated with the release of IL-8 that was 
further  increased  upon  challenge  with  LPS  from  Pseudomonas  aeruginosa  (PA-LPS)  at 
1µg/mL (Figure 5-6/B).  
 
 
Figure 5-6: Increased expression of neutrophils attractant by human CFTR-defective airway epithelial 
cells 
(A) Expression of ICAM-1 (green) in human CFTR-defective cell-line (IB3-1) and the isogenic cell-line rescued 
with functional CFTR (C38). DAPI was used to counterstain the nucleus. Cells were analysed by fluorescence 
microscopy (magnification x40). (B) IL-8 ELISA in C38 and IB3-1 cell-lines with or without challenge with 
LPS  from  Pseudomonas-aeruginosa  (PA-LPS).  Data  shown  are  representative  of  at  least  two  different 
experiments. 
 
p38  Mitogen  Activated  Protein  Kinase  (MAPK)  is  highly  activated  in  cystic  fibrosis 
airways and its inhibition has been shown to dampen inflammation in CF airway (Raia et al. 
2005). Interestingly, IL-8 over-expression has been shown to depend of MAPK and NF-κB 
signaling  pathways  in  CF  epithelial  cells  (Carrabino  et  al.  2006;  Muselet-Charlier  et  al. 
2007). Also, the adherence of neutrophils in CF airways is increased and depends on the 211 
 
activation of NF-κB-induced expression of ICAM-1 (Melotti et al. 2001; Tabary et al. 2006). 
Together these results suggested that cells bearing a defective CFTR protein as a result of 
gene mutation presented an increased pro-inflammatory phenotype favoring the important 
recruitment of neutrophils as shown by the high expression of IL-8 and ICAM-1. 
 
5-2-2/ Increased TG2 expression in CFTR-defective airway epithelial cells  
 
Celiac  disease  (CDis)  is  a  common  pathology  caused  by  an  inappropriate  immune 
response to wheat and gluten and is characterised by local (small intestine) and systemic 
manifestations (Schuppan et al. 2000). Important histological features of untreated patients 
with  CD  are  the  activation  of  gliadin  specific  T  cells,  the  infiltration  of  intraepithelial 
lymphocytes and the flattening of the mucosa of the small intestine (Schuppan et al. 2000). 
 
Tissue transglutaminase 2 (TG2) is essential in the pathogenesis of celiac disease (CDis) 
as  operating  an  important  deamidation  of  glutamine  to  glutamic  acid  of  the  gliadin 
immunodominant epitopes (Molberg et al. 2008). However, the enzymatic activity of TG2 is 
not its only function as it displays other multiple biological activities (Akimov et al. 2000 and 
2001) and is upregulated upon inflammation (Lorand et al. 2003; Ientile et al. 2007). TG2 is a 
calcium-dependent enzyme with a transamidating activity that also results in the cross-linking 
of  proteins  via  ε(γ-glutamyl)  lysine  bonds  (Fesus  et  al.  2002).  More  recent  studies  have 
highlighted  the  important  role  played  by  TG2  in  the  pathogenesis  of  numerous 
neurodegenerative diseases. Indeed, in Parkinson’s disease, TG2 mediates the cross-linking 
and aggregation of α-synuclein in Lewy inclusion bodies (Junn et al. 2003). 
CDis is triggered by a non-immunodominant gliadin peptide which stimulates the innate 
immune response and induces epithelial damage and death by apoptosis (Maiuri et al. 2003). 
This non-immunodominant peptide induces TG2 upregulation whose inhibition controls the 
activation of epithelial changes and damages and the subsequent activation of pathogenic 
gliadin-specific T cells (Maiuri et al. 2005 and Submitted).  
 
Prompted by this unexpected role of TG2 in the modulation of inflammation in CDis, we 
wanted to address whether the increased inflammatory status displayed by IB3-1 cells was 
associated  with  an  increased  expression  of  TG2.  Indeed,  IB3-1  cells  had  an  increased 
expression in TG2 mRNA compared to the control C38 cell-line (Figure 5-7/A). This was 212 
 
associated with the expression of TG2 protein as shown by immunofluorescence (Figure 5-
7/B,  top  panel)  and  western-blot  analysis  (Figure  5-7/B,  bottom  panel).  By  confocal 
microscopy, we also observed an increased TG2 activity in IB3-1 cells as revealed by the 
incorporation of monodansyl-cadaverine by TG2 (Figure 5-7/C). 
 
 
Figure 5-7: CFTR-defective airway epithelial cells have an increased TG2 expression and activity 
(A) mRNA profile of C38 and IB3-1 cell-lines for the expression of TG2 mRNA. mRNA expression of β-actin 
was used as control. (B) The level of expression of TG2 (greeb) by C38 cells and the CFTR-defective IB3-1 
cells  was  assessed  by  fluorescence  microscopy  (magnification  x40)  (top-panel)  and  western-blot  (bottom-
panel). DAPI was used to counterstain the nucleus (C) The enzymatic activity of TG2 (blue) in C38 and IB3-1 
cells was assessed by the incorporation of monodansyl cadaverine and analysed by fluorescence microscopy 
(scale bar, 10µm). Data shown are representative of at least two different experiments. Figure B (western-blots) 
and C were kindly provided by Prof. Luigi Maiuri; figures from (Maiuri et al. 2008). 
 
Mutation of the CFTR gene resulting in a defective CFTR protein confers an increased 
inflammatory  status  to  bronchial  epithelial  cells.  Although  we  expected  an  increased 
expression of the common markers of inflammation such as NF-κB, TNFα and IL-1β, we 
wanted to investigate whether the increased expression of TG2 had any  impact in  IB3-1 
compared to C38 cells. 
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5-3/ PPARγ colocalize in perinuclear aggresomes in CFTR-defective 
airway epithelial cells 
 
We first analyzed whether CF cells presented an altered expression of PPARγ, a key 
regulator  involved  in  dampening  signs  of  inflammation  in  many  inflammatory  diseases 
(Bailey et al. 2005; Pascual et al. 2005). By fluorescence microscopy, we could see that the 
cellular distribution of PPARγ was atypical in IB3-1 cell-line. While PPARγ was distributed 
evenly in the cytoplasm of C38 cells, its distribution in IB3-1 cells suggested that PPARγ had 
aggregated (Figure 5-8/A). To investigate this hypothesis, we analysed the distribution of 
PPARγ  in  C38  and  IB3-1  cells  by  subcellular  confocal  microscopy  (Figure  5-8/B). 
Interestingly, we could confirm that PPARγ proteins were accumulating essentially in the 
proximity of the nucleus while PPARγ was evenly distributed in the cytoplasm of C38 cells.  
 
Numerous  neurodegenerative  diseases  have  in  common  the  intracellular  accumulation 
and aggregation of proteins such as huntingtin in Huntington’s disease (Karpuj et al. 1999) or 
α-synuclein in Parkinson’s disease (Junn et al. 2003) disease. Different types of inclusions of 
aggregated proteins have been described according to the cellular localization, the solubility 
and the level of ubiquitination and aggregation of the proteins. Indeed, soluble ubiquitinated 
proteins form perinuclear aggregates where proteasomes are abundant. These juxta-nuclear 
quality  control  compartments  or  JUNQ  are  associated  with  the  endoplasmic  reticulum 
associated protein degradation or ERAD (Plemper et al. 1999; Kaganovitch et al. 2008). On 
the other hand, aggregated proteins can form perivacuolar inclusions named insoluble protein 
deposits or IPOD associated with high amounts of Hsp104. Interestingly, amyloid proteins 
such as huntingtin and prion are associated with IPOD and their enhanced ubiquitination 
target them to JUNQ perinuclear compartments (Kaganovitch et al. 2008). 
 
Finally,  unfolded  or  misfolded  proteins  not  degraded  by  the  proteasome  can  form 
aggregates that are transported along microtubules via dynein proteins to the microtubule 
organizing  center  (MTOC)  (Kopito,  2000;  Garcia-Mata  et  al.  2002).  These  perinuclear 
inclusions called aggresomes bind dynein via the histone deacetylase 6 (HDAC6) recognizing 
and  binding  poly-ubiquitin  chains  on  aggregated  proteins  (Kawaguchi  et  al.  2003).  We 
wanted to ascertain whether the accumulation of PPARγ in IB3-1 cells was associated with 
one  of  these  inclusions.  By  confocal  microscopy  analysis,  we  found  that  PPARγ  was 214 
 
colocalizing with both ubiquitin (Figure 5-8/C, top panel) and HDAC6 (Figure 5-8/C, bottom 
panel) this confirming that PPARγ accumulated in aggresomes.  
 
 
Figure 5-8: PPARγ colocalizes in perinuclear aggresomes in CFTR-defective airway epithelial cells 
(A) Expression of PPARγ (green) in the human CFTR-defective cell-line (IB3-1) and the isogenic cell-line 
rescued with functional CFTR (C38 cell-line) was analysed by fluorescence microscopy (magnification, x40). 
DAPI was used to counterstain the nucleus. (B) Expression of PPARγ in IB3-1 and C38 cell-lines (green) was 
analysed  by  confocal  microscopy  at  high  magnification.  CyTRAK  (orange)  was  used  to  counterstain  the 
nucleus. (C) Co-localization of PPARγ (green) and ubiquitin (red, top panel) or HDAC6 (red, bottom panel) 
was assessed by confocal microscopy (scale bar, 10µm). Data shown are representative of at least two different 
experiments. Figure B and C were kindly provided by Prof. Luigi Maiuri; figures from (Maiuri et al. 2008). 
 
Perinuclear inclusions have been shown to be associated with proteasomes to allow for 
the degradation of ubiquitinated proteins (Kaganovitch et al. 2008). Indeed, treatment of IB3-
1 cells with the proteasome inhibitor MG132 resulted in an increased level of PPARγ protein 
as  revealed  by  western-blot  analysis  (Figure  5-9/A,  left  panel)  and  confocal  microscopy 
(Figure 5-9/B). Purified PPARγ by immunoprecipitation also revealed that inhibition of the 
proteasome increased its ubiquitination as shown by the increased size obtained by western-
blot (55 kDa for normal PPARγ protein and around 72kDa for ubiquitinated forms of PPARγ) 
(Figure 5-9/A, right panel).  
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HDAC6  dependent  processing  of  misfolded  protein  can  involve  two  mechanisms 
(Kawaguchi et al. 2008). Indeed ubiquitinated proteins can undergo degradation mediated by 
the  proteaseome.  Misfolded  proteins  not  being  degraded  by  the  proteasome  form  toxic 
aggregates that are recognized by HDAC6 through the polyubiquitin chains (Kawaguchi et al. 
2006). We wanted to assess this by inhibiting the degradation of PPARγ by the proteaseome. 
Indeed,  incubation  of  IB3-1  cells  with  MG132  resulted  in  higher  amounts  of 
polyubiquitinated forms of PPARγ as detected by western-blot (Figure 5-9/A, right panel) 
and confocal microscopy analysis (Figure 5-9/C, top panel). Interestingly, treatment of the 
cells with MG132 dramatically increased the amount of HDAC6 expressed (Figure 5-9/C, 
bottom panel).  
 
 
 
Figure 5-9: PPARγ proteins colocalizing in aggresomes of IB3-1 cells are degraded by the proteasome 
(A)  Left  panel,  Presence  of  PPARγ  in  the  human  CFTR-defective  cell-line  (IB3-1)  with  or  without  the 
proteasome  inhibitor  MG132  was  assessed  by  western-blot  analysis.  Right  panel,  Immunoprecipitated  (IP) 
PPARγ proteins are assessed for their immunoreactivity (IB) to ubiquitin in the presence or absence of MG132. 
(B) Effect of the inhibition of the proteasome activity on the cellular distribution of PPARγ (green) in IB3-1 
cells was analysed by confocal microscopy (scale bar, 10µm). (C) Confocal analysis of the co-localization of 
PPARγ (green) with ubiquitin (red, top panel) and HDAC6 (red, bottom panel) in IB3-1 cells. Data shown are 
representative of at least two different experiments. Figures were kindly provided by Prof. Luigi Maiuri; figures 
from (Maiuri et al. 2008). 
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By inhibiting the degradation of PPARγ by the proteasome, we therefore increased the 
amount  of  aggregates  of  ubiquitinated  form  of  PPARγ  hence  favoring  the  formation  of 
aggregates as revealed by the increased expression of HDAC6. 
 
5-4/ Up-regulation of TG2 promotes inflammation in CFTR-defective 
airway epithelial cells 
 
Once synthesized, proteins must acquire a structure that will allow them to exert their 
specific structural, enzymatic and/or signaling functions. The appropriate folding of proteins 
is  mediated  by  chaperones  and  prevents  the  formation  of  misfolded  proteins  and  their 
aggregation that could become detrimental and toxic to the cells (Hartl et al. 2002). Despite 
the  abundance  of  molecular  chaperones,  protein-folding  is  not  efficient  and  it  has  been 
assumed  that  nearly  30%  of  newly  synthesized  proteins  are  defective  products  that  are 
normally  rapidly  ubiquitinated  and  degraded  by  the  proteasome  (Schubert  et  al.  2000). 
However,  the  degradation  of  several  proteins  is  defective.  Indeed,  ∆F508-CFTR  mutant 
proteins are not efficiently degraded by the ubiquitin-proteaseome pathway and have been 
shown to accumulate in aggresomes (Kawaguchi et al. 2003). Although it has been suggested 
that initial aggregation of proteins could occur while translation is still ongoing and nascent 
proteins are generated (Kopito. 2000; Garcia-Marta et al. 2002), this could not explain the 
aggregation of PPARγ in cells bearing the ∆F508 mutation of the CFTR gene. 
 
5-4-1/ Up-regulation of TG2 leads to the Sequestration of PPARγ in the 
CFTR-defective airway epithelial cells 
 
We previously observed an increased expression of TG2 proteins in the IB3-1 CFTR-
defective cell-line (Figure 5-7). Interestingly, PPARγ sequence contains two specific sites 
(QG and QXXP) that are recognized by TG2 mediating its cross-linking activity through the 
glutamine (Q) residues (Lorand et al. 2003). At this point, TG2 was an ideal candidate in 
promoting the aggregation of PPARγ proteins.  
 
We first assessed whether TG2 would co-localize with PPARγ by confocal microscopy in 
C38 and IB3-1 cell-lines using a cross-link isopeptide specifically recognized by TG2 (Figure 217 
 
5-10/A). TG2 proteins colocalized with PPARγ-containing aggresomes in IB3-1 cells while 
PPARγ was diffused in the cytoplasm of C38 cells as observed Figure 5-8.  
 
We then wondered whether  the inhibition of TG2 using the irreversible TG2-specific 
inhibitor R283 (kind gift from M. Griffin, Aston University, Birmingham, UK) would restore 
the levels of PPARγ in IB3-1 cells back to levels present in C38 cells (Figure 5-8 and 5-9). 
Indeed, levels of 55kDa PPARγ were low in IB3-1 cells compared to C38 cells (Figure 5-
10/B, left panel) and restored upon incubation of the cells with R283 (Figure 5-10/B, right 
panel)  as  shown  by  western-blot  analysis.  We  still  needed  to  ascertain  that  TG2  was 
promoting the cross-linking of PPARγ proteins. To do this we used an isopeptide bearing a 
recognition sequence for TG2: TG2 is capable of cross-linking the isopeptides that can be 
identified using an isopeptide-specific antibody. We therefore assessed whether TG2 would 
promote  protein  cross-linking  between  the  TG2  specific  isopeptide  and  PPARγ  by 
immunobloting purified PPARγ proteins previously immunoprecipitated for the isopeptide. 
Several high molecular weight forms of PPARγ ranging between 72kDa and 250kDa could 
be detected with the anti-isopeptide antibody, with major bands at 95kDa and 130kDa (Figure 
5-10/C,  left  panel).  Addition  of  R283  promoted  a  major  reduction  of  PPARγ-isopeptide 
aggregates  (Figure  5-10/C,  right  panel)  while  restoring  normal  levels  of  55kDa  PPARγ 
(Figure 5-10/B, right panel).  
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Figure 5-10: PPARγ co-localize with TG2 in CFTR defective airway epithelial cells 
(A) Confocal analysis of the co-localization of PPARγ (green) with TG2 as revealed by the staining for TG2 
isopeptide (red) in C38(left panel) and IB3-1 (right panel) cell-lines (scale bar, 10µm). (B) The detection of 
PPARγ in C38 and IB3-1 cells (left panel) and the effect of the TG2 specific inhibitor R283 on the level of 
expression of PPARγ in IB3-1 cells (right panel) were assessed by western-blot analysis. (C) Right panel, 
Immunoprecipitated  (IP) PPARγ  proteins  are  assessed  for  their  immunoreactivity  (IB)  to  the  TG2  specific 
isopeptide in C38 and IB3-1 cells. The effect of the inhibition of TG2 by R283 in IB3-1 cells is also assessed 
(right panel). Data shown are representative of at least two different experiments. Figures were kindly provided 
by Prof. Luigi Maiuri; figures from (Maiuri et al. 2008). 
 
We observed that the inhibition of TG2 activity restored the cytoplasmic distribution of 
PPARγ (Figure 5-11/A) by confocal microscopy analysis in both nasal polyp mucosa from 
CF patients and IB3-1 cells. This redistribution of PPARγ in IB3-1 cells promoted by the 
TG2 specific inhibitor R283 was similar to the action of the proteasome inhibitor MG132 we 
previously observed (Figure 5-9/B). Rosiglitazone, a potent PPARγ agonist was capable of 
inducing  the  nuclear  translocation  of  PPARγ  in  C38  cells.  However,  this  could  only  be 
achieved in IB3-1 cells when TG2 activity was also inhibited by R283 (Figure 5-11/B). 
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Figure 5-11: Inhibition of TG2 promotes a redistribution of PPARγ in CFTR-defective cells 
(A) Detection of PPARγ (green) in the human CFTR-defective cell-line (IB3-1) and nasal polyp mucosa from 
CF patients with or without the TG2 inhibitor R283. (B) Effect of the potent PPARγ agonist rosiglitazone on the 
cellular distribution of PPARγ (green) with or without the TG2 inhibitor R283 in C38 and IB3-1 cells. Slides 
were analysed by confocal  microscopy (scale bar, 10µm). CyTRAK (orange)  was  used to counterstain the 
nucleus. Data shown are representative of at least two different experiments. Figures were kindly provided by 
Prof. Luigi Maiuri; figures from (Maiuri et al. 2008). 
 
Altogether  these  results  showed  that  in  CFTR-defective  cells,  PPARγ  proteins  are 
ubiquitinated and degraded via the proteasome. Also, the lack of functional CFTR leads to an 
increased expression of TG2 which promotes the cross-linking of PPARγ into aggresomes.  
 
 PPARγ has been shown to “transrepress” inflammatory responses mediated by NF-κB 
(Bailey et al. 2005; Pascual et al. 2005). Interestingly, we previously showed that IB3-1 cells 
presented an overexpression of the phosphorylated p65 subunit of NF-κB whereas presenting 
an inflammatory phenotype as described by the increased expression of IL-1β, TNFα or IL-8 
(Paragraph 5-2/). This prompted us to investigate whether we could reduce inflammation in 
CFTR-defective cells by abrogating the aggregation and degradation of PPARγ mediated by 
TG2. 
 
5-4-2/ TG2 mediates inflammation in CFTR-defective cells  
 
Calcium (Ca
2+) homeostasis has been shown to be abnormal in airway epithelial cell-lines 
bearing the CFTR-∆F508 mutation (Antigny et al. 2008) with CF cells presenting a high 
mobilization of Ca
2+. As prolonged increase of intracellular Ca
2+ promotes the upregulation 220 
 
of TG2 whose activity also depends on the level of Ca
2+ (Yoo et al. 2005; Lorand et al. 
2005), we wondered whether the increased TG2 activity we previously observed in IB3-1 
cells was driven by the increased Ca
2+ concentrations in these cells. 
Indeed,  TG2  activity  and  p42/44  (also  called  extracellular  signal-regulated  kinase  or 
ERK-1  and  ERK-2  respectively)  phosphorylation  was  drastically  reduced  in  IB3-1  cells 
treated with the calcium chelator BAPTA-AM (Figure 5-12/A, left panel). To mimic the Ca
2+ 
environment present in IB3-1 cells into C38 cells, we used the Ca
2+ ionophore ionomycin 
inducing an important influx of Ca
2+ in the cells. Treatment of isogenic CFTR-corrected C38 
cells with ionomycin considerably increased both TG2 activity and the phosphorylation of 
p42/44 (Figure 5-12/A, right panel).  
TG2 activity also depends on the intracellular content of reactive oxygen species (ROS) 
(Lee et al. 2003) whose production is associated with an efflux of calcium from intracellular 
organelles (Yi et al. 2006; Leo et al. 2008). Interestingly, CF patients and CF cells present an 
increased production of ROS. We wondered whether increased ROS production in CF cells 
was also responsible for promoting TG2 activity (Cowley et al. 2002; Velsor et al. 2006). 
Indeed,  IB3-1 cells treated with the ROS scavenger NAC (N-acetylcysteine) had a slight 
reduction of TG2 expression while TG2 activity was strongly reduced (Figure 5-12/B) as 
shown  by  confocal  microscopy.  We  could  also  see  a  strong  reduction  in  p42/44 
phosphorylation (Figure 5-12/B) and TNFα secretion (Figure 5-12/C) in IB3-1 cells treated 
with NAC. 
Together, these results showed that increased Ca
2+ concentration and ROS production 
promoted by the mutation of the CFTR gene was driving the activation of TG2 and therefore 
the inflammation in CF cells. 
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Figure 5-12: TG2 activity is regulated by calcium and reactive-oxygen species (ROS) in CFTR-defective 
airway epithelial cells 
(A) Left panel, Effect of the calcium chelator BAPTA-AM on TG2 activity (blue) and phosphorylation of 
p42/44 (green) in CFTR-defective IB3-1 cells. Right panel, Analysis of the effect of the calcium ionophore 
ionomycin  on  TG2  activity  (blue)  and  the  level  of  phosphorylation  of  p42/44  (green)  in  C38  cells.  (B) 
Expression  (green,  left  panel)  and  activity  (blue)  resulting  from  the  action  of  the  ROS  chelator  NAC  was 
analysed in IB3-1 cells. Effect of NAC on the level of phospho-p42/44 in IB3-1 cells was also analysed (green, 
right panel). (A, B) The slides were analysed by confocal microscopy (scale bar, 10µm). CyTRAK (orange) was 
used to counterstain the nucleus. Data shown are representative of at least two different experiments. (C) The 
amount of TNFα secreted by IB3-1 cells with or without the ROS chelator NAC was evaluated by ELISA. Data 
shown are representative of at least two different experiments. Figures were kindly provided by Prof. Luigi 
Maiuri; figures from (Maiuri et al. 2008). 
 
We went on to investigate whether we could dampen the signs of inflammation in CF 
airway  epithelial  cells  by  inhibiting  TG2  activity.  Indeed,  R283  induced  a  significant 
reduction of the level of phosphorylation of p42/44 proteins both in nasal polyps from CF 
patients (Figure 5-13/A, top panel) and IB3-1 cells (Figure 5-13/A) as shown by confocal 
microscopy and western-blot analysis. The action of R283 on the level of phospho-p42/44 in 
IB3-1cells could also be mimicked by silencing TG2 expression using TG2 siRNA while 
control siRNA did not have any effect (Figure 5-13/A, bottom panel). IB3-1 cells presented 
high levels of phospho-tyrosine that was absent in C38 cells (Figure 5-5/A). The specific 
PPARγ  antagonist  GW9662  could  abrogate  the  important  decrease  in  tyrosine-
phosphorylation induced by the inhibition of TG2 activity in nasal polyp mucosa from CF 222 
 
patients (Figure 5-13/ B). Finally, we could prevent the release of TNFα by IB3-1 cells by 
inhibiting TG2 expression with TG2 siRNA and TG2 activity with R283 (Figure 5-13/C) 
 
 
Figure 5-13: TG2 promotes inflammation in CFTR-defective airway epithelial cells 
(A) Detection of the level of phosphorylation of p42/44 (green) in nasal polyp mucosa from CF patients and 
IB3-1 cells upon incubation with the TG2 specific inhibitor R283 by confocal microscopy (top panel) and 
western-blot (bottom panel). CyTRAK (orange) was used to counterstain the nucleus. (Scale bar, 10µm) (B) 
Expression of phospho-tyrosines (green) by nasal polyp mucosa from CF patients upon incubation with the TG2 
inhibitor R283 and followed by the PPARγ antagonist GW9662. (C) The effect of the inhibition of TG2 by TG2 
siRNA and TG2 inhibitor R283 on the expression of TNFα by IB3-1 cells was assessed by ELISA. (A, B, C) 
The slides were analysed by confocal microscopy (scale bar, 10µm).Data shown are representative of at least 
two different experiments. Figures were kindly provided by Prof. Luigi Maiuri; figures from (Maiuri et al. 
2008). 
 
Together, these results showed that increased Ca
2+ concentration and ROS production in 
CF cells was driving the activation of TG2 and therefore the inflammation.  
 
To demonstrate that the induction of inflammation was mediated by TG2 promoting the 
functional sequestration of PPARγ, we used the CFTR-selective inhibitor CFTRinh-172 to 
induce a CF phenotype in the normal bronchial 16HBE epithelial cell-line. As previously 
reported (Velsor et al. 2006), the inhibition of CFTR led to an increased production of ROS 
in  16HBE  cells  as  shown  by  confocal  microscopy  (Figure  5-14/A,  top  panel)  and 
fluorescence  (Figure  5-14/A,  bottom  panel)  analysis  using  the  ROS  specific  probe  CM-
H2DCFDA  (5-(and-6)-chloromethyl-2'7'-dichlorodihydrofluorescein  diacetate  acetyl  ester). 223 
 
Similarly, addition of CFTRinh-172 to 16HBE cells promoted an increased phosphorylation 
of p42/44 proteins and nuclear translocation as revealed by confocal microscopy (Figure 5-
14/B, top panel) and western-blot (Figure 5-14/B, bottom panel) analysis. 
 
Interestingly, by blocking the functional CFTR in 16HBE bronchial cells, we induced 
TG2 protein expression and activity (Figure 5-14/C) while the expression of PPARγ was 
drastically decreased (Figure 5-14/D). 
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Figure 5-14: Inhibition of CFTR promotes inflammation in airway epithelial cells 
(A) The effect of CFTR inhibition using CFTRinh-172 on the amount of reactive oxygen species (ROS, green) 
produced by bronchial 16HBE cells was assessed by confocal microscopy (top panel) and fluorescence (bottom 
panel) using the ROS specific probe CM-H2DCFDA. (B) The level of phosphorylation of p42/44 (green) in 
16HBE cells upon inhibition of CFTR with CFTRinh-172 was analysed by confocal microscopy (top panel) and 
western-blot analysis (bottom panel). CyTRAK (orange) was used to counterstain the nucleus. (C) Effect of the 
inhibition  of  CFTR  by  CFTRinh-172  in  16HBE  cells  on  TG2  expression  (green)  and  activity  (blue)  was 
assessed  by  confocal  microscopy.  (D)  Detection  of  PPARγ  (green)  in  the  human  16HBE  cell-line  with  or 
without the inhibition of CFTR with CFTRinh-172 was assessed by confocal microscopy. CyTRAK (orange) 
was used to counterstain the nucleus. (Scale bar, 10µm) Data shown are representative of at least two different 
experiments. Figures were kindly provided by Prof. Luigi Maiuri; figures from (Maiuri et al. 2008). 
 
Altogether, these results specify the central role played by the defective CFTR protein in 
the induction of inflammation in CF. 225 
 
5-5/ Summary  
 
Tissue transglutaminase 2 (TG2) is the major player in the pathogenesis of celiac disease 
(CDis) as operating an important deamidation of glutamine to glutamic acid of the gliadin 
immunodominant epitopes (Molberg et al. 2008). In patients with CDis, a humoral immune 
response is also mounted against TG2 (presence of TG2 specific autoantibodies) making it 
the major autoantigen in CDis (Dieterich et al. 1997; Marsh, 1997; van de Wal et al. 1998; 
Arentz-Hansen et al. 2000). The unexpected role of TG2 in the modulation of inflammation 
in CDis (Maiuri et al. 2005) together with the results exposed in this chapter, confirm the 
central  role  played  by  TG2  in  controlling  inflammation  in  epithelial  cells  during  chronic 
inflammatory diseases. In this study, we demonstrated that CFTR-defective epithelial cells 
present an increased expression of TG2 whose activity is responsible for the sequestration of 
functional PPARγ by promoting their aggregation into aggresomes.  
 
PPARγ  is  a  major  anti-inflammatory  protein  that  repressess  inflammatory  responses 
generated  by  NF-κB  (Bailey  et  al.  2005;  Pascual  et  al.  2005).  Its  downregulation  in  CF 
patients  is  therefore  responsible  for  the  increased  inflammatory  status  of  epithelial  cells. 
Compared to wild-type mice, CFTR
-/- mice are defective in PPARγ expression (Ollero et al. 
2004).  While  patients  with  cystic  fibrosis  upregulate  the  expression  of  IL-8  and  have  a 
reduction of PPARγ expression, they also suffer from osteoporosis (Dif et al. 2004; Hecker et 
al. 2004; Shead et al. 2006) Interestingly, increased levels of IL-8 have been associated with 
bone resorption in cancer patients (Bendre et al. 2003) while PPARγ regulate bone formation 
in  mice  and  favors  bone  progenitors  to  the  osteoclast  lineage  (Wan  et  al.  2007).  The 
important roles played by PPARγ in lung diseases have been at the centre of the therapeutic 
strategies aiming at reducing inflammation in chronic diseases of the airways (Huang et al. 
2005). 
 
We  previously  highlighted  (Paragraph  1-2-2-1/)  the  importance  of  the  degradation  of 
proteins by the ubiquitin-proteasome system. Indeed an alteration of this system promotes the 
aggregation of unfolded / misfolded proteins and functional proteins that are destined for 
degradation. The accumulation of these proteins in the cells being toxic, they aggregate into 
inclusion bodies generally situated close to the nucleus. The aggregation of proteins into 
inclusions  bodies  is  a  common  feature  of  various  neurodegenerative  diseases  such  as 
Huntington’s or Parkinson’s disease (Karpuj et al. 1999; Junn et al. 2003). We have shown 226 
 
that PPARγ aggregates in perinuclear aggresomes in CFTR-defective airway epithelial cells 
as they colocalize with HDAC6 and ubiquitin. In C38 cells, misfolded PPARγ and folded 
PPARγ at the end of their “life” are ubiquitinated and degraded by the proteasome (Figure 5-
15).  
 
 
Figure 5-15: Increased TG2 expression and activity in CFTR-defective airway epithelial cells promotes 
the aggregation of PPARγ into aggresomes 
In  C38  cells,  PPARγ  is  an  anti-inflammatory  protein  that  is  commonly  degraded  by  the  ubiquitin  (Ub)  / 
proteasome system after ubiquitination.  
Airway  epithelial  cells  presenting  a  defective  CFTR  protein  (Cystic  Fibrosis  Transmembrane  Conductance 
Regulator)  upregulate  the  expression  and  activity  of  tissue  transglutaminase  (TG2).  PPARγ  proteins 
ubiquitinated or not are recognized by through the two TG2 specific sites (QG and QXXP) by TG2 which 
mediates  their  aggregation  by  ε-γ  crosslinking.  PPARγ  aggregates  are  recognized  by  histone  deacetylase  6 
(HDAC6) via the poly-ubiquitin chain. This complex then binds dynein that transports the aggregates along the 
microtubules  to  the  microtubule  organizing  centre  (MTOC)  to  form  aggresomes.  The  proteasome  can  still 
degrade single and aggregated ubiquitinated PPARγ proteins. 
 
Inhibition of the proteasome with MG132 prevents the degradation of PPARγ proteins 
thus leading to its accumulation in airway epithelial cells. Upon MG132 exposure CFTR-
defective airway epithelial cells increase the expression of HDAC6, the ubiquitination status 227 
 
of PPARγ and its aggregation into aggresomes. By contrast, inhibition of TG2 prevents the 
aggregation of PPARγ and the formation of aggresomes in CF cells. Ubiquitinated PPARγ 
proteins can therefore be degraded by the proteasome as observed in CFTR competent cells. 
This increase of TG2 expression is dependent on the increased concentration of calcium and 
ROS as a result of the lack of functional CFTR proteins. 
This  is  the  first  report  describing  an  intrinsic  mechanism  promoting  inflammation  in 
airway epithelia of cystic fibrosis patients.  
 
Upregulation  of  TG2  has  also  been  associated  with  metastasis  in  cancer.  Indeed, 
increased  TG2  expression  confers  resistance  to  chemotherapy  and  is  linked  with  the 
overexpression of drug multi resistance genes (Herman et al. 2006; Verma et al. 2007; Cao et 
al. 2008). Tissue transglutaminase promotes metastasis by favoring cell attachment, tissue 
invasion and cell survival. This is partially mediated via the activation of NF-κB resulting 
from the depletion of functional IκBα proteins (Mehta et al. 2004; Mann et al. 2006; Mann et 
al. 2007).  These studies further strengthen the role played by TG2 in inflammation in chronic 
inflammatory diseases and cancer. Our study on the consequences of TG2 upregulation in the 
modulation of inflammation may therefore provide new therapeutic strategies for patients 
with chronic inflammatory diseases. 
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6/ Summary – Induction of autoimmune 
disease in TAZ10 transgenic mice 
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The general aim of this work was to understand and highlight the mechanisms leading to 
chronic inflammatory diseases and the effects of some regulatory pathways/networks that 
control  these  mechanisms.  I  have  addressed  these  issues  using  the  humanized  TAZ10 
transgenic mouse model of spontaneous autoimmune thyroiditis (Quaratino et al. 2004). Here 
I have investigated the initial events involved in the activation of self-reactive CD4
+ T cells 
which mediate the destruction of the thyroid. TAZ10 transgenic mice express a human TCR 
specific  for  a  cryptic  epitope  (TPO524-535)  of  thyroid  peroxidase  (TPO)  generated  upon 
endogenous  processing  by  thyroid  epithelial  cells  (TEC)  and  a  naturally  occurring 
antagonistic epitope (TPO525-536) presented by APC upon exogenous processing of TPO. 
 
I found that TPO cryptic epitopes are present in the thyroid and DLN of WT mice. Thus, 
APCs  such  as  dendritic  cells  are  at  the  origin  of  the  spreading  of  TPO  cryptic  epitopes 
initiated in the thyroid from the physiological turnover of TECs (Figure 6-1; Point 1). I also 
showed that TECs naturally generate the TPO cryptic epitope from the processing of TPO, 
although the exact processing pathway is still unknown. Indeed, as shown in figure 4-20, 
TPO could be degraded after synthesis in the ER and/or upon endocytosis. This issue is 
currently being investigated. In WT mice, naive T cells do not recognize the cryptic epitope 
presented by mDCs in the DLN (Figure 6-2; Point 2). In TAZ10 mice, T cells bear the 
human TCR Vβ1/Vα15 specific for the TPO cryptic epitope. T cells from TAZ10 mice are 
able to recognize the cryptic epitope presented in the context of MHC-II molecules by mDCs 
in the DLN (Figure 6-2; Point 3).   
 
From  this  point,  I  showed  by  adoptive-transfer  that  transgenic  T  cells  are  rapidly 
activated and proliferate in the DLN within a week. We suggest that the onset of autoimmune 
disease is gradual and results from a cumulative response of activated transgenic T cells 
infiltrating the thyroid. At onset, most regulatory networks are absent from DLN of TAZ10 
mice. Indeed, MDSCs are not present (similar to the situation observed in LN from WT mice) 
and Tregs undergo apoptosis upon encounter of the cryptic epitope presented by APCs. APCs 
taking-up dying TEC in the thyroid, take-up both TPO cryptic epitopes and TPO proteins 
from which they generate the antagonist TPO epitope (Quaratino et al. 1996; Quaratino et al. 
2000). We are currently investigating the different concentrations of TPO524-535 and TPO525-
536 by mass-spectometry analysis of peptide extracts from the thyroid and DLN from WT 
mice. 
  
Figure 6-1: Initial events leading to the development of autoimmune disease in TAZ10 transgenic mice
Figure is detailed in the text of this c
myeloid  derived  suppressor  cell;  TEC
MHC-II: MHC class II molecule; DLN
 
 
1: Initial events leading to the development of autoimmune disease in TAZ10 transgenic mice
of this chapter. iDC: immature dendritic cell. mDC: mature dendritic cell; 
TEC:  thyroid  epithelial  cell;  TPO:  thyroid  peroxidase; 
DLN: cervical draining lymph nodes; ?: unknown. 
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1: Initial events leading to the development of autoimmune disease in TAZ10 transgenic mice 
: mature dendritic cell; MDSC: 
:  thyroid  peroxidase;  NO:  nitric  oxide; 231 
 
From this study, we will be able to investigate the forces dictating T cell activation versus 
T cell anergy occurring both in DLN and thyroid of TAZ10 mice at onset.  
While our study focussed on CD4
+ T cells from TAZ10 mice, CD8
+ T cells are MHC-II 
restricted and recognize the TPO cryptic epitope presented in the context of MHC-II by APCs 
(Quaratino et al. 2004). This important point excluded the possibility that the disease could be 
induced by CD8
+ T cells recognizing MHC-I restricted peptides.  
 
Activated CD4
+ T cells migrate and accumulate into the thyroid of TAZ10 mice (Figure 6-
1; Point 4). The release of cytokines such as IFNγ, TNFα and IL-1β by activated transgenic T 
cells in the thyroid (Figure 6-1; Point 5) is the first event leading to the death of thyrocytes.  
Indeed, TECs secrete nitric-oxide and upregulate the expression of Fas and Fas-L upon 
stimulation with inflammatory cytokines (Figure 6-1; Point 6). This triggers a destructive 
cascade of events leading to the death of thyrocytes. TEC expressing Fas and Fas-L die by 
suicide or fratricide and promote the death of activated transgenic Fas
+ CD4
+ T cells. At this 
stage, an amplification loop of inflammation is in place as more T cells are recruited. These T 
cells can come from the DLN and be activated. They can also be activated in the thyroid as 
mature APCs present the TPO cryptic epitope in the context of MHC-II molecules. I showed 
that TECs expressing MHC-II upon stimulation with inflammatory cytokines can present the 
TPO cryptic epitope to T cells from TAZ10 mice.  It is unlikely that the expression of MHC-
II by TEC is involved at onset of disease; it could however be involved in the amplification 
of inflammation after first thyroid damages have occurred. Other cells of the immune system 
are infiltrating the thyroid such as circultating Tregs that undergo apoptosis in the thyroid 
upon recognition of TPO cryptic epitopes.  
 
The increasing inflammation leads to the recruitment of MDSCs in the thyroid (Figure 6-
1; Point 7) and DLNs (Figure 6-1; Point 8). We do not know yet the precise role of these 
cells in the pathogenesis of the disease. It is clear that they are not present at onset of disease 
and  they  accumulate  in  these  tissues  as  inflammatory  processes  amplify.  Despite  their 
immunosuppressive functions, they are not able to prevent the progression of the disease. 
However, they express specific markers of APCs (such as CD11b and F4/80) and activation 
markers  such  as  MHC-II  and  costimulatory  molecules.  It  could  be  possible  that  MDSCs 
differentiate into immunogenic APCs thus contributing to the pathogenesis of the disease. We 
are currently investing this point. 
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I also highlighted the potential role played by TG2 in the pathogenesis of autoimmune 
thyroiditis. Treatment of TAZ10 mice with the TG2 specific inhibitor cystamine drastically 
reduced markers of inflammation such as the expression of MHC-II by TEC. TAZ10 mice 
treated with cystamine had reduced amounts of MDSC and effector CD4
+ T cells in the DLN. 
TG2 promotes inflammation in celiac disease (CDis) and we showed that up-regulation of 
TG2 in cystic fibrosis leads to inflammation mediated by the functional sequestration of anti-
inflammatory PPARγ proteins in perinuclear aggresomes (Maiuri et al. 2008; Chapter 5). 
 
It  is  now  admitted  that  patients  with  autoimmune  thyroiditis  are  more  susceptible  to 
develop CDis (Duntas, 2009). By analysing the diets of TAZ10 mice, we realised that food-
pellets  used  to  feed  TAZ10  and  WT  mice  contained  wheat,  gliadin  and  barley.  More 
interestingly, Rag
+/+ TAZ10 mice have diarrhea, a common symptom of CDis, while Rag
-/- 
TAZ10 mice do not. We are currently assessing whether Rag
+/+ TAZ10 mice develop celiac 
disease.  If  this  is  the  case,  the  study  of  TG2  in  TAZ10  mice  could  unravel  interesting 
mechanisms leading to the generation of CDis. As Rag
-/- TAZ10 only have transgenic CD4
+ 
and CD8
+ T cells, we intend to address whether CDis in TAZ10 mice with autoimmune 
thyroiditis is mediated by T cells, B cells or a combination of the two. 
 
 
From this work, there are a number of questions that have emerged. Future work could 
investigate these questions as follows: 
 
•  The precise sequence of the TPO peptides remains to be determined. The nature of the 
different TPO peptides (ie. TPO524-535 and TPO525-536 and their human equivalent) 
has so far been determined using synthetics peptides (Quaratino et al. 1996 and 2000). 
The  nature  of  these  different  peptides  would  be  determined  by  HPLC  and  Mass 
Spectrometry analysis. To investigate the endogenous processing of TPO, we will 
generate an immortalized thyroid epithelial cell-line using the pSV3-neo expression 
vector (ATCC, USA). To investigate the exogenous processing, we are planning to 
use BM-DCs generated following the Lutz’s method. 233 
 
•  The different mechanisms and proteases involved in the processing of endogenous 
and exogenous TPO by TEC and BM-DC respectively, could be analysed using the  
different cellular systems above.  
•  We also aim to characterize the quantity of the TPO cryptic and APL peptides from 
peptide  extracts  that  will  allow  us  to  measure  the  forces  of  anergy  (TPO525-536) 
versus activation (TPO524-535). This will be performed using proliferation assays by 
flow cytometry and also by studying the different signalling pathways following TCR 
engagment. 
•  Finally, we will analyse the fate of naive CD4
+T cells after adoptive transfer into Rag-
/-  and  WT  mice  to  assess  which  CD4
+  T  cell  subsets  are  generated  following 
recognition of the TPO cryptic epitope in the draining LNs. We will then assess the 
kinetic of recruitment of MDSCs in TAZ10 mice at the onset of the disease. 
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Appendix 1: 1987 Criteria for the Classification of Acute Arthritis of Rheumatoid Arthritis 
 
Criterion   Definition  
1. Morning stiffness  Morning stiffness in and around the joints, lasting at least 1 hour before 
maximal improvement  
2. Arthritis of 3 or more joint areas  At least 3 joint areas simultaneously have had soft tissue swelling or fluid (not 
bony overgrowth alone) observed by a physician. The 14 possible areas are 
right or left PIP, MCP, wrist, elbow, knee, ankle, and MTP joints  
3. Arthritis of hand joints  At least 1 area swollen (as defined above) in a wrist, MCP, or PIP joint  
4. Symmetric arthritis  Simultaneous involvement of the same joint areas (as defined in 2) on both 
sides fo the body (bilateral involvement of PIPs, MCPs, or MTPs is acceptable 
without absolute symmetry)  
5. Rheumatoid nodules  Subcutaneous nodules, over bony prominences, or extensor surfaces, or in 
juxtaarticular regions, observed by a physician  
6. Serum rheumatoid factor  Demonstration of abnormal amounts of serum rheumatoid factor by any 
method for which the result has been positive in <5% of normal control 
subjects  
7. Radiographic changes  Radiographic changes typical of rheumatoid arthritis on posteroanterior hand 
and wrist radiographs, which must include erosions or unequivocal bony 
decalcification localized in or most marked adjacent to the involved joints 
(osteoarthritis changes alone do not qualify)  
 
* For classification purposes, a patient shall be said to have rheumatoid arthritis if he/she has satisfied at least 4 or these 7 
criteria. Criteria 1 through 4 must have been present for at least 6 weeks. Patients with 2 clinical diagnoses are not excluded. 
Designation as classic, definite, or probable rheumatoid arthritis is not to be made.  
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 
revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315---24. 
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Appendix 2: The 1997 Update of the 1982 American College of Rheumatology Revised 
Criteria  for  Classification  of  Systemic  Lupus  Erythematosus 
(http://www.rheumatology.org/publications/classification/SLE/1997UpdateOf1982RevisedCriteriaClassification
SLE.asp?aud=mem ) 
Criterion  Definition 
1. Malar Rash  Fixed erythema, flat or raised, over the malar eminences, tending to spare the 
nasolabial folds 
2. Discoid rash  Erythematous raised patches with adherent keratotic scaling and follicular plugging; 
atrophic scarring may occur in older lesions 
3. Photosensitivity  Skin rash as a result of unusual reaction to sunlight, by patient history or physician 
observation 
4. Oral ulcers  Oral or nasopharyngeal ulceration, usually painless, observed by physician 
5. Nonerosive Arthritis  Involving 2 or more peripheral joints, characterized by tenderness, swelling, or 
effusion 
6. Pleuritis or 
Pericarditis 
a) Pleuritis--convincing history of pleuritic pain or rubbing heard by a physician or 
evidence of pleural effusion  
OR  
b) Pericarditis--documented by electrocardigram or rub or evidence of pericardial 
effusion  
7. Renal Disorder  a) Persistent proteinuria > 0.5 grams per day or > than 3+ if quantitation not 
performed  
OR  
b) Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed  
8. Neurologic Disorder  a) Seizures--in the absence of offending drugs or known metabolic derangements; 
e.g., uremia, ketoacidosis, or electrolyte imbalance  
OR  
b) Psychosis--in the absence of offending drugs or known metabolic derangements, 
e.g., uremia, ketoacidosis, or electrolyte imbalance  
9. Hematologic 
Disorder 
a) Hemolytic anemia--with reticulocytosis  
OR  
b) Leukopenia--< 4,000/mm
3 on ≥ 2 occasions  
OR  
c) Lyphopenia--< 1,500/ mm
3 on ≥ 2 occasions  
OR  
d) Thrombocytopenia--<100,000/ mm
3 in the absence of offending drugs  
10. Immunologic 
Disorder 
a) Anti-DNA: antibody to native DNA in abnormal titer  
OR  
b) Anti-Sm: presence of antibody to Sm nuclear antigen  
OR  
c) Positive finding of antiphospholipid antibodies on:  
1.  an abnormal serum level of IgG or IgM anticardiolipin antibodies,  
2.  a positive test result for lupus anticoagulant using a standard 
method, or  
3.  a false-positive test result for at least 6 months confirmed by 
Treponema pallidum immobilization or fluorescent treponemal 
antibody absorption test 
11. Positive 
Antinuclear Antibody 
An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent 
assay at any point in time and in the absence of drugs  
 
 